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Figure 1: Triglyceride formation in the intestine. 
Dietary triglycerides (TGs) are primarily digested in the small intestine, where bile and pancreatic juice are added. Bile is 
formed in and released from the gall bladder and primarily consists of  bile acids, phospholipids, cholesterol and water (102). 
Bile acids emulsify dietary TGs to facilitate their digestion by enzymes present in the pancreatic juice, such as co-lipase 
and pancreatic lipase (11). Hydrolysis of  TGs by pancreatic lipase results in the release of  fatty acids and monoacylglycerol 
(MAG) (10). These fatty acids are taken up into enterocytes either by passive diffusion or by active transport via proteins such 
as fatty acid transport protein 4 (FATP4) and cluster of  differentiation 36 (CD36) (17, 18). In contrast, MAG is primarily 
taken up by passive diffusion (19). After uptake, the fatty acids and MAGs are transported through the cytosol to the en-
doplasmic reticulum (ER) by intracellular fatty acid-binding proteins (FABPs) (20). Prior to re-esterification, the fatty acids 
are esterified to a CoA molecule to form a fatty acyl-CoA, a process that is catalysed by acyl-coA synthases (21). In the ER, 
the fatty acids and MAG are re-esterified into triglycerides by acyl-coA:monoacylglycerol acyltransferases (MGAT) to form 
diacylglycerol (DAG) and, subsequently, acyl-coA:diacylglycerol acyltransferases (DGAT) to form TGs (10, 22). The newly 
formed TGs accumulate between the ER membrane bilayer and can either partition into the cytosol to form cytosolic lipid 
droplets (LDs) or partition into the ER lumen to form luminal LDs used for short-term storage or chylomicron assembly 
(10, 15, 103). For transport in the circulation, the hydrophobic TGs are transferred onto apolipoprotein B48 (APOB48) in 
the inner leaflet of  the ER by the enzyme microsomal triglyceride transfer protein (MTP) to form primordial, lipid-poor 
chylomicron particles (15, 16). APOB48, a protein encoded by the APOB gene, is the major nonexchangeable apolipopro-
tein present on the surface of  chylomicrons (104). Primordial chylomicrons acquire more lipids and apolipoproteins such 
as APOA4 and are eventually secreted into the lymphatic system to enter the circulation at the level of  the subclavian vein 
(10, 11, 15, 16).
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EFFECTIVE PARTITIONING OF FATTY ACIDS 
Fatty acids are indispensable for human physiology; they are integral components 
of our cell membranes, highly eff icient energy substrates and potent signaling mol-
ecules. Due to their relatively high toxicity, fatty acids are mostly incorporated into 
triglycerides (TGs) to facilitate transport and storage (1, 2). Indeed, the majority of 
circulating fatty acids are found as TGs in so-called triglyceride-rich lipoproteins 
(TRLs), while most intracellular fatty acids are stored as TGs in cytoplasmic lipid 
droplets (3–5). The inability of TGs to move across cellular membranes necessitates 
that TGs are degraded to fatty acids via a process called lipolysis: the hydrolysis of 
TGs into three fatty acids and a glycerol molecule by lipases (6, 7). Lipolysis occurs 
at multiple locations: in the intestinal tract to degrade dietary TGs to fatty acids for 
uptake by the enterocytes, intravascularly to liberate fatty acids from TRLs for uptake 
by the underlying cells, and intracellularly to release fatty acids from lipid droplets 
for secretion into the circulation or usage as fuel (2, 8). To assure that fatty acid 
substrates are eff iciently partitioned in response to metabolic demand, the rates of 
extracellular (gastro-intestinal and intravascular) lipolysis and intracellular lipolysis 
need to be tightly and dynamically controlled. Indeed, a mismatch between the rates 
of lipolysis and the usage of fatty acids by tissues can lead to ectopic lipid accumula-
tion and dyslipidemia, important features of metabolic disorders such as obesity and 
cardiovascular disease (2, 9). However, despite the signif icance of proper regulation 
of lipolysis for metabolic health, the underlying molecular mechanisms are far from 
being completely understood.
EXTRACELLULAR LIPOLYSIS 
Gastro-intestinal lipolysis and TRL formation 
The majority of the fatty acids in our body are derived from TGs that are present 
in our diet. Degradation of dietary TGs to fatty acids and monoacylglycerol (MAG) 
starts in the mouth and stomach, but primarily takes place in the small intestine, 
where pre-digested food is combined with bile and pancreatic juice (8). Bile acids 
present in the bile emulsify dietary TGs to facilitate their hydrolysis by pancreatic 
lipase (10, 11). The activity of pancreatic lipase is extensively regulated by bile acids, 
calcium and the amount and type of dietary fat, but also by the protein Angiopoie-
tin-like 4 (ANGPTL4) that is secreted by the intestine (12–14). The exact nature of the 
crosstalk between intestinal proteins and pancreatic lipase activity remains, however, 
ill-def ined. Upon absorption into enterocytes, the fatty acids and MAGs are trans-
ported to the endoplasmic reticulum (ER), re-esterif ied to form TGs and transferred 
onto apolipoprotein B48 (APOB48) to form so-called chylomicrons, intestine-derived 
TRL particles (10, 15–22) (see Figure 1 for further details). Chylomicrons mature by 
further lipidation and by the incorporation of exchangeable apolipoproteins such as 
APOA4. They subsequently exit the enterocyte and enter the circulation via the lym-
phatic system (10, 11, 15, 16) (Figure 1).
 Whereas the intestine is responsible for the incorporation of exogenous fat-
ty acids into TRLs, the liver incorporates endogenous TGs into TRLs called very 
low-density lipoproteins (VLDLs). Similar to chylomicron formation in the intestine, 
Chapter 1
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Figure 2: Triglyceride formation in the liver 
For the formation of  very low-density lipoproteins (VLDLs), the liver synthesizes triglycerides (TGs) by re-esterification of  
free fatty acids that are derived from multiple sources: 1) the circulation; albumin-bound fatty acids released from adipocytes 
or chylomicron remnants taken up by the liver, 2) the diet; dietary fatty acids absorbed in the intestine and transported 
through the portal vein to the liver, and 3) the liver; from storage or endogenous fatty acid synthesis (FAS) (3, 23). Exoge-
nously derived fatty acids are preferentially incorporated into VLDLs as opposed to de novo synthesized fatty acids (23). The 
pathways of  TG re-esterification in liver mimic the pathways in the intestine, as described in Figure 1 (23, 25). However, ex-
ogenously derived fatty acids can also be directly esterified by the enzyme acyl-coA:diacylglycerol acyltransferase 1 (DGAT1) 
onto diacylglycerols (DAG) liberated from cytosolic lipid droplets (23, 105). Liver TGs are transferred onto APOB100 in 
the endoplasmic reticulum (ER) by microsomal triglyceride transfer protein (MTP) to form a primordial, lipid-poor VLDL 
particle (26). Maturing VLDLs continue to acquire TGs and exchangeable apolipoproteins such as APOE and APOC3 in 
the ER and Golgi, after which the mature VLDLs are secreted into the hepatic vein (3, 27).
the formation of VLDLs heavily relies on the availability of hepatic TGs. The liver 
synthesizes TGs by re-esterif ication of fatty acids from multiple sources: 1) the circu-
lation; albumin-bound fatty acids released from adipocytes by intracellular lipolysis 
or chylomicron remnants, 2) the diet; dietary fatty acids transported through the por-
tal vein to the liver, and 3) the liver; stored or endogenously synthesized fatty acids (3, 
23, 24) (Figure 2). In general, the processes of VLDL formation in the liver closely 
resemble those of chylomicron formation in the intestine, except that in the liver the 
full-length APOB (APOB100) protein and not the truncated APOB48 is lipidated (23, 
25, 26) (see Figure 2 for further details). VLDLs mature by acquiring additional TGs 
and exchangeable apolipoproteins such as APOE and APOC3 in the ER and Golgi 
before being secreted into the hepatic vein (3, 27) (Figure 2). Upon arrival in the 
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circulation, mature chylomicrons and VLDLs gain further exchangeable apolipopro-
teins such as APOC2, APOC3 and APOE (11). Acquisition of APOC2 promotes the 
intravascular lipolysis of TRLs by the enzyme lipoprotein lipase (LPL) that is present 
on the surface of the capillary endothelium in multiple organs, including adipose tis-
sue and heart (28, 29).
Intravascular lipolysis by LPL 
Similar to the importance of pancreatic lipase for gastro-intestinal lipolysis, LPL is 
pivotal for the intravascular lipolysis of TRLs, as underscored by the severe chylo-
micronaemia observed in patients with complete loss-of-function mutations in the 
LPL gene (30). Similarly, common loss-of-function and gain-of-function variants in 
the LPL gene are responsible for modest increases or decreases in plasma TG levels, 
respectively, in the general population (31). Furthermore, the perturbed activity of 
LPL has been repeatedly associated with a dysregulation of insulin action and energy 
homeostasis and with an increased risk for cardiovascular disease (31–33). 
I. From translation to endothelium  
LPL hydrolyses circulating TGs on the surface of the capillary endothelium, but is 
primarily expressed by the underlying parenchymal cells (28, 34). Following tran-
scription, two critical steps in the ER permit LPL to attain catalytic activity: aspar-
agine-linked glycosylation and LPL dimer assembly (35–39) (Figure 3). Asparag-
ine-linked glycosylation of LPL via co-translational transfer of oligosaccharide chains 
high in mannose residues promotes the proper folding of LPL and targets LPL for 
secretion (35–37, 40). Assembly of LPL into a homodimer of two head-to-tail connect-
ed 55 kDa subunits is chaperoned by lipase maturation factor 1 (LMF1), a multi-pass 
transmembrane protein that in complex with Sel-1 suppressor of lin-12-like protein 
(Sel1L) stabilizes the LPL homodimers and controls their ER exit (38, 39, 41). Upon 
translocation from the ER to the Golgi, the high-mannose oligosaccharides on LPL 
are trimmed and sequentially replaced by more complex oligosaccharides to form ma-
ture LPL (35–37) (Figure 3). From the trans-Golgi, mature LPL is either transported 
to the cell surface and secreted or targeted for degradation (Figure 3). Pulse-chase 
experiments have indicated that up to 80% of newly synthesized LPL is directed to-
wards intracellular degradation, although the stimuli that target LPL for degradation 
remain largely unknown (42, 43). Proteins that have been proposed to play a role 
in the intracellular traff icking of LPL include ANGPTL4, sortilin and sortilin-re-
lated receptor (SORLA), but their exact functions have remained elusive (44–46). 
After secretion, LPL is bound to heparan sulphate proteoglycans (HSPGs) on the cell 
surface, from where LPL can be internalized for degradation or transported to the 
endothelium by glycosylphosphatidylinositol-anchored high-density lipoprotein-bind-
ing protein 1 (GPIHBP1) (47–49). Endothelial GPIHBP1 avidly binds to LPL in the 
sub-endothelial spaces and transports LPL to the capillary lumen, where it continues 
to bind and stabilize LPL (48, 49). Indeed, unless stabilized by factors such as LMF1, 
SEL1L, HSPGs or GPIHBP1, the LPL homodimer rapidly dissociates and loses its 
catalytic activity (39, 50). 
Chapter 1
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Figure 3: LPL-mediated hydrolysis of circulating TG.
In the endoplasmic reticulum (ER) of  parenchymal cells, lipoprotein lipase (LPL) attains catalytic activity by asparag-
ine-linked glycosylation and dimer assembly, a process chaperoned by lipase maturation factor 1 (LMF1) (35–39). Upon 
translocation from the ER to the Golgi, the high-mannose oligosaccharides on LPL are trimmed and sequentially replaced 
by more complex oligosaccharides (35–37). Oligosaccharides high in mannose residues are susceptible for cleavage by the 
enzyme EndoH (EndoH-sensitive), while more complex oligosaccharides cannot be cleaved by EndoH (EndoH-resistant). 
Upon acquisition of  complex oligosaccharides, LPL is transported either to the cell surface for secretion or targeted for 
degradation. Secreted LPL is bound to heparan sulphate proteoglycans (HSPGs) on the cellular surface (47). Endothelial-ex-
pressed glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) avidly binds LPL in 
the subendothelial spaces and transports LPL to the capillary lumen, where it continues to bind and stabilize LPL (48, 49). 
Upon hydrolysis of  chylomicrons or very low-density lipoproteins (VLDLs) by LPL, the resultant fatty acids have multiple 
fates. Dependent on the tissue, the fatty acids are transported to the underlying parenchymal cells for either storage in lipid 
droplets or oxidation in mitochondria or, alternatively, lost in the venous blood in a process called ‘fatty acid spillover’ (74). 
Endothelial fatty acid transport is mediated by FATP3 and FATP4, as well as CD36 and FABP4 (69, 75–77).
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II. Regulation of LPL activity 
Continuous changes in metabolic demand require that the partitioning of circulating 
TGs and, accordingly, the levels of tissue LPL activity are highly dynamic. For exam-
ple, during prolonged deprivation of food, fuel utilization shifts towards the exclusive 
utilization of TGs. As a result, the activity of LPL in heart signif icantly increases to 
assure that an adequate amount of fuel is delivered to the heart, while the activity of 
LPL in white adipose tissue (WAT) decreases (51–53). Consequently, the activity of 
LPL is tightly regulated at the transcriptional, translational and post-translational 
levels in a tissue-specif ic manner. At the mRNA level, LPL is controlled by the per-
oxisome proliferator-activated receptor (PPAR) family of transcription factors (54). 
PPARs are a family of nuclear hormone transcription factors that are primarily acti-
vated by fatty acids and of which three isoforms have been identif ied: PPARα, PPARδ 
and PPARγ (55). Other physiologically relevant factors that impact LPL transcription 
include insulin, glucocorticoids and β-adrenergic stimulation (28, 56). However, de-
spite minor regulation at the transcriptional and translational level, LPL activity is 
primarily regulated at the post-translational level.  
 Proteins that regulate LPL activity at the post-translational level can be 
roughly divided into two groups: 1) the exchangeable apolipoproteins APOC1, 
APOC2, APOC3, APOA5 and APOE and 2) members of the angiopoietin-like pro-
tein family, specif ically ANGPTL3, ANGPTL4 and ANGPTL8 (29, 57–60). Of the 
APOC proteins, APOC1, APOC3, and APOE appear to negatively regulate LPL 
activity, while APOC2 and APOA5 potently stimulate endothelial LPL activity at 
physiological levels (29, 57). Indeed, loss-of-function mutations in the APOC2 and 
APOA5 genes result in a pronounced hyperchylomicronaemia (29, 57). Despite their 
impact on LPL activity and TRL clearance, however, it is unlikely that the circulating 
apolipoproteins are responsible for the tissue-specif ic changes in LPL activity that are 
observed during different physiological conditions. 
 Members of the angiopoietin-like protein family are secreted glycoproteins 
that share a common architecture (60). ANGPTL3, ANGPTL4 and ANGPTL8 
potently impact plasma lipid levels by inhibiting the activity of LPL and other re-
lated extracellular lipases, such as pancreatic lipase, endothelial lipase and hepat-
ic lipase (13, 60–65). In contrast to the apolipoproteins, the expression of several 
ANGPTL proteins is highly responsive to changes in metabolic demand. Indeed, 
the upregulation of ANGPTL4 (originally called fasting-induced adipose factor) 
expression in WAT is responsible for the reduction of LPL activity levels in WAT 
upon fasting (52, 66). In contrast, the expression of ANGPTL8 in WAT is increased 
upon refeeding, which has led to the suggestion that ANGPTL8, in collaboration 
with ANGPTL3, assures the replenishment of adipose tissue stores during refeed-
ing by inhibiting LPL activity specif ically in oxidative tissues (67). In Chapter 2 
& Chapter 3 of this thesis, the mechanisms by which the ANGPTL proteins in-
f luence plasma lipid levels and LPL activity are more elaborately described. 
 A specif ic physiological condition that dramatically impacts tissue energy 
demands and lipid distribution is cold exposure. During cold exposure, brown adi-
pose tissue (BAT), the main metabolic organ dedicated to the generation of heat, is 
activated to assure the maintenance of core body temperature. Activation of BAT by 
Chapter 1
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Figure 4: Pathways of lipid droplet biogenesis & intracellular lipolysis in adipocytes. 
To generate the triglycerides (TGs) required for lipid droplet formation, exogenous or endogenous fatty acids need to be 
activated by esterification to a CoA molecule to form fatty acyl-CoAs, a process catalysed by acyl-coA synthases (ACS) 
(21). Upon activation, de novo TG synthesis occurs by re-esterification of  fatty acyl-CoAs to glycerol-3-phosphate (G3P) 
via the G3P-pathway. First, G3P acyltransferase (GPAT) combines a fatty acyl-CoA to G3P to form lysophosphatidic acid 
(lyso-PA), where after 1-acyl-G3P acyltransferase (AGPAT) adds another fatty acyl-CoA to form phosphatidic acid (PA). 
Next, phosphatidic acid phosphatase (PAP) removes a phosphate group and acyl-coA:diacylglycerol acyltransferase (DGAT) 
adds another fatty acyl-CoA to form TGs (80, 81). Alternatively, TGs may be synthesized from fatty acyl-CoAs and DAGs 
by DGATs or from re-esterification of  fatty acyl-CoAs to MAG by MGATs and DGATs (10, 23, 79, 83). Condensation of  
fatty acyl-CoAs with cholesterol, a step catalysed by acyl-CoA:cholesterol acyltransferases (ACATs), yields cholesterylesters, 
the major neutral lipid component of  lipid droplets besides TGs (79). Newly formed TGs and cholesterylesters accumulate 
in the inner leaflet of  the ER bilayer to form blisters that eventually bud off to form small cytosolic lipid droplets (79, 82). 
Nascent lipid droplets may become larger via fusion, diffusion-mediated transfer of  core TGs, or local synthesis of  additional 
TGs on the lipid droplet surface by the acquisition of  enzymes involved in TG synthesis from the ER such as GPAT4 and 
DGAT2 (85, 86). To release fatty acids from lipid droplets, catecholamines such as norepinephrine bind to the β3-adrenergic 
receptors on the cell surface of  adipocytes and activate protein kinase A (PKA) via an intracellular signalling cascade that in-
volves cyclic AMP (cAMP) (91). PKA promotes lipolysis by phosphorylating multiple proteins involved in lipolysis, including 
hormone-sensitive lipase (HSL) and perilipin 1 (PLIN1) (90, 91). PLIN1 normally binds comparative gene identification-58 
(CGI-58), a potent stimulator of  adipose triglyceride lipase (ATGL) activity, but upon phosporylation PLIN1 releases CGI-
58 to allow for ATGL activation (92). Similarly, phosphorylation of  HSL results in translocation of  HSL to the lipid droplet. 
Next, ATGL, HSL and monoglyceride lipase (MGL) act in consecutive steps to release one fatty acid each (90). The resultant 
fatty acids can either be secreted into the circulation or re-esterified by ACS to form fatty acyl-CoAs that are reincorporated 
into lipid droplets. 
β3
TG
TG
PLIN3
PLIN2
PLIN1
cAMP
PKA
CGI-58
CGI-58
P
ATGL
HSL
P HSLP
TGFA
MGL
FA
FA
glycerolGPAT
AGPAT
PAP
FA-CoA + G3P
Lyso-PA
PA
DAG
DGAT
FA-CoA
ACS
glycerolFAFA
FA
ACS
GPAT4 DGAT2
TG
NE
General  Introduction 
9
1
β-adrenergic signaling results in the combustion of fatty acids and subsequent heat 
generation via the uncoupling of ATP production from mitochondrial respiration by 
the protein uncoupling-protein 1 (UCP1) (68). To replenish intracellular energy stores, 
the uptake of glucose, fatty acids and TG-derived fatty acids by BAT is dramatical-
ly increased upon cold exposure. Indeed, the activity of LPL in BAT signif icantly 
increases during cold exposure, although it is currently unclear what mechanisms 
promote the increase in LPL activity during cold exposure and whether the ANGPTL 
proteins are implicated  (68–71). 
From intravascular lipolysis to fatty acid storage or oxidation
For intravascular lipolysis to occur, chylomicrons and VLDLs must f irst dock to the 
capillary endothelium via a process called margination. Multiple lines of evidence 
suggest that the combined actions of LPL and GPIHBP1 are essential for intravas-
cular TRL margination. Studies in mice with a tissue-specif ic expression of LPL 
indicated that the degree of margination ref lects the amount of LPL present on the 
endothelium (72). Similarly, the absence of TRL margination in Gpihbp1-/- mice over-
expressing endothelial LPL indicated an essential role for GPIHBP1 in margination 
(73). Upon TRL margination and intravascular hydrolysis of TGs by LPL, the re-
sultant fatty acids have multiple fates. Dependent on the tissue, the fatty acids are 
transported through the endothelium to the underlying parenchymal cells for either 
storage or oxidation, or lost in the venous blood in a process called ‘fatty acid spillo-
ver’ (74) (Figure 3). While it is clear that fatty acid spillover signif icantly contributes 
to circulating fatty acid levels, the mechanisms underlying fatty acid spillover have 
remained enigmatic (74). Part of the ambiguousness stems from the lack of insight into 
the mechanisms responsible for the endothelial transport of fatty acids. Only recently, 
the fatty acid transport proteins 3 and 4 (FATP3 and FATP4), as well as cluster of 
differentiation 36 (CD36) and fatty acid binding protein 4 (FABP4) were identif ied as 
mediators of endothelial fatty acid transport (69, 75–77). Furthermore, a recent study 
identif ied two transcription factors, mesenchyme homeobox 2 and transcription fac-
tor 15, that drive the expression of CD36 and, surprisingly, LPL in endothelial cells 
to promote and facilitate the uptake of circulating and hydrolyzed fatty acids (78). 
INTRACELLULAR LIPOLYSIS 
Lipid droplet biogenesis 
Upon arrival in the parenchymal cells, part of the fatty acids is re-esterif ied and 
incorporated into cytoplasmic lipid droplets. In eukaryotes, lipid droplet formation 
occurs in the ER, the location of TG and cholesterylester synthesis, in a process that 
closely resembles chylomicron and VLDL formation. First, fatty acids are re-esteri-
f ied either to glycerol-3-phosphate (G3P) to form TGs via the G3P-pathway or to cho-
lesterol to form cholesterylesters, the major neutral lipid component of lipid droplets 
besides TGs (79–81) (see Figure 4 for further details). Newly formed TGs and cho-
lesterylesters accumulate at low concentrations in the inner leaf let of the ER bilayer. 
With increasing concentrations, ‘blisters’ that contain higher concentrations of TGs 
and cholesterylesters form in the bilayer and subsequently bud off to form small cy-
Chapter 1
10
tosolic lipid droplets (79, 82) (Figure 4). It has been suggested that various proteins, 
such as Seipin, the fat storage–inducing transmembrane protein (FITM/FIT) and 
members of the perilipin (PLIN) family facilitate, but are not essential for the budding 
and the subsequent formation of lipid droplets (79, 83). In fact, PLINs may have spe-
cif ic spatial and temporal functions during lipid droplet formation, with PLIN3 pri-
marily coating nascent lipid droplets, PLIN2 coating intermediate-sized lipid droplets 
and PLIN1, in adipocytes, coating large cytosolic lipid droplets (84). Nascent lipid 
droplets may enlarge via two specif ic mechanisms; 1) by the local synthesis of TGs 
on the lipid droplet surface via the acquisition of enzymes involved in TG synthesis, 
such as G3P acyltransferase (GPAT4) and acyl-coA:diacylglycerol acyltransferase 2 
(DGAT2), from the ER (85, 86) or 2) by fusion with another lipid droplet or the dif-
fusion-mediated transfer of TGs from one lipid droplet to another (87). For example, 
cell death–inducing DFF45-like effector C (CIDEC/FSP27) has been suggested to 
promote lipid droplet growth by stimulating the transfer of TGs from smaller to larger 
lipid droplets (88). 
From intracellular lipolysis to fatty acid release or oxidation 
Cytoplasmic lipid droplets are found in all metabolically active tissues, including 
heart, skeletal muscle, liver, BAT and WAT, but fulf il different functions dependent 
on the tissue. For example, fatty acids generated from intracellular lipolysis of WAT 
lipid droplets are released into the circulation during fasting conditions to directly 
fuel tissues such as the heart or to be incorporated into VLDLs in the liver. In con-
trast, fatty acids generated from lipolysis in other tissues are not released into the 
circulation, but are used by these tissues for lipid synthesis or fatty acid oxidation. It is 
of interest that accumulating evidence suggests that in oxidative tissues such as muscle 
and heart most exogenous fatty acids cycle through the process of re-esterif ication at 
least once before entering the mitochondria for oxidation (81, 89). 
 Despite the differences in lipid droplet function, the main steps of intracel-
lular lipolysis are similar between all tissues and include three lipases that act in 
consecutive steps to release one fatty acid each: adipose triglyceride lipase (ATGL), 
the rate-limiting enzyme, hormone-sensitive lipase (HSL) and monoglyceride lipase 
(MGL) (90). In the adipose tissue, lipolysis is initiated by a reduction in insulin lev-
els and an increase in catecholamine levels (91). Catecholamines bind to β-adrener-
gic receptors on the cell surface of adipocytes and activate protein kinase A (PKA) 
via an intracellular signalling cascade that involves cyclic AMP (91). PKA promotes 
lipolysis by phosphorylating multiple proteins, including HSL and PLIN1 (90, 91) 
(Figure 4). PLIN1 phosphorylation releases comparative gene identif ication-58 
(CGI-58/ABHD5), a protein that binds and potently stimulates ATGL activity 
(92). Other recently identif ied regulators of adipocyte lipolysis include members of 
the PLIN family, the CIDE protein family and G0/G1 switch gene 2 (G0S2), al-
though their exact functions in lipolysis are far from being understood (6, 93–98). 
 The importance of the proper regulation of intracellular lipolysis is illustrat-
ed by the numerous human and mouse studies in which key regulatory enzymes are 
disrupted. For example, loss-of-function mutations in the ATGL stimulating ABHD5 
(CGI-58)result in dysfunctional lipolysis, cellular lipid accumulation and neutral li-
pid storage disease (99, 100). However, dysregulation of intracellular lipolysis is also 
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present in the general population, as exemplif ied by the increased basal rates of intra-
cellular lipolysis in obese subjects (101). Overall, intracellular lipolysis is remarkably 
complex and substantial further investigation is required to identify the specif ic func-
tions of the increasing number of regulatory proteins. 
OUTLINE OF THIS THESIS 
During changing metabolic demand, the dynamic regulation of extracellular and in-
tracellular lipolysis assures the effective partitioning of lipid fuel. The main aim  of 
this thesis was to increase our understanding of the molecular mechanisms 
that underlie the regulation of extracellular and intracellular lipolysis. In 
the f irst part, the focus lies on the regulation of extracellular lipolysis by the ANGPTL 
proteins, in particular. As brief ly noted above, the ANGPTL proteins regulate extra-
cellular lipolysis by inhibiting LPL and other members of the extracellular lipase fam-
ily. A contemporary overview of the role of the ANGPTL proteins in lipid metabo-
lism is provided in Chapter 2. In Chapter 3, ANGPTL4 and ANGPTL4-mediated 
regulation of LPL activity are discussed in further detail. In Chapter 4, we extend 
our understanding of the function of ANGPTL4 by demonstrating that ANGPTL4 
is indispensable for the proper distribution of TRL-derived fatty acids during cold 
exposure. By employing Angptl4 -/-, wild-type, and Angptl4-Tg mice, we elegantly show 
that the reduction in ANGPTL4 expression in BAT facilitates the increase in BAT 
LPL activity that is observed during sustained cold exposure.
 Although ANGPTL4 has been known to inhibit LPL for nearly 15 years, 
the location and the mechanisms by which ANGPTL4 inhibits LPL have remained 
largely elusive. In Chapter 5, we show that ANGPTL4 inhibits LPL intracellularly 
in adipocytes, by demonstrating that LPL is more secreted from adipocytes of mice 
without Angptl4 than from wild-type adipocytes. In Chapter 6, we further extend 
these observations and propose that ANGPTL4 might inhibit intracellular LPL by 
promoting the cleavage of LPL by proprotein subtilisin/kexins (PCSKs) in the adipo-
cytes.Besides regulating LPL activity, ANGPTL4 also potently impacts the activity of 
pancreatic lipase in the gastro-intestinal tract. Therefore, in Chapter 7, we switch to 
gastro-intestinal lipolysis and investigate the role of intestinal ANGPTL4. We show 
that intestinal ANGPTL4, possibly via its impact on pancreatic lipase, regulates intes-
tinal bile acid uptake and is associated with an altered gut microbial composition. 
 In the second part of this thesis, we focus on the regulation of intracellu-
lar lipolysis and on the newly-identif ied PPAR-target gene hypoxia-inducible lipid 
droplet-associated (HILPDA), in particular. In Chapter 8, we show that overex-
pression of HILPDA in adipocytes modestly inhibits intracellular lipolysis, whereas 
knockdown of HILPDA in adipocytes does not affect lipolytic rates. Furthermore, we 
demonstrate that the adipocyte-specif ic deletion of Hilpda in mice does not impact 
plasma non-esterif ied fatty acid levels or other relevant metabolic parameters upon 
fasting, cold exposure or pharmacologic β-adrenergic stimulation. Our data thus not 
support a major role for HILPDA in the regulation of adipocyte lipolysis, in contrast 
to a previous study that identif ied a role for HILPDA in the regulation of intracellu-
lar lipolysis in the liver. Finally, in Chapter 9, the data presented in this thesis are 
integrated with current literature and elaborately discussed.   
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ABSTRACT 
Purpose of Review 
The angiopoietin-like proteins (ANGPTLs) 3, 4 and 8 have emerged as key regulators 
of plasma lipid metabolism by serving as potent inhibitors of the enzyme lipoprotein 
lipase. In this review, we provide an integrated picture of the role of ANGPTL3, 
ANGPTL4 and ANGPTL8 in lipid metabolism by focusing on their impact on lipo-
protein lipase activity and plasma triglyceride clearance during physiological condi-
tions such as fasting, refeeding, exercise and cold exposure.
Recent findings 
Upon refeeding, circulating ANGPTL3 and ANGPTL8 promote the replenishment 
of white adipose tissue depots by specif ically inhibiting lipoprotein lipase activity 
in oxidative tissues. During exercise and cold exposure, ANGPTL4 represses local 
lipoprotein lipase activity to assure that plasma triglycerides are specif ically shuttled 
to exercising muscle and BAT, respectively. Overall, ANGPTL4 is the central com-
ponent of a fatty acid-driven feedback mechanism that regulates plasma triglyceride 
hydrolysis and subsequent tissue fatty acid uptake in response to changes in lipid 
availability and cellular fuel demand. 
Summary 
ANGPTL3, ANGPTL4 and ANGPTL8 together ensure that triglycerides from tri-
glyceride-rich lipoproteins are adequately distributed during different physiological 
conditions. The impact of the ANGPTLs on plasma lipid levels has led to scrutiny of 
ANGPTLs as therapeutic targets for dyslipidemia.
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INTRODUCTION 
The angiopoietin-like (ANGPTL) proteins (ANGPTL1-8) are secreted glycoproteins 
composed of an N-terminal coiled-coil domain and a f ibrinogen-like C-terminal do-
main. Despite their common architecture, the eight family members carry distinct 
physiological functions, with suggested roles in angiogenesis, expansion of stem cells, 
inf lammation, tissue remodeling and lipid metabolism (1, 2). A shared feature of AN-
GTPL3, ANGPTL4 and ANGPTL8 is their involvement in lipoprotein metabolism. 
Indeed, genetic studies have revealed pronounced effects of common variants in the 
ANGPTL3, ANGPTL4 and ANGPTL8 genes on plasma lipid levels (1, 3, 4). Functional 
studies have indicated that ANGPTL3, ANGPTL4 and ANGPTL8 inf luence plasma 
lipid levels by inhibiting the activity of extracellular lipases, including the structurally 
related lipoprotein lipase (LPL), hepatic lipase, endothelial lipase and pancreatic li-
pase (4–9). In this review, we aim to provide an integrated picture of the impact of the 
angiopoietin-like proteins on lipid metabolism, with special emphasis on the function-
al roles of ANGPTL3, ANGPTL4 and ANGPTL8 in governing the activity of LPL 
during physiological conditions such as fasting, refeeding, exercise and cold exposure. 
ANGPTL3
ANGPTL3 was linked to lipid metabolism via identif ication of an Angptl3-mutant 
KK/San mouse strain characterized by abnormally low plasma triglycerides (10). 
Since then, biochemical and animal studies have convincingly established that 
ANGPTL3 serves as an inhibitor of LPL and thereby reduces plasma triglyceride 
clearance, partially explaining the hypolipidemic phenotype of the KK/San mice 
(6, 10–12). Consistent with these f indings, genome wide association studies as well 
as dedicated studies of common variants in and near the ANGPTL3 gene locus have 
repeatedly associated ANGPTL3 with plasma triglyceride and plasma HDL choles-
terol levels (13–19). Furthermore, exome sequencing in patients with severe familial 
combined hypolipidemia—a condition characterized by low plasma LDL cholesterol, 
HDL cholesterol and triglyceride levels—revealed rare loss-of-function mutations in 
the ANGPTL3 gene (20, 21). Affected individuals exhibit markedly elevated plasma 
LPL activity and LPL mass (20).
 Besides inhibiting LPL, there is some evidence that ANGPTL3 also inter-
feres with the activity of endothelial lipase (9, 22). Endothelial lipase mainly carries 
phospholipase activity and lowers plasma HDL cholesterol levels (23–25). Treatment 
of mice with a monoclonal antibody against ANGPTL3 signif icantly reduced plasma 
HDL cholesterol levels in wild-type but not endothelial lipase-def icient mice (22). 
In line with human genetic data and consistent with inhibition of endothelial lipase 
by ANGPTL3, several studies have reported a positive association between plasma 
ANGPTL3 levels and plasma HDL cholesterol levels in humans (9, 20, 23, 26, 27).  
 Even though ANGPTL3 potently inhibits LPL, the level of ANGPTL3 in 
plasma does not seem to correlate with plasma triglyceride concentrations (9, 26–28). 
A possible explanation for the apparent discrepancy is that the human plasma sam-
ples were collected in the fasted state (26, 27). It has been shown that differences in 
tissue LPL activity levels and VLDL-derived triglyceride uptake between wild-type 
and Angptl3-/- mice are most pronounced in the postprandial state, suggesting that 
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ANGPTL3 mainly affects LPL activity and plasma triglyceride levels shortly after 
feeding. Upon feeding, loss of Angptl3 led to a signif icant increase in LPL activity in 
post-heparin plasma and in several tissues (12, 29). Intriguingly, however, the increase 
in LPL activity was accompanied by decreased post-prandial uptake of VLDL-de-
rived triglycerides into WAT and increased uptake into heart, muscle and BAT (29). 
Based on these data, it was proposed that ANGPTL3 promotes the replenishment of 
WAT triglyceride stores upon refeeding by primarily inhibiting the uptake of circulat-
ing triglycerides into heart and BAT (29). These data underscore that measurement of 
LPL activity in post-heparin plasma or in tissue biopsies may not always give a proper 
impression of functional LPL activity at the endothelium (30). For now, the underlying 
mechanism for this tissue-specif ic action of ANGPTL3 remains unclear. One possi-
bility is that it somehow has to do with the ill-def ined interaction between ANGPTL3 
and ANGPTL8. ANGPTL3 and ANGPTL8 have been suggested to interact to effec-
tively inhibit LPL (4, 29). Clearly, additional studies are required to better understand 
the tissue-specif ic action of ANGPTL3. 
 As indicated above, carriers of ANGPTL3 loss-of-function mutations have 
reduced LDL cholesterol levels (20, 21). In addition, a positive association was 
found between plasma ANGPTL3 and plasma LDL cholesterol (26). The f indings 
have led to exploration of the potential mechanism underlying the relation between 
ANGPTL3 and LDL (20, 21, 26). Carriers of ANGPTL3 mutations and mice treated 
with ANGPTL3-inactivating human monoclonal antibody display reduced VLDL 
secretion rates (20, 31). Lower VLDL secretion is likely caused by a reduced hepatic 
inf lux of fatty acids from the plasma due to absence of ANGTPL3-stimulated adipose 
tissue lipolysis (31, 32). However, inactivation of Angptl3 specif ically affected secretion 
of triglycerides and not of ApoB100 lipoproteins, ruling out decreased VLDL secre-
tion as an explanation for reduced plasma LDL (20, 21, 31). Since the reduction in 
plasma LDL cholesterol levels in mice treated with anti-ANGPTL3 antibody was in-
dependent of LDLR, LRP1, APOE and Syndecan-1, it was suggested that ANGPTL3 
may inhibit clearance of APOB-containing lipoproteins via inhibition of LPL (31). 
Indeed, LPL has been suggested to act as a molecular bridge between lipoproteins and 
the hepatocyte cell surface, which could promote clearance of VLDL remnants and 
reduce the fraction of VLDL that is converted to LDL (31, 33, 34). While the impact 
of ANGPTL3 on LDL cholesterol levels via LPL complements the established function 
of ANGPTL3 as an inhibitor of plasma triglyceride clearance, further studies should 
clarify how inhibition of LPL by ANGPTL3 impacts VLDL remnant clearance and 
plasma levels of LDL cholesterol. Furthermore, it remains to be determined how the 
role of ANGPTL3 in triglyceride distribution upon refeeding can be linked to its effect 
on LDL and HDL cholesterol levels, which are both not substantially altered upon re-
feeding (35). A f inal point of interest is the discrepancy between the stimulatory effect 
of ANGPTL3 on intracellular WAT lipolysis described in a number of studies and 
the purported inhibitory effect of ANGPTL3 on WAT lipolysis observed during the 
replenishment of WAT triglyceride stores upon refeeding (20, 29, 31, 32). Answers to 
these questions may provide further insight into the functioning of ANGPTL3. 
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ANGPTL4
ANGPTL4, originally referred to as fasting-induced adipose factor, is a glycosylat-
ed protein that is highly expressed in liver and adipose tissue and to a lesser extent 
in heart, skeletal muscle, intestine, and several other tissues (7, 36, 37). Expression 
of ANGPTL4 is sensitively regulated by the fatty acid-activated peroxisome prolif-
erator-activated receptors (PPARs) (36, 38–40). Human and mouse genetic studies 
strongly support a role for ANGPTL4 in lipid metabolism via regulation of LPL ac-
tivity (3, 12, 41–45). The E40K gene variant has repeatedly been associated with 
decreased plasma triglyceride and increased HDL cholesterol levels (3, 41–43).  Ge-
nome-wide association studies have linked common variants near the ANGPTL4 gene 
to HDL cholesterol levels, but so far no studies have linked common ANGPTL4 gene 
variants to plasma triglyceride levels (14, 16). 
 The inhibitory effect of ANGPTL4 on LPL activity has been extensively doc-
umented in numerous in vivo and in vitro studies (5, 12). Several recent studies suggest 
that ANGPTL4 is the master regulator of plasma triglyceride metabolism during 
physiological conditions such as fasting, cold exposure and exercise (35, 37, 46). The 
data point to a scenario where ANGPTL4 is the central component of a feedback 
mechanism that regulates plasma triglyceride hydrolysis and subsequent tissue fatty 
acid uptake in response to changes in lipid availability and cellular fuel demand (35, 
37, 40, 46, 47). According to this mechanism, Angptl4 expression is induced by elevated 
plasma free fatty acid levels via PPARs, subsequently leading to inhibition of LPL and 
decreased plasma triglyceride-derived fatty acid uptake (40, 46). In WAT, induction of 
ANGPTL4 during fasting leads to repression of LPL activity, thereby preventing lipid 
storage and ensuring adequate provision of lipid fuels to other tissues (35). In skeletal 
muscle, ANGPTL4 is induced by exercise via elevated free fatty acids specif ically in the 
non-exercising muscle, leading to reduced local uptake of plasma triglyceride-derived 
fatty acids to spare for use by the exercising muscle (46). In exercising muscle, the 
free fatty acid-induced upregulation of ANGPTL4 is countered by AMPK-mediated 
downregulation, promoting the use of plasma triglycerides as fuel for active muscles 
(46). In BAT, ANGPTL4 is markedly suppressed by cold exposure via activation of 
AMPK, enhancing LPL activity and uptake of plasma triglyceride-derived fatty acids 
(37). By contrast, ANGPTL4 is induced by cold in WAT, thereby limiting LPL activ-
ity and prioritizing fuel provision to BAT to generate heat (37). In addition to being 
important for physiological regulation of plasma triglyceride metabolism, there is ev-
idence that ANGPTL4 is also implicated in certain clinical forms of hypertriglycer-
idemia. Specif ically, ANGPTL4 may mediate the hypertriglyceridemia of nephrotic 
syndrome (48) .
 Despite the strong genetic and experimental evidence for a key role of 
ANGPTL4 in plasma triglyceride metabolism, most studies have failed to f ind a sig-
nif icant correlation between plasma ANGPTL4 and plasma triglyceride levels (26, 27, 
49–53). This result is somewhat surprising but does not refute an important function 
of ANGPTL4 in human lipid metabolism. One possibility is that the lack of associa-
tion of plasma ANGPTL4 levels with plasma triglycerides is explained by the inability 
of the employed enzyme-linked immunosorbent assays (ELISAs) to detect N-terminal 
ANGPTL4 (53, 54). An alternative explanation is that circulating ANGPTL4 is not 
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exclusively responsible for regulation of LPL activity (47, 55, 56). Indeed, recent stud-
ies are suggestive of a model in which ANGPTL4 may regulate LPL intracellularly 
and in the sub-endothelial space rather than along the capillary lumen (55, 57, 58). 
Both circulating triglyceride-rich lipoproteins and glycosylphosphatidylinositol-an-
chored high density lipoprotein binding protein 1 (GPIHBP1)—the protein respon-
sible for translocation of LPL to the endothelial cell surface—prevent inhibition of 
LPL activity by ANGPTL4 (56, 59, 60). Further studies should elucidate the exact 
molecular mechanism and location of inhibition of LPL by ANGPTL4. 
 In contrast to the clear inhibition of LPL, ANGPTL4 has not been report-
ed to inhibit endothelial lipase, while the effects of ANGPTL4 on hepatic lipase 
have been contradictory (8, 12, 16). Remarkably, a recent study provided evidence 
that ANGPTL4 inhibits pancreatic lipase in the intestinal tract and suggested that 
ANGPTL4 acts as a gatekeeper in the regulation of intestinal lipid uptake to protect 
against enterocyte lipid overload (7). Expression of ANGPTL4 in the intestinal tract 
is sensitively stimulated by specif ic probiotic bacteria and short-chain fatty acids, 
while conventionalization of germ-free mice allegedly suppressed the expression of 
Angptl4 in the intestine (61–67). Exactly how the microbial community affects intesti-
nal Angptl4 expression and how changes in intestinal Angptl4 expression in turn affect 
intestinal lipid metabolism and the microbial community remains to be investigated. 
ANGPTL8
In 2012, three research groups independently identif ied ANGPTL8—also referred 
to as RIFL, lipasin and betatrophin—as a novel lipid-modulating member of the 
ANGPTL family with a high homology to ANGPTL4 and ANGPTL3 (4, 68, 69). 
ANGPTL8 has the characteristic N-terminal coiled-coil domain required for the in-
hibition of lipase activity but lacks the C-terminal f ibrinogen-like domain (4, 68, 69). 
In vitro, a clear dose-dependent inhibitory effect of recombinant ANGPTL8 on LPL 
activity was found (68). ANGPTL8 and ANGPTL3 likely have a shared origin, as both 
genes are located in introns of genes from the DOCK family (4, 68, 69). However, the 
tissue distribution of ANGPTL8 is more similar to ANGPTL4, with relatively high 
expression levels in liver and adipose tissue (4, 68, 69). In contrast to ANGPTL4, 
expression of Angptl8 in liver and adipose tissue is highest in the (re)fed state (4, 69).
 Similar to ANGPTL3 and ANGPTL4, ANGPTL8 was found to associate with 
plasma HDL cholesterol and triglyceride levels in a study that focused on low-frequen-
cy DNA sequence variants and rare alleles (3). In the Dallas Heart Study, the R59W 
gene variant was associated with reduced plasma LDL and HDL cholesterol levels 
but not triglycerides (4). Following these f indings, multiple studies have tried to link 
plasma ANGPTL8 levels to various lipid and metabolic parameters. So far, the results 
have been contradictory. One serious concern is that the specif icities of the ELISAs 
used to measure ANGPTL8 have been insuff iciently established, casting doubt on the 
validity of the data (70–75).  
 Several studies in mice have demonstrated a pronounced effect of ANGPTL8 
on LPL activity and plasma triglyceride levels, which is mainly evident in the fed 
state. Adenoviral-mediated overexpression of ANGPTL8 in liver signif icantly raised 
plasma triglyceride and free fatty acid levels (4, 68). Conversely, whole body knock-
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out of Angptl8 and antibody-mediated inactivation of ANGPTL8 in mice increased 
post-heparin LPL activity and lowered plasma triglyceride levels (76, 77). As brief ly 
noted previously, ANGPTL8 and ANGPTL3 likely cooperate to regulate plasma tri-
glyceride levels, which is largely based on the observation that adenoviral overexpres-
sion of ANGPTL8 increased plasma triglyceride levels in wild-type but not Angptl3-/- 
mice (4, 77). In line with a predominant role of ANGPTL8 in the fed state, loss of 
Angptl8 signif icantly lowered the increase in VLDL-derived triglyceride uptake in 
adipose tissue upon refeeding, suggesting that ANGPTL8 promotes the postprandial 
f lux of triglycerides into adipose tissue (77). Even though Angptl8 expression is much 
higher in adipose tissue than in heart and muscle, loss of Angptl8 or antibody-mediated 
inactivation of ANGPTL8 increased LPL activity in heart and muscle but not in WAT 
(4, 69, 76, 77). Another intriguing observation is that both feeding and cold exposure 
lead to a parallel increase in Angptl8 expression and LPL activity in WAT and BAT, 
respectively (4, 35, 37, 69, 78). These data suggest that ANGPTL8 serves to f ine-
tune LPL activity and may be unable to overcome the dominant inhibitory effect on 
LPL activity by ANGPTL4. Alternatively, ANGPTL8 may mainly have an endocrine 
function. In agreement with that notion, ANGPTL8 has been reported to circulate as 
part of high molecular weight complexes in the blood together with ANGPTL3 (4, 77). 
 Besides regulating triglyceride metabolism, ANGPTL8 has also been linked 
to pancreatic β-cell function. Specif ically, it was suggested that ANGPTL8 stimulates 
β-cell expansion, generating considerable excitement and turning ANGPTL8 into a 
promising therapeutic target for the treatment of diabetes (79). Several subsequent 
studies have failed to detect an effect of ANGPTL8 on glucose metabolism and/or 
β-cell expansion (77, 80–83). Indeed, faced with the overwhelming contradictory ev-
idence, the initial authors acknowledged that the consequences of Angptl8 deletion do 
not support the idea that ANGPTL8 is capable of inducing pancreatic β-cell prolifer-
ation (84).
INTEGRATED VIEW OF THE ROLE OF ANGPTL3, ANGPTL4 AND 
ANGPTL8 IN LIPID METABOLISM 
The recent literature leads to the emergence of a collective picture in which ANGPTL3, 
ANGPTL4 and ANGPTL8 together ensure that circulating triglycerides are ade-
quately distributed during different physiological conditions. Circulating ANGPTL3 
and ANGPTL8 together promote the replenishment of WAT in the fed state by in-
hibiting LPL activity and subsequent uptake of circulating triglycerides into oxidative 
tissues (4, 29, 77). Conversely, ANGPTL4 prevents uptake of plasma triglycerides into 
WAT and other tissues in the fasted state, while at the same time stimulating adipose 
tissue lipolysis, thereby favoring the use of free fatty acids as fuel (35, 85) (Figure 
1). During exercise and cold exposure, alterations in local expression of Angptl4 and 
concomitant changes in LPL activity ensure that muscle and BAT receive an adequate 
supply of triglycerides, ref lecting an overall role of ANGPTL4 to specif ically shut-
tle plasma triglycerides to the tissues in need (35, 37, 46). Whether ANGPTL3 and 
ANGPTL8 impact the distribution of plasma triglycerides during exercise and cold 
exposure remains an open question. Nevertheless, it is likely that LPL activity levels 
in different tissues and during different physiological conditions ref lect a balance 
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Figure 1: Hypothetical model of how angiopoietin-like 3 (ANGPTL3), angiopoietin-like 4 (ANGPTL4) and angio-
poietin-like 8 (ANGPTL8) may ensure the adequate distribution of circulating triglycerides during fasting and 
refeeding conditions. 
During fasting (left panel), the expression of  Angptl4 is increased in the white adipose tissue (WAT) to inhibit the activity of  
lipoprotein lipase (LPL) in WAT. This inhibition ensures that circulating triglycerides are hydrolyzed by LPL in muscle and 
heart and that the resultant fatty acids are subsequently taken up into heart and muscle. Upon refeeding (right panel), the 
expression of  Angptl4 is decreased in WAT, whereas the expression of  the circulating factor Angptl8 is increased in both liver 
and WAT. Together with circulating ANGPTL3, ANGPTL8 specifically inhibits the activity of  LPL in oxidative tissues such 
as heart and muscle. This inhibition permits for the hydrolysis of  circulating triglycerides by LPL in WAT and promotes the 
replenishment of  WAT depots upon refeeding.
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between the systemic effects of circulating ANGPTL3 and ANGPTL8 and the local 
effects of ANGPTL4. To what extent the f luctuations in LPL activity during different 
physiological conditions are primarily dictated by regulation of ANGPTLs or are also 
partially achieved via variation in the production of LPL-inhibiting or LPL-activating 
apolipoproteins such as APOCs, APOA5 or APOE, remains to be determined (86).
CONCLUSION
In conclusion, ANGPTL3, ANGPTL4 and ANGPTL8 play a crucial role in the regu-
lation of lipid metabolism. The signif icant effects of the ANGPTL proteins on plasma 
lipid levels in combination with the emerging genetic evidence indicating that elevat-
ed plasma triglyceride levels represent a causal risk factor for coronary heart disease 
have sparked interest of pharmaceutical companies in ANGPTLs as drug targets (87). 
Recently, a human monoclonal antibody (REGN1500) was demonstrated to potently 
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bind and inhibit ANGPTL3 in vivo, lowering plasma lipid levels in dyslipidemic mice 
and cynomolgous monkeys (22). Furthermore, a conjugated anti-sense oligonucleotide 
against ANGPTL3 from IONIS pharmaceuticals successfully lowered plasma triglyc-
eride levels in healthy individuals in phase I clinical trials and will be evaluated in a 
phase 1/2 clinical study (88). The position of ANGPTL4 as a pharmacological tar-
get remains uncertain, as loss of Angptl4 and treatment of mice with anti-ANGPTL4 
antibodies—despite effectively lowering plasma triglycerides—causes a pro-inf lam-
matory state characterized by the appearance of giant cells in enlarged mesenteric 
lymph nodes and progressive illness of the mice involving chylous ascites, cachexia 
and death (45, 89). The current status of ANGPTLs as therapeutic targets for dyslipi-
demia warrants further investigation into the biology of ANGPTL3, ANGPTL4, and 
ANGPTL8. An important outstanding question relates to the nature of the coopera-
tion between ANGPTL3 and ANGPTL8. In addition, the role of local versus systemic 
ANGPTL4 and ANGPTL8 in the regulation of extracellular lipase activity deserves 
further study. Resolving these questions and other questions postulated in this review 
would greatly benef it from the generation of double knock-out mice and tissue-specif-
ic knock-out mice of the three ANGPTLs. Together, these efforts should further elu-
cidate the specif ic role of ANGPTL3, ANGPTL4 and ANGPTL8 in lipid metabolism 
and provide a solid foundation for further clinical research on ANGPTL-targeting 
therapeutics as treatment for dyslipidemia. 
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ABSTRACT 
Triglyceride-rich chylomicrons and very-low density lipoproteins distribute fatty acids 
to various tissues by interacting with the enzyme lipoprotein lipase (LPL). The pro-
tein angiopoietin-like 4 (ANGPTL4) is under sensitive transcriptional control of fatty 
acids and the fatty acid-activated peroxisome proliferator activated receptors and its 
tissue expression largely overlaps with that of LPL. Growing evidence indicates that 
ANGPTL4 mediates the physiological f luctuations in LPL activity, including the de-
crease in adipose tissue LPL activity during fasting. This review focuses on the major 
ambiguities concerning the mechanism of LPL inhibition by ANGPTL4, as well as 
the physiological role of ANGPTL4 in lipid metabolism by highlighting its function in 
a variety of tissues, and uses this information to make suggestions for further research.
Regulation of lipoprotein lipase by ANGPTL4
37
3
REGULATION OF PLASMA TRIGLYCERIDE CLEARANCE  
Fatty acids (FA) are a principal fuel for numerous cell types and serve as substrate for 
energy storage in fat tissue. A major portion of FA taken up by cells is transported 
through the blood in the form of triglycerides (TG) as part of chylomicrons and very 
low-density lipoproteins (VLDL). Chylomicrons are formed from dietary TG and cho-
lesterol in enterocytes and reach the bloodstream after passing through the splanchnic 
lymphatic system. VLDL are assembled from TG synthesized in liver and are secreted 
directly into the blood. In the circulation, chylomicrons and VLDL distribute TG to 
various tissues such as heart, adipose tissue and skeletal muscle by interacting with the 
enzyme lipoprotein lipase (LPL), which catalyzes the hydrolysis of TG in the capillary 
bed (1). The resulting free fatty acids (FFA) are taken up by adipocytes and (cardio)
myocytes to be either stored or oxidized. In order to properly match uptake of plasma 
TG-derived FA to the needs of the underlying tissue, the activity of LPL is subject 
to multiple regulatory inf luences. A mismatch in regulation of TG uptake and usage 
by tissues can lead to cellular lipid overload and is an important feature of metabolic 
disorders such as obesity, diabetes type II and cardiovascular disease (2, 3). 
 Although LPL mRNA levels within a certain tissue do vary, the prevailing 
notion is that LPL activity is primarily governed via post-translational mechanisms. 
Three proteins that are able to inhibit LPL activity and thereby inf luence plasma TG 
values are angiopoietin-like 3 (ANGPTL3), angiopoietin-like 4 (ANGPTL4, FIAF), 
and angiopoietin-like 8 (ANGPTL8, betatrophin), all part of the family of angio-
poietin-like proteins. Overexpression of all three proteins profoundly increases plas-
ma TG levels in mice, whereas antibody-mediated inactivation or genetic deletion of 
these proteins lowers plasma TG levels (4–9). Interestingly, ANGPTL3, ANGPTL4 
and ANGPTL8 share a common structure yet differ in their tissue expression pattern 
and regulation by various stimuli. Whereas ANGPTL3 is mainly produced by the 
liver, the expression of ANGPTL4 and ANGPTL8 is more ubiquitous and is regu-
lated by stimuli such as fasting (10–12). Consequently, it has been suggested that the 
three angiopoietin-like proteins are important during different metabolic states. For 
example, whereas deletion of ANGPTL3 has more pronounced effects in the fed state, 
the effects of ANGPTL4 deletion are more evident in the fasted state (4). Likewise, the 
expression levels of ANGPTL4 and ANGPTL8 in adipose tissue show opposite changes 
in response to fasting (12). The interrelationship between ANGPTL3, ANGPTL4 and 
ANGPTL8 requires, however, further investigation. 
 Of the three angiopoietin-like proteins, ANGPTL4 has been the most ex-
tensively studied and is the subject of the present manuscript. Although a wealth of 
knowledge on ANGPTL4 has been collected since its discovery in 2000 (13–15), var-
ious aspects of its inhibitory action on LPL activity have remained unclear and/or 
are controversial. This review is aimed at highlighting the major ambiguities related 
to the mechanism of action of ANGPTL4 by reviewing the current knowledge on 
ANGPTL4 structure, cleavage and biochemical action, as well as the physiological 
role of ANGPTL4 in lipid metabolism, and uses this information to make suggestions 
for further research. The review will focus entirely on the role of ANGPTL4 in lipid 
metabolism, and will not discuss evidence linking ANGPTL4 to endothelial function, 
tumor biology, wound healing and the extra-cellular matrix (16). Complementary 
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background information on LPL can be found in Box 1, whereas an overview of the 
role of ANGPTL3 in lipid metabolism can be found elsewhere (17, 18).
BIOCHEMICAL ASPECTS OF ANGPTL4
Structure of ANGPTL4 
Similar to other family members, ANGPTL4 can be divided into distinct regions: 
a N-terminal signal peptide, a region containing two separate coiled-coil domains, 
a linker region and a large C-terminal f ibrinogen-like domain (19, 20). During evo-
lution, the C-terminal and N-terminal regions were present separately in different 
organisms, suggesting that the different domains of ANGPTL4 may have distinct 
physiological functions (20). In agreement with that notion, full-length ANGPTL4 
(f lANGPTL4, 50 kDa) is proteolytically cleaved by proprotein convertases (PCs) to 
yield an N-terminal (nANGPTL4) and a C-terminal (cANGPTL4) fragment. Com-
bined in vivo and in vitro data now indicate that only nANGPTL4 and f lANGPTL4 
inhibit LPL, whereas cANGPTL4 has entirely different biological functions and does 
not appear to play a role in lipid metabolism (17, 21–25). The inhibition of LPL by 
f lANGPTL4 and nANGPTL4 is mediated by a relatively short amino acid sequence 
close to the N-terminus (6, 21, 26).
 Several PCs including PACE4, furin, PC5/6, and PC7 are capable of cleaving 
ANGPTL4 at the PC recognition motif RRKR in vitro, but which enzyme is predom-
inantly responsible for proteolytic processing in vivo is unclear (19, 20, 23, 25). The 
proteolytic cleavage of f lANGPTL4 has been suggested to increase its functionality 
by stimulating release of ANGPTL4 from the cell surface (20).  Based on data from 
liver and adipose tissue, it can be hypothesized that ANGPTL4 is differentially pro-
cessed between tissues and even within a single tissue, presumably due to differential 
expression of PCs (20, 27, 28). 
 In vivo, both nANGPTL4 and f lANGPTL4 form high molecular weight struc-
tures (19, 23, 26), which is at least partially mediated by two disulf ide bond-forming 
cysteine residues in nANGPTL4 (25, 26). Mutations of these cysteine residues limit the 
extracellular accumulation of both nANGPTL4 and f lANGPTL4, thereby reducing 
LPL inhibition by ANGPTL4, possibly by destabilizing ANGPTL4 and rendering it 
a better substrate for degradation by proteases (23). Following cleavage, nANGPTL4 
remains oligomerized, whereas cANGPTL4 dissociates into monomers (19) and this 
oligomerization is required for the inhibition of LPL activity by ANGPTL4 (26). 
Whether ANGPTL4 oligomerizes inside the cell or late in the secretory pathway on 
the cellular surface and whether this process is chaperoned by another yet unidenti-
f ied protein remains debatable (23, 29, 30). 
 One of the key questions is whether (patho)physiological variations in LPL 
activity are mediated via regulation of ANGPTL4 cleavage and/or oligomerization 
and which factors are involved in modulating ANGPTL4 in vivo. Recent biochemical 
evidence suggests that FA may be able to promote dissociation of oligomers, which by 
destabilizing the protein would impair its ability to inhibit LPL (29). Destabilization 
of ANGPTL4 by FA is, however, seemingly at odds with the marked stimulatory effect 
of FA on ANGPTL4 production observed in vitro and in vivo (31–35).
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BOX 1:  LIPOPROTEIN LIPASE & TRIGLYCERIDE METABOLISM 
LPL belongs to a family of lipases that also includes hepatic lipase, pancreatic lipase 
and endothelial lipase. Since LPL is essential in the lipolytic processing of chylo-
microns and VLDL, LPL is primarily expressed in tissues that either require large 
amounts of FA as fuel or are responsible for TG storage, including heart, skeletal mus-
cle and adipose tissue. Upon production by the underlying parenchymal cells, LPL is 
released into the subendothelial space and transported to the luminal side of the cap-
illary endothelium by the protein GPIHBP1 (glycosylphosphatidylinositol-anchored 
high density lipoprotein-binding protein), which after transport continues to anchor 
LPL to the capillary endothelium (39, 40). The essential role for LPL in the clearance 
of plasma TG is well-demonstrated by the severe hypertriglyceridemia of patients 
carrying homozygous mutations in the LPL gene (2). Similarly, the generalized dele-
tion of LPL in mice results in severe hypertriglyceridemia, resulting in the premature 
death of pups within 24 hours after birth (93). Analogous to the deletion of LPL, the 
mislocalization of LPL to the subendothelial spaces due the absence or misfolding of 
GPIHBP1 also results in severe chylomicronemia and hypertriglyceridemia (39, 40).
 The LPL enzyme is catalytically active as a non-covalent head-to-tail dim-
er with a catalytic amino-terminal domain and a non-catalytic carboxyl-terminal 
domain (94, 95). Folding of LPL into its dimer conformation occurs in the endoplas-
mic reticulum, chaperoned by lipase maturation factor 1, calreticulin and calnexin 
(96–98). In its active three-dimensional conformation, the catalytic site of LPL is 
postulated to be covered by a lid, which can be opened by the binding of chylomicrons 
and VLDL to the carboxyl-terminus (95). The active LPL dimers rapidly exchange 
subunits, indicating that a dynamic equilibrium exists between LPL dimers and di-
merization-competent monomers. Dimerization-competent monomers have, however, 
not yet been isolated and it is unclear whether this monomer is catalytically active (2, 
24, 94). The enzymatic activity of LPL is lost when the LPL dimer is converted into in-
active, folded monomers (94). This conversion to inactive monomers is mainly regulat-
ed via post-translational mechanisms and is dependent on nutritional state (99–101). 
Enzymatic activity of inactive monomers can be regained in vitro by the addition of 
calcium, which indicates that inactivation of LPL is a reversible process (102).
LPL inhibition by ANGPTL4
Multiple studies, both in vitro and in vivo, have now convincingly shown that ANGPTL4 
inhibits LPL activity (4, 5, 17, 21–24, 26, 36). Indeed, overexpression of Angptl4 as 
well as injection of recombinant ANGPTL4 signif icantly increase plasma TG levels, 
in concert with a decrease in post-heparin plasma and tissue LPL activity, in mice 
(4, 5, 22, 36). Conversely, the complete knockout of Angptl4 results in pronounced 
hypotriglyceridemia with a concomitant elevated tissue LPL activity and post-hep-
arin plasma LPL activity (4). The exact mechanism by which ANGPTL4 inhibits 
LPL is, however, still debated. In many tissues, including heart, skeletal muscle and 
adipose tissue, ANGPTL4 is co-expressed and produced in the same cell with LPL 
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(11), raising the possibility for direct interaction between the two proteins inside the 
cell and/or upon secretion into the subendothelial space. According to that scenario, 
ANGPTL4 may inactivate LPL before it reaches the endothelial surface. In support 
of this notion, it was found that ANGPTL4 and LPL co-localize inside the cell when 
overexpressed in cultured muscle cells (31). A recent study indicates, however, that in 
3T3-L1 adipocytes inactivation of LPL by ANGPTL4 occurs after both proteins have 
arrived at the cell surface, suggesting that inhibition of LPL activity by ANGPTL4 
takes place in the subendothelial space or at the endothelium (37). Interestingly, in-
travenous injection of ANGPTL4 as well as overexpression of Angptl4 in liver in mice, 
a tissue that does not produce LPL, raises plasma TG levels and lowers post-heparin 
plasma LPL activity (4), clearly indicating that the inhibitory action of ANGPTL4 on 
LPL is not limited to the subendothelial space. Currently, the full scope of interaction, 
location of interaction and possible co-secretion of ANGPTL4 and LPL is unclear 
and requires further investigation, possibly by employing novel methodologies such 
as Fluorescence Resonance Energy Transfer (FRET) and Proximity Ligation Assay. 
 The currently accepted molecular model for the inhibition of LPL by 
ANGPTL4 is that ANGPTL4 stimulates the conversion of catalytically active LPL 
dimers into inactive monomers, following in vitro studies showing that coincubation 
of LPL and ANGPTL4 increase the abundance of LPL monomers (21, 24). Subse-
quent studies revealed that the proportion of LPL dimers is reduced in post-heparin 
plasma of mice that overexpress Angptl4 in favor of LPL monomers, providing in vivo 
support for the dimer to monomer conversion (22). The elucidation of the purported 
biochemical mechanism has strengthened the status of ANGPTL4 as LPL inhibitor, 
yet several questions related to the in vivo mechanism remain unanswered. Whereas 
the original in vitro experiments favored the hypothesis that ANGPTL4 enzymatically 
and irreversibly catalyzes the LPL dimer-to-monomer conversion (21, 24), an in vivo 
study of Angptl4 transgenic mice suggested that ANGPTL4 is physically bound to LPL 
monomers, thereby driving the LPL dimer-monomer equilibrium towards inactive 
monomers (22). The latter study also revealed that the relative decrease in post-hepa-
rin plasma LPL activity upon Angptl4 overexpression is much more pronounced than 
the relative decrease in heparin-releasable LPL dimers, pointing to an additional 
or alternative mechanism (22). In support, a recently published study suggests that 
ANGPTL4, instead of acting as a catalyst, functions as a conventional, non-compet-
itive inhibitor that binds to LPL to prevent the hydrolysis of substrate (38). Evidence 
was provided indicating that inhibition of LPL by ANGPTL4 is of a reversible nature 
that may not necessarily require a dimer-to-monomer conversion, even though the 
exact mechanism of inhibition remains to be determined (38).  Altogether, the avail-
able data suggests that the in vivo mechanism of action of ANGPTL4 is perhaps more 
complex that currently envisaged and requires further study.
 One complicating factor in vivo is glycosylphosphatidylinositol-anchored high 
density lipoprotein binding protein 1 (GPIHBP1), a small glycoprotein required for 
the lipolytic processing of TG-rich lipoproteins. GPIHBP1 is responsible for trans-en-
dothelial transport of LPL from the underlying parenchymal cells towards the capil-
lary lumen and has a high binding aff inity for LPL (39–41). It has been demonstrated 
that the inhibitory action of ANGPTL4 on LPL in vitro is diminished when LPL is 
bound by GPIHBP1, which may be mediated by stabilization of LPL in the active 
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dimer conformation or, alternatively, by competition of ANGPTL4 and GPIHBP1 
for binding to LPL (42). One possible scenario is that by binding LPL in the suben-
dothelial space, GPIHBP1 displaces ANGPTL4 from LPL, thereby neutralizing its 
inhibitory action. Such an action of ANGPTL4 in the subendothelial space has been 
previously proposed by Nilsson and colleagues (43). Since f lANGPTL4 binds the ex-
tracellular matrix (ECM) through interactions with heparan and dermatan sulfate 
chains as well as with f ibronectin and vitronectin (25, 44, 45), it is conceivable that by 
physically interacting with LPL, ANGPTL4 retains LPL in the subendothelial space 
bound to the ECM. Intriguingly, Sonnenburg and colleagues observed that knockout 
of Angptl4 almost completely abolished the severe hypertriglyceridemia in Gpihbp1-/- 
mice, indicating that in the absence of Gpihbp1 the loss of Angptl4 allows substantial 
amounts of LPL to reach the endothelial surface and catalyze TG hydrolysis (42). This 
indicates that there may be another transport mechanism for LPL to the endothelial 
surface, which is suppressed by ANGPTL4. Such a mechanism is also compatible 
with reversible non-competitive inhibition of LPL by ANGPTL4, as proposed by Laf-
ferty and colleagues (38). In summary (see Figure 1), we postulate that GBIHBP1 and 
ANGPTL4 compete for binding to LPL, with ANGPTL4 trying to keep LPL in the 
subendothelial space via its binding to the ECM, and GPIHBP1 opposing that action 
by drawing LPL across the endothelium. To further elucidate possible interactions 
between GPIHBP1, ANGPTL4 and LPL, immunof luorescence co-localization stud-
ies on human or mouse tissues should be performed. Further characterization of the 
molecular mechanism of action of ANGPTL4 would also benef it immensely from elu-
cidation of the molecular structure of LPL and ANGPTL4 via X-ray crystallography. 
Despite considerable effort, no structures are available for either protein as yet.
ROLE OF ANGPTL4 IN PHYSIOLOGICAL REGULATION OF LIPID METAB-
OLISM
LPL and ANGPTL4 are regulated by changes in nutritional state in a tissue-specif ic 
manner, ref lecting the different functions of these tissues and their corresponding 
differences in physiological requirements for lipids (13, 14, 46). Below, we discuss 
current knowledge on the regulation of ANGPTL4 and LPL in response to various 
physiological stimuli and address the importance of ANGPTL4 in lipid uptake. An 
overview of the role of ANGPTL4 in physiological regulation of lipid metabolism is 
presented in Figure 2. 
White Adipose Tissue 
White adipose tissue (WAT) continuously shifts between net storage of FA in the fed 
state, and net release of FA after fasting, which is mediated via f luctuations in intra-
vascular and intracellular lipolysis (2). In contrast to the marked oscillations in LPL 
activity, WAT LPL mRNA and protein mass vary only slightly, suggesting that the 
activity of LPL in WAT is primarily regulated at the post-translational level (47). Re-
cent studies have indicated that the decrease in adipose LPL activity during fasting 
is mediated by induction of Angptl4 (47, 48). In contrast to wild-type mice, mice lack-
ing Angptl4 do not show any decrease in WAT LPL activity during fasting and have 
almost undetectable plasma TG levels, whereas mice overexpressing Angptl4 in WAT 
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and other tissues exhibit reduced uptake of plasma TG-derived FA into adipose tissue 
and elevated plasma TG levels (22, 47). Whether Angptl4 expressed in WAT primarily 
functions locally or also has systemic effects has yet to be resolved. 
 Induction of WAT Angptl4 expression during fasting is probably mediated via 
multiple transcriptional mechanisms. As FAs serve as peroxisome proliferator-acti-
vated receptor gamma (PPARγ) agonists and are potent activators of ANGPTL4 gene 
expression in adipocytes, the increased plasma FFA levels during fasting may stim-
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Figure 1: Hypothetical model for mechanisms of LPL inhibition by ANGPTL4. 
Angiopoietin-like 4 (ANGPTL4) and lipoprotein lipase (LPL) are expressed in the parenchymal cells of  muscle, heart and 
adipose tissue. Following secretion of  LPL and ANGPTL4 into the subendothelial space, transport of  LPL to the capillary 
lumen is mediated by two mechanisms. The principal transport mechanism (a) relies on GPIHBP1 (glycosylphosphatidylin-
ositol-anchored high density lipoprotein-binding protein) picking up LPL from the subendothelial space and transporting it 
to the capillary lumen. This action by GPIHBP1 is opposed by ANGPTL4, which is bound to extracellular matrix proteins 
and retains and inhibits LPL. In the presence of  GPIHBP1, high expression levels of  ANGPTL4 are needed to overcome 
the competition with GPIHBP1. ANGPTL4 secreted into the capillary lumen, primarily as N-terminal truncation frag-
ment generated by cleavage by proprotein convertases (PCs), inhibits LPL activity on the endothelium by promoting the 
irreversible conversion of  LPL dimers into inactive monomers and/or via a reversible mechanism that requires binding 
of  ANGPTL4 to LPL. The second transport mechanism (b) involves a yet unidentified carrier and can be disrupted by 
ANGPTL4. In the absence of  GPIHBP1, ANGPTL4 fully retains LPL in the subendothelial space. The additional loss of  
ANGPTL4 liberates LPL and allows it to be transported to the endothelial surface via the unidentified carrier. This model 
suggests that ANGPTL4 and LPL start interacting before arrival in the capillary lumen, either in the parenchymal cells or 
in the subendothelial space.
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ulate transcription of ANGPTL4 via activation of PPARγ (34, 35). Also, the reduc-
tion in plasma insulin levels may relieve the suppressive effect of insulin on adipose 
ANGPTL4 mRNA (49). Finally, elevated levels of plasma glucocorticoids may stimu-
late ANGPTL4 transcription via the Glucocorticoid Receptor (GR) (28). Interestingly, 
ANGPTL4 has also been linked to the stimulation of lipolysis in adipocytes during 
fasting (5, 50–52). The combined action of stimulating intracellular lipolysis and in-
hibiting LPL-mediated lipolysis points to a key role of ANGPTL4 in promoting fat 
liberation and reducing fat storage.
Liver 
The liver lies at the crossroad of TG metabolism as it actively takes up lipids associ-
ated with remnant particles as well as FFA originating from adipose tissue lipolysis, 
while secreting TG-rich VLDL into the blood. The TG-containing remnant particles 
are not metabolized by LPL, which is expressed very weakly in liver, but are taken 
up via receptor-mediated endocytosis after some of its lipid cargo is hydrolyzed by 
hepatic lipase. Whereas LPL expression is low, ANGPTL4 mRNA levels are high in 
liver (13). Studies using mice that specif ically overexpress Angptl4 in liver revealed 
that liver-derived ANGPTL4 is capable of inhibiting LPL in peripheral tissues (4, 27). 
Thus, whereas ANGPTL4 produced in adipose tissue, heart and skeletal muscle may 
primarily target local lipid uptake, liver-derived ANGPTL4 likely serves as an endo-
crine factor. The implication of an endocrine role of ANGPTL4 is that any regulation 
of hepatic Angptl4 expression presumably impacts LPL activity universally and not 
selectively targets plasma TG clearance in certain tissues. Whether liver-expressed 
ANGPTL4 may have an inhibitory effect on hepatic lipase remains controversial, as 
divergent results have been obtained (4, 22). 
 The regulation of ANGPTL4 in liver has not yet been extensively studied, but 
no profound changes in hepatic Angptl4 expression have been observed on either a 
high fat diet (13) or during chronic intermittent hypoxia (53). Similar to WAT, how-
ever, Angptl4 expression in liver is rapidly increased during fasting (13, 54). Currently, 
the physiological relevance of the induction of liver Angptl4 during fasting is not fully 
clear, but it can be envisaged that secreted ANGPTL4 may suppress LPL activity 
in peripheral tissues to favor tissue uptake of plasma FFA at the expense of plasma 
TG-derived FA, which would save energy by circumventing hepatic re-synthesis of 
TG from plasma FFA. Whereas PPARα is a key determinant of basal Angptl4 expres-
sion in liver, the up-regulation of Angptl4 in liver during fasting is mediated inde-
pendently of PPARα via activation of GR by circulating glucocorticoids, activation of 
PPARδ by plasma FFA, and/or the drop in plasma insulin levels during fasting (27, 
28, 52, 55). 
Heart
The energy requirements of the heart are primarily met by oxidation of FA, with the 
remainder of the energy coming from glucose and lactate. Most of these FA are de-
rived from LPL-dependent hydrolysis of circulating TG (56). Whereas an insuff icient 
FA supply may impair cardiac function, excessive uptake of FA may result in lipid 
overload and lipotoxicity of the heart (57). Hence, it is imperative that the activity of 
LPL in heart is carefully regulated. As opposed to WAT, a high proportion of LPL in 
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Figure 2: Regulation and role of ANGPTL4 in lipid metabolism. 
Angiopoietin-like 4 (ANGPTL4) is expressed in parenchymal cells of  white adipose tissue (WAT), liver, heart and muscle, as 
well as in macrophages, where it is subject to cell- and tissue-specific regulation. ANGPTL4 is a sensitive target of  peroxi-
some proliferator-activated receptor (PPAR) transcription factors in several tissues. In WAT, the expression of  ANGPTL4 is 
induced during fasting and by the transcription factors PPARγ, glucocorticoid receptor (GR) and hypoxia-inducible factor 
1α (HIF1α). In WAT, ANGPTL4 stimulates lipolysis of  stored triglycerides and inhibits lipoprotein lipase (LPL) activity. Ex-
pression of  ANGPTL4 in liver is stimulated by PPARα, PPARδ and GR. Since the liver does not express LPL, ANGPTL4 is 
mainly released into the blood, affecting LPL activity in peripheral tissues. ANGPTL4 may also impact hepatic lipase activity 
in liver. Expression of  ANGPTL4 in heart and skeletal muscle is potently induced by fatty acids via PPARδ activation. Car-
Regulation of lipoprotein lipase by ANGPTL4
45
3
the heart is present intracellularly, with the result that changes in total tissue LPL ac-
tivity mostly ref lect changes in total LPL mass rather than functional LPL. A role for 
ANGPTL4 in the regulation of LPL activity in heart was demonstrated in mice with 
cardiac-specif ic overexpression of Angptl4. These mice exhibit reduced heparin-re-
leasable LPL activity in the heart and elevated circulating TG levels (57). Similarly, 
following an oral fat load, transgenic mice that overexpress Angptl4 in various tis-
sues including heart had markedly lower cardiac FA uptake from [3H]triolein-labeled 
VLDL-like particles compared to wild-type mice (32). The expression of Angptl4 in 
heart is induced by dietary FA via the transcription factor PPARδ as part of a possible 
feedback mechanism aimed at protecting the heart against lipid overload and thereby 
averting FA-induced toxicity (31, 32, 58). Interestingly, both Angptl4 expression and 
heparin-releasable LPL activity are increased by fasting in the heart, concomitant 
with enhanced uptake of plasma TG-derived FA (22, 59, 60). These data suggest 
that a factor different from ANGPTL4 is responsible for the increase in cardiac LPL 
activity during fasting. The increase in Angptl4 expression may serve to limit the in-
crease in LPL activity during fasting in order to prevent lipid overload that may be 
driven by elevated plasma FFA levels (60). Detailed study of cardiac heparin-releas-
able LPL activity in Angptl4 knockout mice during fasting and refeeding is expected 
to further clarify the mechanism responsible for up-regulation of LPL activity during 
fasting.  
Skeletal Muscle
A key feature of the skeletal muscle is its metabolic f lexibility, enabling the muscle 
to employ a variety of carbohydrate and lipid fuels. Important sources of energy for 
skeletal muscle are FA derived from plasma FFA and circulating TG-rich lipoproteins 
(56, 61). Expression of ANGPTL4 in muscle is markedly increased during fasting in 
mouse and humans, probably via elevation of plasma FFA levels (22, 62). Similar to 
heart, induction of ANGPTL4 expression is likely regulated via the PPARδ/RXR axis, 
as agonists for both PPARδ and RXR enhance ANGPTL4 mRNA levels in cultured 
myocytes, concomitant with a reduction in secreted LPL activity (31, 63). In as much 
as there is no evidence that functional LPL activity in muscle is altered by fasting, 
the functional implications of the fasting-induced increase in ANGPTL4 expression 
remain unclear (64–67). Besides fasting, a primary modulator of LPL activity in skel-
etal muscle is exercise. Both acute exercise and chronic exercise training markedly 
induce LPL activity, at least partly via changes in LPL mRNA and protein expression 
(68, 69). A role of ANGPTL4 in modulation of LPL activity in muscle during exercise 
is likely but remains unsubstantiated. Existing data indicate that exercise increases 
diac and likely skeletal muscle LPL activities are inhibited by ANGPTL4. Fatty acids also stimulate ANGPTL4 expression in 
macrophages via PPARδ, leading to local inhibition of  LPL activity. We hypothesize that macrophage LPL enables uptake of  
remnant particles containing lipid antigens, which are subsequently presented to Natural Killer T cells. In the intestine, fatty 
acids stimulate ANGPTL4 expression via one of  the PPARs. ANGPTL4 produced by enterocytes may be released towards 
the lumen and inhibit pancreatic lipase activity. ANGPTL4 produced by enteroendocrine cells is released towards the blood 
and may inhibit LPL in distant tissues.
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plasma ANGPTL4 levels in humans, an elevation that was entirely abolished when 
subjects were given oral glucose, which suppresses plasma FFA levels (35). 
Intestine 
ANGPTL4 is relatively well expressed in the intestine and is upregulated upon high-
fat feeding (70). In contrast, LPL is only weakly expressed in the intestine and is not 
known to play a role in intestinal lipid metabolism. Accordingly, it is possible that 
intestinal ANGPTL4 may serve an endocrine function by inhibiting LPL in distant 
tissues (71). Alternatively, ANGPTL4 may target another lipase in the small intes-
tine. Indeed,  ANGPTL4 was recently proposed to inhibit pancreatic lipase, a fam-
ily member of LPL, thereby reducing fat absorption (70). Pancreatic lipase is not 
known to form a dimer, excluding a mechanism involving dimer dissociation. In-
stead, ANGPTL4 may reversibly inhibit pancreatic lipase by forming an inhibitory 
complex, in analogy with a mechanism that was recently postulated for LPL (38). 
ANGPTL4 has received considerable attention in connection with the gut microbiota. 
Intestinal ANGPTL4 expression was found to be markedly reduced in germ-free mice 
compared to conventionally raised mice and upon conventionalization of germ-free 
mice or zebra f ish (72–75). Evidence was provided that suppression of ANGPTL4 
accounts for enhanced fat gain upon conventionalization via increased adipose tissue 
LPL activity (72). However, a direct link between intestinal-derived ANGPTL4 and 
adipose LPL activity has not been established (73). In apparent conf lict with reduced 
ANGPTL4 expression following conventionalization, multiple bacterial strains stim-
ulate ANGPTL4 expression in colonic cell lines (76, 77). Likewise, recent data show 
that the microbial metabolites propionate and butyrate but not acetate potently in-
duce ANGPTL4 expression in intestinal cells (71, 78).  A possible explanation is that 
regulation of intestinal ANGPTL4 in vivo depends on gut microbiota composition, 
which together with substrate provision determines the mixture of microbial metab-
olites formed. Whereas colonization of germ-free mice with Bacteroides thetaiotaomi-
cron or Methanobrevibacter smithii, which produce acetate and methane, respectively, 
reduces intestinal ANGPTL4 expression, colonization with Clostridium tyrobutyricum, 
a butyrate-producing bacteria, markedly elevated intestinal ANGPTL4 expression 
(78, 79).  Hence, the ability of gut microbial strains to produce butyrate may be a key 
determinant of induction of intestinal ANGPTL4. Altogether, intestinal ANGPTL4 
expression is modulated by the gut microbiota via generation of specif ic fermentation 
products, including butyrate. It can be speculated that induction of ANGPTL4 may 
play a role in mediating effect of dietary f ibers on a number of parameters, including 
plasma lipoproteins and lipid absorption.
Macrophages
Expression of ANGPTL4 in macrophages is relatively high and stimulated by FA 
and PPAR agonists, likely via PPARδ (30, 80). Similar to muscle, WAT and heart, 
macrophages are capable of hydrolyzing TG-rich lipoproteins via a LPL-dependent 
mechanism, but unlike the other organs macrophages can also take up the resultant 
TG-depleted and cholesterol-enriched remnant molecules (81). The reason for the 
expression of LPL by macrophages and not by other leukocytes is puzzling, but it has 
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been suggested that TG-derived FA serve as an important fuel for macrophages dur-
ing low glucose availability and during periods of intense metabolic activity such as 
phagocytosis (82). However, except in the subscapular sinus of the mesenteric lymph 
nodes, tissue macrophages may hardly get in contact with circulating TG-rich lipo-
proteins, as they cannot easily cross the endothelium. 
 Macrophages have been extensively studied for their role in foam cell forma-
tion in the vascular wall and associated atherogenesis. Consistent with the well-es-
tablished pro-atherogenic effect of LPL (83), ANGPTL4 was found to protect against 
atherosclerotic plague development in mice (80). Specif ically, in vivo overexpression of 
Angptl4 signif icantly reduced lesion size and area in atherosclerosis-prone ApoE3-Lei-
den transgenic mice, while addition of recombinant ANGPTL4 in vitro limited the 
uptake of VLDL and oxidized LDL by macrophages (80). Intriguingly, reduced ath-
erosclerosis was observed in Angptl4 knockout mice on a ApoE background, which was 
likely due to a decrease in circulating LDL-C and TG levels and probably unrelated 
to a direct effect of ANGPTL4 on foam cell formation (84). 
 Theoretically, foam cell formation may occur whenever macrophages take 
up excess lipid. A unique location where macrophages are exposed to extremely high 
concentrations of TG-rich lipoproteins is the subscapular sinus of the mesenteric 
lymph nodes, which are part of the drainage route for freshly synthesized chylomi-
crons. It was shown that ANGPTL4 inhibits lipid uptake by macrophages present in 
the mesenteric lymph nodes (85). In the absence of Angptl4, feeding mice a diet high 
in saturated fat causes a complex and ultimately lethal phenotype originating from 
excess chylomicron-derived lipid uptake by mesenteric lymph node macrophages (85). 
These f indings have led to the proposition that macrophages in mesenteric lymph 
nodes and elsewhere survey the chyle for so-called lipid antigens via LPL-mediat-
ed lipolysis. Lipid antigens encompass a broad scope of lipids carried by pathogenic 
microbes and gut microbiota, which are presented to Natural Killer T-cells (NKT 
cells) by antigen presenting macrophages and dendritic cells. The purported role of 
macrophage ANGPTL4 is to control LPL activity and to balance the need to sample 
chylomicrons for lipid antigens yet prevent excessive lipid uptake, especially when 
chylomicron levels are elevated. Additional studies are clearly needed to validate this 
model but for now it provides a reasonable explanation for the coexpression of LPL 
and ANGPTL4 by macrophages. 
Physiological role of LPL inhibition by ANGPTL4 
From the available data on ANGPTL4 in different tissues, several common de-
nominators are apparent, allowing for construction of a more integrative picture 
of ANGPTL4 function (Figure 2). The present view on the physiological role of 
ANGPTL4 may perhaps be best described as ensuring the proper distribution of plas-
ma TG over various tissues during different nutritional states, which requires on the 
one hand that FA are taken up by tissues for rapid oxidation or are effectively stored 
for later use, and on the other hand that excess lipid uptake is avoided and cellular 
lipotoxicity is averted. ANGPTL4 executes this function by being the primary physi-
ological regulator of LPL activity.
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CLINICAL PERSPECTIVES OF ANGPTL4
In support of the mice studies, genetic studies have provided support for a similar 
function of ANGPTL4 in humans. Specif ically, a genetic loss-of-function variant of 
ANGPTL4 (E40K) that is found in 3% of European Americans is associated with 
reduced plasma TG levels (86). Remarkably, none of the genome wide association 
studies performed so far has linked SNPs in or near the ANGPTL4 gene to plasma 
TG levels. Likewise, so far no positive correlation has been found between plasma 
ANGPTL4 and plasma TG levels (35, 87–90). A possible explanation for the lack 
of correlation between plasma ANGPTL4 and TG levels may be the inability of the 
employed enzyme-linked immunosorbent assays (ELISAs) to detect nANGPTL4, 
the cleavage form that potently inhibits LPL activity (88). It has been shown that 
the ELISA used in all studies published so far exclusively detects f lANGPTL4 and 
cANGPTL4 (88, 91). Hence, further studies utilizing newly developed ELISAs that 
specif ically recognize nANGPTL4 and/or f lANGPTL4 should help to clarify the 
relation between plasma ANGPTL4 and plasma TG levels. Alternatively, it is possible 
that ANGPTL4 in blood may not represent fully functional ANGPTL4, meaning that 
plasma ANGPTL4 concentrations may not ref lect the ANGPTL4 level in the vicinity 
of LPL, as proposed in this paper (43). 
 Since elevated plasma TGs are considered a (minor) risk factor for athero-
sclerosis, ANGPTL4 has been extensively scrutinized as a putative therapeutic target 
for cardiovascular disease. It appears, however, that the progressive development of 
a severe clinical phenotype in mice lacking Angptl4 and in mice injected with an-
ti-ANGPTL4 antibodies has led  to permanent dismissal of ANGPTL4 as pharmaco-
logical target (85, 7). Besides being a potential therapeutic target, plasma ANGPTL4 
levels could perhaps also serve as biomarker for a specif ic disease. Currently, the po-
tential of ANGPTL4 as biomarker has mainly been examined in the context of cancer 
and to a lesser extent in the context of lipid-related diseases. In contrast to the lack 
of correlation between plasma TG and plasma ANGPTL4 levels, clear associations 
have been found between plasma ANGPTL4 levels and plasma FFA levels in humans 
in the fasted state (88, 89, 92). Likewise, obese subjects generally have higher levels 
of plasma ANGPTL4 (87, 92). The scarcity and inconsistency of the available data 
render it diff icult to attach a clear value to plasma ANGPTL4 levels in the context of 
lipid-related disorders and studies with ELISAs specif ically detecting one of the three 
(truncated) forms of the ANGPTL4 protein are necessary. An interesting observation 
with the current ELISA is that a very small fraction of the subjects studied have plas-
ma ANGPTL4 levels that far exceed the average level (up to ~50 fold) without having 
any other metabolic abnormalities. 
CONCLUDING REMARKS & FUTURE PERSPECTIVES
In the past decade, angiopoietin-like proteins have been demonstrated to powerfully 
regulate plasma TG levels in mice and humans. The elucidation of these proteins as 
inhibitors of LPL activity has led to a paradigm shift of how clearance of circulating 
TG and thereby tissue uptake of FA is regulated. Most of our understanding on angi-
opoietin-like proteins has resulted from detailed study of ANGPTL4. From the data 
described in this review, it is becoming increasingly clear that a major portion of the 
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BOX 2: OUTSTANDING QUESTIONS
• What is the importance of ANGPTL4 cleavage and oligomerization for 
ANGPTL4 function in vivo?
• What is the precise biochemical mechanism behind the inhibition of LPL ac-
tivity by ANGPTL4?
• At which cellular location(s) does the inhibition of LPL by ANGPTL4 occur 
and, if at multiple locations, what is the relative contribution of both tissue-pro-
duced ANGPTL4 compared to circulating ANGPTL4 with respect to inhibi-
tion of tissue LPL activity. 
• What is the interplay between GPIHBP1 and ANGPTL4 in the regulation of 
LPL activity?
physiological variation in LPL activity in various tissues can be attributed to regula-
tion of ANGPTL4 production. We predict that ANGPTL4 will turn out to be equally 
important for governing LPL activity in muscle during exercise, in brown adipose 
tissue during cold, and in a number of tissues during fasting. Whether an additional 
layer of regulation is conferred by tissue-specif ic cleavage of the ANGPTL4 protein 
and/or formation of oligomers remains to be determined.
 Besides the increasing recognition of the pivotal role of ANGPTL4 in lipid 
metabol ism as an inhibitor of LPL, major insight has been gained into the molecular 
mechanism of action of ANGPTL4 over the past years. Key questions remain, how-
ever, especially related to the interaction between LPL, GPIHBP1 and ANGPTL4 on 
the endothelium and in the subendothelial space. Several other points of interest have 
been highlighted throughout the text and include the elucidation of the molecular 
structure for LPL and ANGPTL4 by X-ray crystallography and the clarif ication of in 
vivo ANGPTL4 cleavage and oligomerization (for an overview see Box 2: Outstand-
ing Questions). A f inal subject that needs to be addressed more extensively is the in-
terrelationship between ANGPTL4, ANGPTL3 and ANGPTL8, which all have the 
capacity to inhibit LPL in vivo and modulate plasma TG levels. Overall, it is fascinat-
ing to witness how a small set of proteins, principally GPIHBP1 and ANGPTL4, have 
reinvigorated the LPL f ield over the past years, more than f ive decades after LPL was 
f irst identif ied as the clearing factor lipase. Let us hope that an equally fruitful time 
is lying ahead of us.
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ABSTRACT 
Brown adipose tissue (BAT) activation via cold exposure is increasingly scrutinized 
as a potential approach to ameliorate cardio-metabolic risk. Transition to cold tem-
peratures requires changes in the partitioning of energy substrates, re-routing fatty 
acids to BAT to fuel non-shivering thermogenesis. However, the mechanisms behind 
the redistribution of energy substrates to BAT remain largely unknown. Angiopoi-
etin-like 4 (ANGPTL4), a protein that inhibits lipoprotein lipase (LPL) activity, is 
highly expressed in BAT. Here, we demonstrate that ANGPTL4 is part of a shuttling 
mechanism that directs fatty acids derived from circulating triglyceride-rich lipo-
proteins to BAT during cold. Specif ically, we show that cold markedly down-reg-
ulates ANGPTL4 in BAT, likely via activation of AMPK, enhancing LPL activity 
and uptake of plasma triglyceride-derived fatty acids. In contrast, cold up-regulates 
ANGPTL4 in WAT, abolishing a cold-induced increase in LPL activity. Together, our 
data indicate that ANGPTL4 is an important regulator of plasma lipid partitioning 
during sustained cold.
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INTRODUCTION
Adipose tissue can be classif ied into white adipose tissue (WAT) and brown adipose 
tissue (BAT). Whereas WAT represents the main energy storage organ in the body, 
BAT is dedicated to the generation of heat via the burning of lipids. BAT is activated 
during cold exposure, when additional heat production is needed to maintain core 
body temperature. Heat production by BAT is stimulated via release of norepineph-
rine by the sympathetic nervous system, causing activation of β-adrenergic signalling 
and subsequent uncoupling of ATP production from mitochondrial respiration (1). 
Uncoupling in BAT is mediated by the uncoupling protein UCP1, which is highly 
abundant specif ically in BAT (1). Studies in the last decade have shown the presence 
of BAT in humans and have provided preliminary evidence for an inverse relationship 
between BAT activity and parameters of obesity (2–4). As a consequence, interest in 
BAT function and the possible targeting of BAT for treatment or prevention of meta-
bolic diseases has surged. 
 Upon cold exposure, oxidation of fuels by BAT is dramatically increased. 
In addition to circulating glucose and free fatty acids, fatty acids derived from cir-
culating triglyceride-rich lipoproteins (TRLs) represent a major fuel source for BAT 
(1). The liberation of fatty acids from TRLs is catalyzed by the enzyme lipoprotein 
lipase (LPL), which is highly abundant in BAT (5, 6). Cold exposure markedly stimu-
lates LPL activity in BAT, causing a concomitant increase in TRL-derived fatty acid 
uptake and even uptake of whole lipoprotein particles (6–8). The increase in fatty 
acid uptake upon cold exposure, which can be mimicked by pharmacological ß3-adr-
energic receptor activation, is highly specif ic for BAT, suggesting that the body may 
specif ically re-direct lipid fuels to BAT during cold exposure (6, 7, 9). Both transcrip-
tional and (post-)translational regulation has been implicated in the increased LPL 
activity in BAT upon cold exposure. However, the specif ic underlying mechanisms 
have remained elusive (10–12).  
 Angiopoietin-like 4 (ANGPTL4) has previously been identif ied as an inhib-
itor of LPL activity in muscle and WAT. Alterations of Angptl4 expression in these 
tissues mediate the changes in LPL activity observed during exercise and fasting, 
respectively (13, 14). In the initial paper describing the cloning of ANGPTL4, we 
had seen high expression of Angptl4 mRNA in BAT (15). Since the exact mechanisms 
behind regulation of LPL activity in BAT upon cold exposure are currently unclear, 
we hypothesized that ANGPTL4 may act as an important regulator of LPL-mediated 
fatty acid uptake into BAT. Accordingly, in the present paper we studied the role of 
ANGPTL4 in lipid metabolism during cold exposure, taking advantage of Angptl4-de-
f icient (Angptl4 -/-) mice and Angptl4-overexpressing (Angptl4-Tg) mice.
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MATERIALS & METHODS
Mice 
Three- to four-month old Angptl4 -/-, wild-type and Angptl4-Tg mice were either placed 
at a thermo-neutral temperature (~28˚C) (n=7/8, as indicated in f igure legends) or 
at a cold temperature (~4˚C) (n=7-10, as indicated in f igure legends) for a period of 
10 days. All animals are backcrossed on a pure C57Bl/6J background for multiple 
generations (>10). Wild-type and Angptl4-Tg mice are littermates. Angptl4 -/- mice have 
been obtained via homologous recombination of embryonic stem cells and lack part 
of the Angptl4 gene, resulting in a non-functional ANGPTL4 protein (16, 17). Angptl4-
Tg mice over-express the Angptl4 gene in various tissues under its own promoter (18). 
Food intake, body weight and body temperature were monitored daily. Body temper-
ature of cold-exposed mice was monitored via read-out of transponders (IPTT-300) 
that were injected subcutaneously prior to the experiment (Bio Medic Data Systems, 
Seaford, USA). The Animal Ethics Committees of Wageningen University and Uni-
versity Medical Center Hamburg-Eppendorf approved all experiments.
TRL labeling 
Radiolabeled VLDL-like emulsion particles were essentially prepared as described 
previously (19). Brief ly, 100 mg of lipids (triolein, egg yolk phosphatidylcholine, lys-
ophosphatidylcholine, cholesteryl-oleate and cholesterol) were mixed with glycerol 
tri[3H]oleate and [14C]cholesteryl-oleate (GE Healthcare, Little Chalfont, UK) and 
sonicated (Soniprep 150, MSE Scientif ic Instruments, UK). The emulsion was frac-
tionated by consecutive density gradient ultracentrifugation (Beckman, California, 
USA) to yield VLDL-like particles with a diameter of ~80 nm. 
 Radiolabeled chylomicron-like particles with a diameter of ~250 nm were pre-
pared from lipids derived from human TRLs of apoCII-def icient subjects (approved 
by Ärtzekammer Hamburg, Germany) as described previously (20). Brief ly, 10 mg of 
isolated lipid was mixed with glycerol tri[14C]oleate and [3H]cholesteryl-oleyloleate 
(Perkin Elmer, Rodgau, Germany) in chloroform, after which solvent was removed 
and TRL particles were formed by sonication in 1 mL of PBS for 10 minutes at 60˚C. 
Aggregates were removed by f iltration through a 450 nm f ilter (Millipore). TRL par-
ticles used for intravital microscopy were prepared similarly, but radiolabels were 
replaced by hydrophobic f luorescent nanocrystals (QD-TRLS).  
TG clearance experiments 
To study the clearance of radiolabeled TRL-like particles (80 & 250 nm), Angptl4 -/-, 
wild-type and Angptl4-Tg mice were exposed to cold or thermo-neutral temperature 
for 10 days (see Supplemental Figure 1 for an overview). Prior to the experiment, 
animals were fasted for 4h. To asses TG clearance, mice were injected intravenously 
with 200 μL radiolabeled TRL-like particles (0,2 mg TG for VLDL-like particles, 2 
mg TG for chylomicron-like particles). Lipid turnover was determined for VLDL-like 
particles from plasma taken at 2,5,10 and 15 min following injection. Total plasma 
volumes were calculated as 0.04706 x body weight (g) (21). 15 minutes after injection, 
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mice were sacrif iced and perfused via the heart with ice-cold PBS containing 50 IU/
mL heparin. Multiple organs were collected, weighed and solubilized in Tissue Sol-
ubilizer (Amersham Biosciences, Roosendaal, the Netherlands; for VLDL-like parti-
cles) or Solvable (Perkin Elmer; for chylomicron-like particles) overnight. 3H and 14C 
radioactivity was determined via liquid scintillation counting. Uptake of radioactivity 
derived from TRL-like particles was calculated as % uptake of the injected radiolabel 
per gram tissue.
  
Intravital Microscopy 
For intravital microscopy, interscapular BAT was exposed in anesthetized Angptl4 -/-, 
wild-type and Angptl4-Tg mice and visualized by a confocal microscope with resonant 
scanner (Nikon A1R). QD-TRLs were injected via a tail vein catheter in anesthetized 
mice, where after 30 confocal images per second of the interscapular BAT were re-
corded for a period of 15 minutes. The acquired data were edited in Nikon NIS Ele-
ments. After recording, mice were perfused with PBS containing 50 IU/mL heparin. 
Then, BAT, gonadal WAT and inguinal WAT were taken out for subsequent cryosec-
tioning, to assess the uptake of QD-TRLs via confocal microscopy. 
Plasma measurements
Plasma concentrations of glucose (Sopachem, Ochten, the Netherlands), triglycer-
ides, cholesterol (Instruchemie, Delfzijl, the Netherlands), glycerol (Sigma-Aldrich, 
Houten, the Netherlands) and free fatty acids (Wako Chemicals, Neuss, Germany; 
HR(2) Kit) were determined following the manufacturers’ instructions. 
LPL activity measurements 
LPL activity in whole tissue homogenates from BAT, gonadal WAT and inguinal 
WAT was measured as described previously (22). Brief ly, extracts of frozen tissue 
samples were prepared in 9 ml lysis buffer / g tissue (0.025 M NH3, 5 mM Na2EDTA, 
and per ml: 1 mg bovine serum albumin, 10 mg Triton X-100, 1 mg SDS, 5 IU hep-
arin, and Complete protease inhibitors (Roche)) by homogenization with a Polytron 
homogenizer. Homogenates were spun down for 15 min at 3000 x g to obtain the 
supernatant used to measure LPL activity. 2 μl of supernatant was assayed, in a total 
volume of 200 μL, with a 3H-oleic acid-labeled triolein containing substrate emulsion 
having 100 mg soybean triglycerides and 10 mg egg yolk phospholipids per mL. Incu-
bation was at 25˚C for 30-100 min, dependent on the expected level of LPL activity. 
One milliunit (mU) of enzyme activity corresponds to 1 nmol of fatty acid released 
per min.
RNA isolation & qPCR 
Total RNA was isolated using TRIzol reagent (Life Technologies Europe BV, Bleiswi-
jk, the Netherlands). RNA from WAT depots was purif ied using the Qiagen RNeasy 
Micro kit (Qiagen, Venlo, the Netherlands). RNA was reverse transcribed using a 
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First-Strand cDNA Synthesis Kit (Thermo Scientif ic, Landsmeer, the Netherlands) 
(for cells) or iScript cDNA Synthesis Kit (Bio-Rad, Veenendaal, the Netherlands) (for 
tissues). Real-time PCR was carried out using SensiMiX (Bioline, GC Biotech, Al-
phen aan de Rijn, the Netherlands) on a CFX 384 Bio-Rad thermal cycler (Bio-Rad). 
TBP and 36B4 were used as housekeeping genes. Primer sequences can be found in 
Table 1. 
Tissue H&E staining 
Fresh tissues (WAT and BAT) were f ixed in 4% paraformaldehyde, dehydrated and 
embedded in paraff in. H&E staining was performed using standard protocols. 
Tissue immunofluorescence 
Frozen human BAT sections obtained during surgery (5 µm thick) were f ixated dur-
ing 15 min in 3.7% formaldehyde in PBS, followed by incubation for 45 min at room 
temperature with a primary antibody (polyclonal rabbit hANGPTL4 or a polyclonal 
rabbit  UCP1-antibody (kind gift of Dr. B. Cannon, Stockholm University)) (23, 24) 
diluted in 0.05% Tween20 in PBS. After three washing steps with PBS, sections were 
incubated for 45 min at room temperature with the appropriate f luorescently labelled 
secondary antibodies. The specif icity of the antibody for ANGPTL4 was demonstrat-
ed previously via immunoblot of human plasma using appropriate peptide controls 
and was validated by staining of ANGPTL4 in human heart, intestine and muscle 
(14, 25, 26).
Human cold exposure experiment & hANGPTL4 ELISA
Plasma ANGPTL4 levels were measured in plasma samples from a published study 
in which lean and obese human subjects were exposed to a mild cold (16˚C) for 48h 
(27). Plasma hANGPTL4 levels were measured as described previously (28). Brief ly, 
96-well plates were coated with anti-human ANGPTL4 polyclonal goat IgG anti-
body (AF3485; R&D Systems) and were incubated overnight at 4˚C. After blocking, 
100 μL of 20-fold diluted human plasma was applied to each well, followed by in-
cubation at room temperature for 2 h. Next, 100 μL of diluted biotinylated anti-hu-
man ANGPTL4 polyclonal goat IgG antibody (BAF3485; R&D Systems) was added 
and incubated for 2 h. Subsequently, streptavidin-conjugated HRP was added for 20 
min, followed by tetramethylbenzidine substrate reagent for 6 min. The reaction was 
stopped by adding 50 μL of 10% H2SO4. The absorbance was measured at 450 nm.
Western Blot 
Tissues were lysed in a mild RIPA-like lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1% NP-40 and 5% glycerol; Thermo Scientif ic) with protease 
and phosphatase inhibitors (Roche). Cells were lysed directly in 2x laemmli sample 
buffer (LSB) with DTT. Protein lysates (20–30 μg protein per lane) were loaded on 
a denaturing gel (Bio-Rad) and separated by SDS gel electrophoresis. Proteins were 
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transferred to a PVDF membrane by means of a Transblot Turbo System (Bio-Rad). 
The primary antibody [rabbit anti–phospho-AMPK antibody (Thr172), rabbit an-
ti-AMPKα1,α2 antibody (Cell Signaling Technology, #2535 and #2532), rabbit an-
ti-mouse/human AMPKα1 (Cell Signaling Technology, #2795), rabbit anti-mouse/
human AMPKβ1 and AMPKβ2 (Cell Signaling Technology, #4148 and #4178),  rab-
bit anti-mouse AMPKα2 antibody (Abcam, #ab3760), rat anti-mouse ANGPTL4 an-
tibody (Adipogen, #Kairos 142–2), goat anti-mouse LPL antibody (kind gift from 
André Bensadoun),  rabbit anti-mouse HSP90 antibody (Cell Signaling Technolo-
gy, #4874S), or mouse anti-mouse β-tubulin antibody (Santa-Cruz Biotechnology, 
#sc23949)] was used at a ratio of 1:1,000 (AMPKα1,α2, AMPKα2, AMPKα1, AMP-
Kβ1, AMPKβ2, ANGPTL4, HSP90, β-tubulin), 1:2,000 (phospho–AMPK) or 1:5,000 
(LPL). Corresponding secondary antibodies (HRP-conjugated) (Sigma-Aldrich) were 
used at 1:5,000 dilutions. All incubations were performed in Tris-buffered saline, pH 
7.5, with 0.1% Tween-20 (TBS-T) and 5% dry milk, except for anti-AMPKα1,2 and 
anti-phospho-AMPK Thr172 antibody, where 5% bovine serum albumin (BSA) was 
used instead of milk. All washing steps were in TBS-T without dry milk or BSA. Blots 
were visualized using the ChemiDoc MP system (Bio-Rad) and Clarity ECL substrate 
(Bio-Rad). 
Cell culture 
3T3-F442a cells (P8-P14, Sigma) were maintained in DMEM (Lonza), supplement-
ed with 10% newborn calf serum and 1% penicillin/streptomycin (P/S) under 5% 
CO2 at 37˚C. At conf luency, cells were switched to DMEM (Lonza, Verviers, Bel-
gium), supplemented with 10% fetal bovine serum (FBS), 1% P/S and 5 μg/mL insu-
lin (Sigma-Aldrich) to stimulate differentiation. During differentiation, medium was 
changed every 2/3 days. After 10 days of differentiation, cells were switched back to 
regular medium for 2/3 days, after which experiments were performed. 
 T37i cells (P31-36; kind gift of Marc Lombès) were cultured in DMEM/F-12 
(Gibco, Life Technologies, Blijswijk, the Netherlands), supplemented with 10% FBS 
and 1% P/S. Two days post-conf luency, cell culture medium was supplemented with 
112 ng/mL insulin and 2 nM T3 (Sigma-Aldrich) to induce differentiation. After 7 
days of differentiation, cells were switched back to regular medium and used for ex-
periments 2/3 days after (29). 
 HepG2 cells (passage unknown) were maintained in DMEM (Lonza) sup-
plemented with 10% FBS and 1% P/S. At each passage, the cell pellet was f iltered 
through a 40 μm f ilter to reduce cell clumping.  
 Culture of BA adipocytes was performed as described previously (30). Brief ly, 
immortalized brown adipocytes are grown to conf luence with differentiation medium 
(DMEM, 10% FBS, 20 nM insulin, 1 nM T3). Upon conf luence, cells were treated 
with induction medium (differentiation medium supplemented with 0.5 mM IBMX, 
0.5 μM dexamethasone, 0.125 mM indomethacin) for two days. After washing, cells 
were incubated in differentiation medium for another 5 to 7 days. 
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Isolation of primary adipocytes 
WAT was dissected from C57Bl/6J mice and put in DMEM supplemented with 1% 
P/S and 1% BSA. Tissues of 3-4 mice were pooled, minced with scissors and digested 
for 1h at 37˚C in collagenase-containing medium (DMEM with 3.2 mM CaCl2, 1.5 
mg/mL Collagenase type II (Sigma-Aldrich), 10% FBS, 0.5% Bovine Serum Albu-
min (Sigma-Aldrich) and 15 mM HEPES, f iltered). After digestion, cell mixture was 
passed over a 100 μm cell strainer and centrifuged at 1600 rpm for 10 minutes. Su-
pernatant was removed and the pellet containing the stromal vascular fraction was 
re-suspended in erythrocyte lysis buffer (155 mM NH4Cl, 12 mM NaHCO3, 0.1 mM 
EDTA) and incubated for 2-3 minutes at room temperature. Following neutralization, 
cells were centrifuged at 1200 rpm for 5 minutes. Cells were re-suspended in DMEM 
containing 10% FBS and 1% P/S and plated. Upon conf luence, cells were differenti-
ated following standard protocol of 3T3-L1 cells, as described previously (31).
 For isolation of primary brown adipocytes, BAT from 1-month-old pups was 
used. Tissues of 5-10 pups were pooled, minced with scissors and digested for 30 
min in collagenase-containing medium at 37˚C (DMEM w/o serum, 2 mg/mL Colla-
genase type II, 2% BSA, 25 mM HEPES). After digestion, cells were passed through 
a 70 or 100 μM f ilter, mature adipocytes were discarded and cells were centrifuged 
at 800*g for 5 min. Cells were re-suspended in differentiation medium (DMEM, 10% 
FBS, 20 nM insulin, 1 nM T3) and plated. Upon conf luence, cells were treated with 
induction medium (differentiation medium supplemented with 0.5 mM IBMX, 0.5 
μM dexamethasone, 0.125 mM indomethacin) for two days. After washing, cells were 
incubated in differentiation medium for another 5 to 7 days.
siRNA experiments 
T37i cells were cultured and differentiated as described above. At day 10 of differ-
entiation, mature adipocytes were trypsinized and replated at 70% density. 2 hours 
post-plating, siRNAs against AMPKα1 and AMPKα2, or non-target control (Dhar-
macon, via Thermo Fisher) complexed to Lipofectamine RNAimax reagent (Life 
Technologies) were added, according to the manufacturer’s protocol. 48h post-trans-
fection, cells were washed and treated as indicated before harvesting for RNA anal-
yses.   
BAT and WAT explants 
BAT and WAT tissues were dissected from male C57Bl/6J mice and transferred to 
DMEM supplemented with 1% P/S and 1% BSA. Tissues of 4 mice were pooled and 
minced f inely with scissors. Approximately 50 mg of tissue was transferred to a well of 
a 24-wells tissue culture plate and equilibrated for 1h in DMEM, supplemented with 
1% P/S. After 1h, explants were treated as indicated before being harvested for RNA 
and protein analyses. 
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Chemicals
Isoproterenol, AICAR, metformin, rosiglitazone, Wy14,643, GW510516, GW742, 
dexamethasone, insulin, 3-isobutyl-1-1methylxanthine (IBMX), actinomycin D were 
purchased from Sigma-Aldrich. A769662 was purchased from Abcam (Cambridge, 
United Kingdom), phenformin hydrochloride was purchased from Cayman Chemi-
cals (via SanBio, Uden, the Netherlands).
mAngptl4 PPRE construct 
A fragment of 1517 bp containing intron 3 of the mouse Angptl4 gene was amplif ied 
from DNA of the mouse Angptl4 gene, using the primers: Fwd 5’-TTGCTGTCATCT-
GGCAACTC-3’ and Rev 3’-CACCTAAAGCCTACCCCACA-5’. The resulting 
fragment was gel-purif ied using QIAquick Gel Extraction Kit (Qiagen) and subjected 
to a second PCR to specif ically amplify the three functional PPREs of Angptl4 and 
to introduce Xho1 and Kpn1 restriction sites. Amplif ication of the 565 bp fragment 
was done with the following primers: mouse Fwd 5’-atggtaccTTCACACCCTAA-
GGCTGC-3’, and mouse Rev 3’-atctcgagGGGGGAAGAGGAAGAAAA-5’. Follow-
ing purif ication from gel, the fragment was subjected to restriction with Xho1 and 
Kpn1 enzymes and cloned into the Xho1 and Kpn1 sites of the pGL3 promoter vector 
(Promega, Leiden, the Netherlands). Presence of the correct insert was validated by 
sequencing (EZ-Seq, Macrogen, Amsterdam, the Netherlands) using a RV3 primer: 
‘5-CTAGCAAAATAGGCTGTCCC-3’. 
Transactivation assays
mAngptl4 PPRE pGL3 reporter vector was transfected into the human hepatocellular 
cell line HepG2 (ATCC, Manassas, USA) in the presence or absence of pSG5 vectors 
expressing Pparγ and Rxr and pcDNA vector expressing HA-P300 (kind gift of Eric 
Kalkhoven, University Medical Centre Utrecht, the Netherlands). A vector express-
ing renilla luciferase under a SV40 promoter was co-transfected with all samples to 
determine transfection eff iciency. Transfections were performed using polyethylen-
imine (PEI) (Polysciences Inc. via Qiagen). 16h post-transfection cells were incubated 
with rosiglitazone (5μM) and/or AICAR (1 mM) for 9h. Firef ly and renilla luciferase 
activity were determined using the Dual Glo Luciferase Assay system (Promega), ac-
cording to manufacturer’s instructions, on a Fluoroskan Ascent apparatus (Thermo 
Scientif ic). 
Statistics 
Data are expressed as mean ± SEM, unless otherwise indicated. Differences were 
evaluated for statistical signif icance by student t-test or two-way ANOVA, followed 
by a post-hoc Tukey HSD test, and considered statistically signif icant when p < 0.05.
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RESULTS 
ANGPTL4 expression in BAT is down-regulated upon sustained cold exposure
ANGPTL4 and LPL protein are co-expressed in BAT (Figure 1A), suggesting a pos-
sible role for ANGPTL4 in regulating LPL in BAT. The specif icity of the antibody 
used in the immunoblotting for ANGPTL4 was demonstrated by the lack of observ-
able signal in BAT of Angptl4 -/- mice (Figure 1B - left panel). Interestingly, we 
detected bands for ANGPTL4 at a molecular weight of ~52 kDa and ~45 kDa. The 
expected molecular weight of ANGPTL4 protein is 45 kDa, with a predicted glyco-
sylation site at amino acid Asparagine-177 (in humans) or Asparagine 181 (in mice) 
(32–35). Consistent with the notion that these bands represent glycosylated (~52 kDa) 
and non-glycosylated forms (~45 kDa) of ANGPTL4, the 52 kDa band disappeared 
following treatment of BAT lysates with the endoglycosidase PGNase, while the 45 
kDa band became more intense (Figure 1B – right panel). These data indicate 
that ANGPTL4 protein is present in BAT in glycosylated and non-glycosylated forms. 
Immunof luorescent staining on sections from human BAT obtained during surgery 
(as qualif ied based on UCP1 staining) showed that ANGPTL4 is also expressed in hu-
man BAT (Figure 1C). In agreement with high ANGPTL4 expression levels in BAT, 
Angptl4 mRNA increased markedly upon differentiation of a mouse brown adipocyte 
cell line (Figure 1D). 
 We next explored the possible impact of cold on ANGPTL4 expression in 
BAT. Intriguingly, whereas 1 day of cold exposure did not affect Angptl4 expression, 
10 days of cold exposure led to a marked reduction in Angptl4 mRNA (Figure 1E). 
The reduction in Angptl4 mRNA was paralleled by a marked decrease in ANGPTL4 
protein, particularly the glycosylated form of ANGPTL4 (Figure 1F). Expression of 
Lpl, on the other hand, was mildly elevated after both 1 and 10 days of cold exposure 
(Figure 1G).
Down-regulation of ANGPTL4 expression promotes BAT LPL activity upon 
sustained cold exposure
To investigate a possible role for ANGPTL4 in BAT function, we exposed Angptl4 -/-, 
wild-type and Angptl4-Tg mice to a cold (4˚C) or thermo-neutral (28˚C) environment 
for 10 days in order to activate and recruit BAT (Figure 2A). The Angptl4-Tg mice 
overexpress Angptl4 under its own promoter and show elevated Angptl4 expression in 
a variety of tissues, including BAT (18). The sustained cold exposure resulted in pro-
nounced changes in BAT morphology, food intake, body weight, weights of BAT and 
WAT and body temperature, but no clear differences between the genotypes could 
be observed (Figure 2B-F). Likewise, expression of the key thermogenic genes Ucp1 
and Elovl3 was signif icantly increased upon cold exposure but not affected by Angptl4 
genotype (Figure 2G). 
 Following cold exposure, the energy requirements of BAT increase dramati-
cally. Two major fuel sources for BAT are plasma glucose and free fatty acids, both of 
which were unaltered by cold and Angptl4 genotype (Figure 2H&2I ). Also, plasma 
glycerol, which is perhaps a better indicator of adipose tissue lipolysis than free fatty 
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Figure 1: ANGPTL4 expression in BAT is down-regulated upon sustained cold exposure. 
(A) Immunoblot for mouse ANGPTL4 and mouse LPL in lysates of  kidney, spleen, heart, muscle, gonodal WAT, inguinal 
WAT and BAT of  a C57BL/6J wild-type mouse. (B) Validation of  anti-mANGPTL4 antibody in BAT lysates of  Angptl4-/-, 
wild-type and Angptl4-Tg mice (left panel). Detection of  glycosylated and non-glycosylated mANGPTL4 following treatment 
of  BAT homogenate of  a wild-type mouse with PGNase (right panel). (C) Immunofluorescent staining of  UCP1 (upper panel; 
UCP1=green, DAPI=blue), DAPI only (middle panel) and hANGPTL4 (lower panel; hANGPTL4 = green, DAPI=blue) in 
frozen sections (5 μm) of  human BAT. (D) Angptl4 mRNA in T37i cells after 0, 3, 6 or 9 days of  differentiation. (E) Angptl4 
mRNA in BAT lysates of  wild-type mice exposed to 4˚C or 28˚C for 1 or 10 days. (F) Immunoblot for ANGPTL4 in BAT 
homogenates of  wild-type mice exposed to 4˚C or 28˚C for 10 days, following treatment with or without PGNase. (G) Lpl 
mRNA in BAT lysates of  wild-type mice exposed to 4˚C or 28˚C for 1 or 10 days. * Statistically significant compared to 
control wells or compared to mice exposed to 28˚C according to Student’s t-test (p<0.05). Error bars represent ± SEM. n= 
8-10 mice per group.
acids, was not different between the three genotypes (Figure 2J ). Additionally, ex vivo 
treatment of differentiated primary white adipocytes with the non-selective β-adren-
ergic receptor agonist isoproterenol indicated a lack of effect of Angptl4 genotype on 
adipose tissue lipolysis (Figure 2K ). Besides glucose and free fatty acids, circulating 
triglycerides (TG) represent a major fuel for BAT during cold (1). Based on the marked 
decrease in Angptl4 mRNA levels in BAT upon prolonged cold exposure, we hypothe-
sized that ANGPTL4 might play a role in the metabolism of circulating TG by BAT 
during cold. In line with this notion, the reduction in plasma TG visible in wild-
type and Angptl4 -/- mice in response to cold was greatly attenuated in Angptl4-Tg mice 
(Figure 2L). Lipoprotein prof iling by fast protein liquid chromatography (FPLC) 
supported markedly augmented plasma TRL levels in cold-exposed Angptl4-Tg mice 
(Figure 2M ). 
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Figure 2: Down-regulation of ANGPTL4 in BAT upon sustained cold exposure affects plasma TG levels. 
(A) Schematic representation of  cold exposure experiment with Angptl4-/-, wild-type and Angptl4-Tg mice. (B) Haematoxylin 
& Eosin staining on BAT sections (5 μm) of  Angptl4-/-, wild-type and Angptl4-Tg mice exposed to 4˚C or 28˚C for 10 days. (C) 
Food intake of  Angptl4-/-, wild-type and Angptl4-Tg mice exposed to 4˚C for 10 days. (D) Weight gain of  Angptl4-/-, wild-type 
and Angptl4-Tg mice exposed to 4˚C during 10 days. (E) BAT and WAT tissue weights and (F) body temperature of  Angptl4-/-, 
wild-type and Angptl4-Tg mice exposed to 4˚C or 28˚C for 10 days. (G) Elovl3 and Ucp1 mRNA expression levels of  Angptl4-/-, 
wild-type and Angptl4-Tg mice exposed to 4˚C or 28˚C for 10 days. (H) Plasma glucose, (I) plasma free fatty acids, and (J) 
plasma glycerol levels of  Angptl4-/-, wild-type and Angptl4-Tg mice exposed to 4˚C or 28˚C for 10 days. (K) Glycerol levels in 
medium of  differentiated primary white adipocytes from Angptl4-/-, wild-type and Angptl4-Tg mice, serum-starved and treated 
with 10 μM isoproterenol for 3h. (J) plasma TG levels of  Angptl4-/-, wild-type and Angptl4-Tg mice exposed to 4˚C or 28˚C 
for 10 days. (K) Fast protein liquid chromatography (FPLC) on pooled plasma samples of  Angptl4-/-, wild-type and Angptl4-Tg 
mice exposed to 4˚C for 10 days, followed by analysis of  TG levels in all fractions. * Statistically significant compared to mice 
of  equal genotype at 28˚C or between groups as indicated by bars according to two-way ANOVA followed by a post-hoc 
Tukey HSD test (p<0.05). Error bars represent ± SEM. n = 8-10 mice per group.
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 It is well-established that cold-induced reductions in plasma TG levels are 
mediated by increased LPL activity in BAT (5, 6, 8). Accordingly, we tested whether 
ANGPTL4 levels inf luence changes in BAT LPL activity upon prolonged cold expo-
sure. Whereas wild-type mice respond to cold with a reduction in BAT ANGPTL4 
mRNA and protein levels, Angptl4-Tg mice maintain higher ANGPTL4 mRNA and 
protein levels (Figure 3A & 3B). Mirroring the levels of ANGPTL4, the cold-induced 
changes in LPL activity in BAT exhibited a gradient across the three Angptl4 geno-
types, with highest LPL activity observed in Angptl4 -/- mice and lowest LPL activity 
in Angptl4-Tg mice (Figure 3C). Furthermore, the marked increase in LPL activity 
during cold observed in the wild-type mice was signif icantly blunted in Angptl4-Tg 
mice (Figure 3C). Interestingly, the two-fold increase in LPL activity by cold in 
Angptl4 -/- mice indicates that part of the induction of LPL activity in BAT is independ-
ent of ANGPTL4 (Figure 3C), possibly via an increase in Lpl mRNA, which was 
observed in all three genotypes (Figure 3D) (6, 8). Overall, the marked gradient in 
LPL activity between Angptl4 -/-, wild-type, and Angptl4-Tg mice strongly suggests that 
ANGPTL4 acts as an inhibitor of LPL activity in BAT.
Down-regulation of ANGPTL4 expression promotes uptake of TRL-derived 
fatty acids by BAT upon sustained cold exposure
To investigate the role of ANGPTL4 in plasma TG clearance by BAT, we injected 
cold-exposed Angptl4 -/-, wild-type and Angptl4-Tg mice with radiolabeled VLDL-like 
emulsion particles containing glycerol tri[3H]oleate (hydrolysable by LPL; TRL-de-
rived fatty acids) and [14C]cholesteryl-oleate (not hydrolysable by LPL; TRL-Chol) 
(see Supplemental Figure 1 for experimental set-up) (19). After 15 minutes, the 
mice were sacrif iced and the tissue distribution of 3H and 14C activity was deter-
mined. As expected, cold exposure markedly increased the rate of clearance of the 
injected VLDL-like particles from the plasma (Figure 4A & 4B). However, after 
cold exposure, plasma clearance of glycerol tri[3H]oleate (TRL FA), but not [14C]
cholesteryl-oleate (TRL Chol), was signif icantly slower in Angptl4-Tg mice, indicating 
that Angptl4-overexpression inhibits LPL-mediated plasma TG clearance in the cold 
(Figure 4C & 4D). Cold exposure caused a marked increase in TRL-derived fatty 
acid uptake into BAT in all three genotypes, indicating that part of the increase in 
fatty acid uptake is independent of ANGPTL4 (Figure 4E). However, similar to 
LPL activity, a clear gradient in TRL-derived fatty acid uptake into BAT was ob-
served between the three genotypes, with lowest uptake in Angptl4-Tg mice (Figure 
4E). Similar results were obtained for [14C]cholesteryl-oleate, showing a marked de-
crease in BAT uptake in the Angptl4-Tg mice (Figure 4F ). We repeated the plasma 
TG clearance studies using radiolabeled lipoprotein particles with a larger diameter, 
resembling postprandial chylomicrons. Again, Angptl4-overexpression markedly re-
duced uptake into BAT of the TRL-derived fatty acids and the core label cholester-
yl-oleyloleate (Figure 4G & 4H). To visualize the TRL uptake process, we injected 
hydrophobic f luorescent nanocrystals embedded in lipoprotein particles (QD-TRLs) 
into cold-exposed Angptl4 -/-, wild-type and Angptl4-Tg mice (20). In agreement with a 
role for ANGPTL4 in TRL processing in BAT, increased accumulation of QD-TRLs 
was observed after cold exposure of wild-type mice, but not of Angptl4-Tg mice (Fig-
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Figure 3: Down-regulation of ANGPTL4 in BAT upon sustained cold exposure promotes an increase in BAT LPL 
activity. 
(A) Angptl4 mRNA in BAT of  Angptl4-/-, wild-type and Angptl4-Tg mice exposed to 4˚C or 28˚C for 10 days. (B) Immunoblot 
for ANGPTL4 and LPL in BAT homogenates from Angptl4-/-, wild-type and Angptl4-Tg mice exposed to 4˚C or 28˚C for 
10 days. (C) Total LPL activity and (D) Lpl mRNA in BAT of  Angptl4-/-, wild-type and Angptl4-Tg mice exposed to 4˚C or 
28˚C for 10 days. * Statistically significant compared to mice of  equal genotype at 28˚C or between groups as indicated by 
bars, according to two-way ANOVA followed by a post-hoc Tukey HSD test (p<0.05). Error bars represent ± SEM. n = 
8-10 mice per group.
ure 4I ). Furthermore, Angptl4 -/- mice show an accumulation of QD-TRLs in BAT 
even when maintained at 28°C (Figure 4I ). Together, these data are supportive of a 
major role for ANGPTL4 as a regulator of LPL activity and concomitant uptake of 
fatty acids into BAT upon prolonged cold exposure. 
ANGPTL4 expression and LPL activity are oppositely regulated in WAT and 
BAT upon sustained cold exposure  
Whereas BAT utilizes lipids to fuel thermogenesis, WAT provides lipid fuels to be 
used by BAT. Accordingly, lipid uptake and LPL activity are expected to be regulat-
ed differently in BAT as compared to WAT. Indeed, whereas in wild-type mice LPL 
activity in BAT increased dramatically during cold, LPL activity in WAT remained 
unchanged, at least in wild-type and Angptl4-Tg mice (Figure 5A). However, LPL 
activity was increased by cold in Angptl4 -/- mice, indicating that ANGPTL4 prevents 
LPL activity in WAT from going up during cold (Figure 5A). In support of this func-
tion for ANGPTL4, cold exposure caused a marked increase in Angptl4 mRNA and 
protein levels in WAT (Figure 5B & 5C). In contrast to Angptl4, Lpl mRNA levels 
were not signif icantly altered in WAT upon sustained cold exposure (Figure 5D). 
Interestingly, exposure of human subjects to mild cold (16˚C) for 48h signif icantly 
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Figure 4: Down-regulation of ANGPTL4 in BAT upon sustained cold exposure promotes an increase in TRL-derived 
fatty acid uptake by BAT. 
(A&B) Plasma 3H (A) and 14C (B) activity in wild-type mice exposed to 4˚C or 28˚C for 10 days levels, intravenously injected 
with VLDL-like particles, labelled with glycerol tri[3H]oleate (TRL FA) and [14C]cholesteryl-oleate (TRL Chol). (C & D) 
Plasma 3H (C) and 14C (D) activity in Angptl4-/-, wild-type and Angptl4-Tg mice intravenously injected with VLDL-like emul-
sion particles, labelled with glycerol tri[3H]oleate (TRL FA) and [14C]cholesteryl-oleate (TRL Chol), following exposure to 
4˚C for 10 days. (E & F) 3H activity (E) and 14C activity (F) in BAT of  Angptl4-/-, wild-type and Angptl4-Tg mice exposed to 4˚C 
or 28˚C for 10 days and intravenously injected VLDL-like particles, labelled with glycerol tri[3H]oleate (TRL FA) and [14C]
cholesteryl-oleate (TRL Chol). (G&H) 14C and 3H activity in BAT of  Angptl4-/-, wild-type and Angptl4-Tg mice exposed to 4˚C 
or 28˚C for 10 days, intravenously injected with chylomicron-like particles, labelled with glycerol tri[14C]oleate (TRL FA) (G) 
and [3H]cholesteryl-oleyloleate (TRL Chol). (I) Fluorescent image of  uptake of  intravenously injected QD-TRLs into BAT 
of  Angptl4-/-, wild-type and Angptl4-Tg mice exposed to 4˚C or 28˚C for 9 days. Image was taken 12 minutes post-injection. 
n=2 mice per group* Statistically significant compared to mice of  equal genotype at 28˚C or between groups as indicated 
by bars, according to two-way ANOVA followed by a post-hoc Tukey HSD test (p<0.05). Error bars represent ± SEM. n = 
7 mice per group, unless otherwise indicated.
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Figure 5: Up-regulation of ANGPTL4 in WAT upon sustained cold exposure suppresses WAT LPL activity and 
TRL-derived fatty acid uptake. 
(A) Total LPL activity levels and (B) Angptl4 mRNA in WAT of  Angptl4-/-, wild-type and Angptl4-Tg mice exposed to 4˚C or 
28˚C for 10 days. (C) Immunoblot for ANGPTL4 and LPL in WAT homogenates of  wild-type mice exposed to 4˚C or 28˚C 
for 10 days. (D) Lpl mRNA in WAT of  Angptl4-/-, wild-type and Angptl4-Tg mice exposed to 4˚C or 28˚C for 10 days. (E-H) 
Activity of  3H and 14C radiolabels in WAT of  Angptl4-/-, wild-type and Angptl4-Tg mice exposed to 4˚C or 28˚C for 10 days, 
intravenously injected with radiolabelled VLDL-like and chylomicron-like particles. TRL FA uptake (E&F) reflects uptake 
of  glycerol tri[3H/14C]oleate, whereas TRL Chol uptake (G&H) reflects uptake of  the core labels [14C]cholesteryl-oleate or 
[3H]cholesteryl-oleyloleate. (I) Fluorescent image of  uptake of  intravenously injected QD-TRLs into WAT of  Angptl4-/-, wild-
type and Angptl4-Tg mice exposed to 4˚C or 28˚C for 9 days. Image was taken after perfusion of  mice with PBS containing 
50 IU/mL heparin and upon cryosectioning of  tissues. n = 2 mice per group. * Statistically significant compared to mice of  
equal genotype at 28˚C or between groups as indicated by bars, according to two-way ANOVA followed by a post-hoc Tukey 
HSD test (p<0.05). Error bars represent ± SEM. n = 7-10 mice per group, unless otherwise indicated.
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increased plasma ANGPTL4 levels in obese subjects, but not in lean subjects. Con-
sidering the higher adipose tissue mass in obese individuals, these data suggest that 
the increase in ANGPTL4 production in WAT dominates ANGPTL4 levels in human 
plasma (Supplemental Figure 2). 
 To determine if the suppressive effect of ANGPTL4 on LPL activity had 
any impact on uptake of TRL-derived fatty acids in WAT during cold, we measured 
fatty acid uptake following injection of radiolabeled VLDL-like and chylomicron-like 
emulsion particles. Even though the uptake behaviour of the two types of TRL-par-
ticles was somewhat different, ANGPTL4 expression caused a clear dose-dependent 
reduction in uptake of TRL-derived fatty acids and the core labels cholesteryl-oleate/
cholesteryl-oleyloleate (Figure 5E-H). In addition, inhibition of TRL processing by 
ANGPTL4 in WAT was visually conf irmed by injection of QD-TRLs, showing in-
creased accumulation of QD-TRLs in WAT of Angptl4 -/- mice, as compared to wild-
type and Angptl4-Tg mice (Figure 5I). 
 It is noteworthy that in the inguinal fat depot, cold-induced changes in Lpl 
mRNA, Angptl4 mRNA and LPL activity were similar to the changes observed in 
the gonadal fat depot described above, whereas changes in uptake of TRL-derived 
fatty acids upon cold exposure were quite distinct, most likely due to marked acti-
vation of browning in inguinal fat (Figure 6A&6B; Supplemental Figure 3). In 
contrast to BAT and WAT, uptake of TRL-derived fatty acids or cholesteryl-oleate/
cholesteryl-oleyloleate from VLDL-like particles and chylomicron-like particles was 
minimally different between Angptl4 -/-, wild-type and Angptl4-Tg mice in liver, skeletal 
muscle and spleen (Figure 6A & 6B). Taken together, our data indicate that in BAT 
down-regulation of ANGPTL4 promotes uptake of plasma TRL-derived fatty acids 
via enhanced LPL activity, whereas in WAT ANGPTL4 suppresses uptake of plasma 
TRL-derived fatty acids via inhibition of LPL activity, thereby directing plasma TG 
to BAT to be used as fuel.
The opposite regulation of ANGPTL4 expression in BAT and WAT may be medi-
ated by differential activation of AMPK 
We next explored the mechanism accounting for the inverse regulation of ANGPTL4 
expression in BAT and WAT. Since many of the cold-induced adaptations are trig-
gered by β-adrenergic signaling, we examined the effect of β-adrenergic activation 
on ANGPTL4 expression in BAT and WAT using murine BAT (T37i cells) and WAT 
(3T3-F442a) cell lines and primary cells (29). In both BAT and WAT cells, treatment 
with isoproterenol, a non-selective agonist of β-receptors, consistently resulted in a 
marked increase in expression of Angptl4 mRNA (Figure 7A & 7B). Induction of 
ANGPTL4 by β-adrenergic stimulation was conf irmed at the protein level (Figure 
7C). From these data, it is evident that activation of the β-adrenergic signaling path-
way may contribute to the cold-induced up-regulation of ANGPTL4 in WAT, but 
cannot explain the down-regulation of ANGPTL4 observed in BAT. Levels of Lpl 
mRNA and protein in white and brown adipocytes were only mildly affected by treat-
ment with β-adrenergic agonists (Figure 7C & 7D). 
 We, therefore, considered mechanisms that are clearly different between 
BAT and WAT. Previously, it had been shown that 5’AMP-activated protein kinase 
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(AMPK) is progressively activated with prolonged cold exposure and that AMPK 
expression is signif icantly higher in BAT compared to WAT (36). Consistent with this 
f inding, we found that the catalytic α-subunits of AMPK, as well as phosphorylation 
of AMPK at Threonine-172—indicative of AMPK activity—are barely detectable in 
WAT in the basal state (Figure 7E) (37, 38). Previously, differential tissue expression 
of isoforms of the α, β, and γ subunits of the AMPK heterotrimer was suggested to 
determine cellular and systemic responses to different metabolic stressors (37, 38). 
Intriguingly, we detected large basal differences in AMPK α- and β-subunit isoform 
distribution between BAT and WAT and, more specif ically, found a high expression 
of the AMPKα2 catalytic subunit and the AMPKβ1 regulatory subunit in BAT com-
pared to WAT (Figure 7E). The differences in total AMPK expression and subunit 
distribution may explain why WAT AMPK levels remain weak following sustained 
cold exposure, whereas a strong increase in AMPK and phospho-AMPK is observed 
in BAT (Figure 7F). 
 In muscle cells, we found that AMPK activation strongly down-regulates 
ANGPTL4 mRNA and protein levels (14). To examine the consequences of AMPK 
activation in BAT, we treated differentiated T37i brown adipocytes with multi-
ple AMPK activators, including AICAR, A769662, metformin and phenformin 
hydrochloride. Without exception, AMPK activation markedly down-regulated 
Angptl4 mRNA expression (Figure 8A). To further conf irm the down-regulation of 
ANGPTL4 by AMPK, we treated different in vitro model systems for BAT with the 
AMPK activator AICAR. AICAR treatment of differentiated T37i adipocytes, BA 
adipocytes (30) or murine primary brown adipocytes resulted in a marked decrease 
in ANGPTL4 mRNA and protein levels (Figure 8B & 8C). Part of the inhibitory ef-
fect of AMPK activation on Angptl4 expression could be rescued by siRNA-mediated 
knock-down of AMPKα1 and AMPKα2 in differentiated T37i adipocytes, corrobo-
rating the suppressive effect of AMPK on Angptl4 expression (Figure 8D-8F ). Con-
sistent with the notion that the negative regulation of ANGPTL4 by AMPK is specif ic 
for BAT, AICAR treatment markedly reduced ANGPTL4 mRNA and protein levels 
in BAT explants, but not WAT explants (Figure 8G & 8H ). Based on these data, we 
propose that the different amount and activation of AMPK between BAT and WAT 
may be the critical factor in the differential regulation of ANGPTL4 between the two 
tissues during sustained cold. 
AMPK may act through PPARγ to regulate ANGPTL4 levels
We further pursued the mechanism behind the down-regulation of ANGPTL4 by 
AMPK. Treatment of brown adipocytes with AICAR and the transcriptional inhib-
itor actinomycin D showed that both compounds reduced Angptl4 gene expression by 
nearly the same extent. Co-treatment of actinomycin D and AICAR did not result 
in an additive effect, suggesting that AMPK activation almost completely inhibited 
Angptl4 gene transcription (Figure 9A). 
 Expression of ANGPTL4 is under sensitive control of peroxisome prolifer-
ator-activated receptors (PPARs) in many tissues, with PPARγ being the dominant 
regulator of ANGPTL4 in adipose tissue (15, 35, 39). We found that in BA and T37i 
brown adipocytes ANGPTL4 mRNA and protein are highly induced by PPARγ ago-
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Figure 6: Uptake of TRL-like particles in liver, spleen and muscle is not affected by Angptl4 genotype. 
(A) 3H and 14C activity in liver, spleen, muscle, inguinal WAT (iWAT) and subscapular BAT (sBAT) of  Angptl4-/-, wild-type 
and Angptl4-Tg mice exposed to 4˚C or 28˚C for 10 days, intravenously injected with VLDL-like emulsion particles, labelled 
with glycerol tri[3H]oleate (TRL FA) and [14C]cholesteryloleate (TRL Chol). (B) 3H and 14C activity in liver, spleen, muscle, 
iWAT and sBAT of  Angptl4-/-, wild-type and Angptl4-Tg mice exposed to 4˚C or 28˚C for 10 days, intravenously injected 
with chylomicron-like particles, labelled with glycerol tri[14C]oleate (TRL FA) and [3H]cholesteryl-oleyloleate (TRL Chol). 
*Statistically significant compared to values of  wild-type mice, for each tissue, and 4˚C and 28˚C separately, according to 
Student’s t-test (p<0.05). Error bars represent ± SEM. n = 7 mice per group.
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Figure 7: AMPK is activated in BAT, but not WAT, upon sustained cold exposure. 
(A) Angptl4 mRNA in differentiated mouse white adipocytes (primary adipocytes and 3T3F442a adipocytes) upon treatment 
with 10 μM isoproterenol (ISO) or H2O control medium (CTRL) for 3h. (B) Angptl4 mRNA in differentiated brown adipo-
cytes (primary adipocytes and T37i adipocytes) treated with 10 μM isoproterenol (ISO) or H2O control medium (CTRL) for 
2.5h. (C) Immunoblot for ANGPTL4 and LPL protein in differentiated 3T3F422a cells treated with 10 μM isoproterenol 
(ISO) or H2O control medium (CTRL) for 3h. (D) Lpl mRNA in differentiated mouse primary white or brown adipocytes 
upon treatment with 10 μM isoproterenol (ISO) or H2O control medium (CTRL) for 2.5h (BAT) or 3h (WAT). (E) Immunob-
lot for AMPKα1,2 and phospho-AMPK Thr172, AMPKα1, AMPKα2, AMPKβ1 and AMPKβ2 in tissue lysates of  kidney, 
spleen, heart, muscle, liver, inguinal WAT, gonodal WAT and BAT. Homogenates are identical to the homogenates presented 
in Figure 1A. (F) Immunoblot for AMPKα1,2 and phospho-AMPK Thr172 in BAT and WAT lysates of  wild-type mice 
exposed to 4˚C or 28˚C for 10 days. *Statistically significant compared to control samples or between indicated treatments 
according to Student’s t-test (p<0.05). Error bars represent ± SEM.
nists and to a lesser extent by agonists for PPARα and PPARδ (Figure 9B & 9C). 
 Previous studies have shown that AMPK may inhibit PPARα and PPARγ 
transcriptional activity (40, 41). Indeed, we observed that AMPK activation almost 
completely blocked the induction of Angptl4 mRNA following treatment with the 
PPARγ agonist rosiglitazone (Figure 9D). Accordingly, we hypothesized that acti-
vation of AMPK following prolonged cold exposure may inhibit PPARγ-mediated 
transcription of the Angptl4 gene. To examine this possibility, a luciferase construct 
was prepared containing the three conserved PPAR response elements (PPREs) of 
intron 3 of the murine Angptl4 gene. These three PPREs have previously been shown 
to be responsible for PPAR-mediated up-regulation of Angptl4 (39, 42). Upon trans-
fection of the Angptl4 PPRE construct into HepG2 cells, rosiglitazone treatment sig-
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Figure 8: Activation of AMPK down-regulates ANGPTL4 expression specifically in brown adipocytes. 
(A) Angptl4 mRNA in differentiated T37i adipocytes treated for 6h with 1 mM AICAR, 100 μM A769662, 1 mM metformin 
or 250 μM phenformin hydrochloride. (B) Angptl4 mRNA in differentiated primary brown adipocytes, BA adipocytes, or 
T37i adipocytes treated for indicated times with 1 mM AICAR. (C) Immunoblot for ANGPTL4, LPL, AMPKα1,2 and 
phospho-AMPK Thr172 in differentiated T37i cells treated with H2O control medium (CTRL) or 1 mM AICAR for 3h.  (D) 
Angptl4 mRNA in differentiated T37i adipocytes treated with CTRL siRNA or siRNA against AMPKα1 and AMPKα2 for 
48h, followed by incubation with H2O control medium (CTRL) or 1 mM AICAR for 3h. (E) Angptl4 mRNA in differentiated 
T37i adipocytes treated with CTRL siRNA or siRNA against AMPKα1 and AMPKα2 for 48h, followed by incubation with 
H2O control medium (CTRL) or 100 μM A769662 for 6h. (E) Ampkα1 and Ampkα2 mRNA in differentiated T37i adipocytes 
treated with CTRL siRNA or siRNA against AMPKα1 and AMPKα2 for 48h. (F) Angptl4 mRNA levels in BAT and WAT 
explants from C57BL/6J wild-type mice (~50 μg) treated with H2O control medium (CTRL) or 1 mM AICAR for 3h. (G) 
Immunoblot for ANGPTL4 in BAT and WAT explants from C57BL/6J wild-type mice (~50 mg) treated with H2O control 
medium (CTRL) or 1 mM AICAR for 3h.  *Statistically significant compared to control samples or between indicated treat-
ments, according to Student’s t-test (p<0.05). Error bars represent ± SEM.
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nif icantly induced luciferase activity, which was further increased upon co-transfec-
tion with Pparγ/Retinoid X receptor (Rxr). Co-treatment with AICAR, on the other 
hand, blunted the increase in luciferase activity (Figure 9E). Interestingly, whereas 
co-transfection of the PPARγ co-activator P300 (43) further stimulated luciferase ac-
tivity in the absence of AICAR, it failed to do so in the presence of AICAR, suggest-
ing that regulation of P300 may be part of the mechanism of inhibition of ANGPTL4 
by AMPK (Figure 9E). In support of this possibility, treatment of brown adipocytes 
with AICAR resulted in phosphorylation of P300 at serine residue 89, which is known 
to reduce the capacity of P300 to co-activate nuclear transcription factors, whereas 
no change in total P300 protein levels was observed (Figure 9F ). Collectively, these 
data suggest that the negative regulation of ANGPTL4 in BAT upon cold exposure 
may be mediated by the inhibition of PPARγ transcriptional activity by AMPK.
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Figure 9: Down-regulation of Angptl4 expression by AMPK is likely mediated via inhibition of PPARγ-mediated 
transcription of Angptl4. 
(A) Angptl4 mRNA in differentiated T37i adipocytes pre-incubated with 0.5 μg/mL actinomycin D (ActD) or DMSO-con-
taining control medium for 1h and treated with 1 mM AICAR or H2O control medium for 3h. (B) Angptl4 mRNA in differen-
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compared to control samples or between indicated samples according to Student’s t-test (p<0.05). Error bars represent 
±SEM, unless otherwise specified.
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DISCUSSION
The energy requirements of BAT increase manifold during cold exposure. The in-
creased energy demands coincide with a marked increase in LPL activity, stimulating 
uptake of TRL-derived fatty acids (6–8, 44, 45). Increased LPL activity has been 
shown to be essential for the lipid-lowering effect of cold exposure, as injection of 
heparin or tetrahydrolipstatin compromises LPL-dependent uptake of TRLs and 
TRL-derived fatty acids (6). Since Lpl mRNA in BAT is only moderately increased 
upon prolonged cold exposure, it has been suggested that the pronounced increase in 
LPL activity in BAT occurs at the post-translational level (8, 12). Our data demon-
strate that a substantial part of the increase in LPL activity in BAT during prolonged 
cold exposure is mediated by down-regulation of ANGPTL4. 
 Overall, our f indings reveal a major role for ANGPTL4 in the regulation of 
lipid partitioning during sustained cold. Specif ically, the data implicate ANGPTL4 
as an important mediator of preferential shuttling of TRL-derived fatty acids to BAT 
during cold exposure. Via direct effects on local LPL activity and subsequent fatty acid 
uptake, the reciprocal regulation of ANGPTL4 in BAT and WAT assures an adequate 
fuel delivery to BAT during cold exposure. The differential regulation of ANGPTL4 
and LPL between BAT and WAT leads to corresponding changes in fatty acid uptake 
from TRLs, with our data showing a clear dose-dependent and causal relationship 
between ANGPTL4 expression and TRL-derived fatty acid uptake into both tissues. 
The importance of ANGPTL4 in the regulation of LPL activity during cold comple-
ments the already established role of ANGPTL4 in regulation of LPL during fasting 
and exercise in WAT and skeletal muscle, respectively (13, 14). ANGPTL4 can thus 
be viewed as the master regulator of tissue LPL activity and fatty acid uptake during 
physiological conditions such as fasting, exercise and cold exposure. 
 Our data suggest that the opposite regulation of ANGPTL4 expression dur-
ing prolonged cold between BAT and WAT may be explained by the differential ex-
pression and activation of AMPK between the two tissues. Heterotrimeric AMPK 
has one catalytic (α), and two regulatory (β and γ) subunits, each having distinctive 
isoforms with a tissue-specif ic distribution (37, 38). Tissue-specif ic combinations of 
different subunit isoforms may confer tissue-specif ic properties to AMPK by deter-
mining subcellular localization and substrate targeting, thereby controlling cellular 
and systemic responses to metabolic stressors, including sustained cold (37, 38). In-
deed, with prolonged cold exposure, AMPK becomes progressively activated in BAT 
and only to a minor extent in WAT (36, 46). 
 Systemic activation of AMPK has been previously shown to increase the 
activity of LPL in both heart and muscle and to lower plasma TG levels (14, 47–
51). Furthermore, AMPK activation was found to cause a pronounced reduction in 
ANGPTL4 expression in muscle cells (14). Similar to muscle and heart, we found 
the AMPKα2 catalytic subunit to be abundantly present in BAT, but not WAT (37). 
Together, the increased AMPK activation and different AMPK subunit expression 
in BAT as compared to WAT may explain why the repressive effect of cold-induced 
AMPK activation on ANGPTL4 expression is much more pronounced in BAT than 
in WAT. We suggest that regulation of ANGPTL4 in WAT during cold may be dom-
inated by activation of β-adrenergic signaling, which may explain the increase in 
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ANGPTL4 expression observed in WAT during sustained cold exposure. 
 We provide evidence that regulation of ANGPTL4 by AMPK occurs at the 
transcriptional level, affecting PPARγ-mediated transcription of the Angptl4 gene. 
ANGPTL4 has been repeatedly shown to be a highly sensitive target of all PPAR 
transcription factors in a variety of tissues and cells and following a variety of physi-
ological stimuli (15, 25, 39, 52). Previously, PPARγ-mediated transcription has been 
shown to be inhibited by activation of AMPK (40, 53, 54). A potential link between 
PPARγ and AMPK may be the modulation of co-activator recruitment to PPARγ by 
AMPK. A well-established co-activator of PPARγ that has been shown to be regulat-
ed by AMPK is P300 (41, 43, 55). P300 is a key regulator of the assembly and mobi-
lization of the transcriptional machinery by connecting transcription factors to the 
transcriptional machinery and enhancing DNA accessibility (56). AMPK activation 
enhances P300 degradation and causes phosphorylation of P300 at serine residue 89, 
thereby blocking the interaction of P300 with PPARγ and reducing PPARγ transcrip-
tional activity (41, 55, 57). Although our in vitro data suggest an involvement of P300 
and PPARγ in the suppression of ANGPTL4 by AMPK activation, whether P300 is 
also involved in in vivo regulation of ANGPTL4 during cold exposure remains to be 
determined.
 Despite the unmistakable dependency of BAT LPL activity on ANGPTL4 
expression, a modest cold-induced increase in LPL activity and TRL-derived fatty 
acid uptake is observed in BAT of Angptl4 -/- mice, which may be (partially) explained 
by the moderate increase in Lpl mRNA in BAT in the cold. Alternatively, there may 
be a role for another, yet to be identif ied, cold-induced post-translational modulator 
of LPL. It may be hypothesized that this post-translational modulator is also involved 
in the rapid increase in LPL activity during acute cold exposure (8). 
 No overt abnormalities in cold-tolerance were observed in the Angptl4 -/- or 
Angptl4-Tg mice as compared to wild-type mice. This observation, however, does not 
refute the importance of ANGPTL4 in fuel delivery to BAT during cold exposure. 
BAT is a well-conserved organ, that is postulated to have conferred to mammals the 
evolutionary advantage to survive cold stressors such as birth or low environmental 
temperatures (1). It is likely that differential uptake of TG in other organs and altered 
uptake of other available fuels (free fatty acids, glucose) compensate for the reduced 
uptake of TRL-derived fatty acids to BAT in Angptl4-Tg mice. Strikingly, adipose 
tissue-specif ic deletion of LPL in mice does not result in an overt phenotype (58, 59). 
While plasma TG levels are elevated in these mice, no other parameters were altered, 
indicating that even in mice completely lacking LPL in adipose tissue, alternative 
mechanisms exist to fuel BAT and WAT (58, 59). 
 In conclusion, our data show that regulation of ANGPTL4 is an important 
factor in directing lipid fuels towards BAT and away from WAT during prolonged 
cold exposure. Better understanding of the mechanisms underlying fuel re-distribu-
tion may pave the way for new strategies to combat metabolic diseases, such as car-
diovascular disease and diabetes type 2, in which a mismatch in regulation of lipid 
uptake and usage by tissues is an important feature  (60, 61). 
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SUPPLEMENTAL FIGURES 
Table 1. Primer sequences. 
Gene  Forward primer Reverse Primer 
m36b4 ATGGGTACAAGCGCGTCCTG GCCTTGACCTTTTCAGTAAG 
mAngptl4 GTTTGCAGACTCAGCTCAAGG CCAAGAGGTCTATCTGGCTCTG 
mLpl  GGGAGTTTGGCTCCAGAGTTT GGGAGTTTGGCTCCAGAGTTT 
mUcp1  CCTGCCTCTCTCGGAAACAA TGTAGGCTGCCCAATGAACA 
mPgc1α  AGTCCCATACACAACCGCAGTCGCAACATG CCCTTTCTTGGTGGAGTGGCTGCCTTGG 
mCidea  TGACATTCATGGGATTGCAGAC GGCCAGTTGTGATGACTAAGAC 
mElovl3 TTCTCACGCGGGTTAAAAATGG GAGCAACAGATAGACGACCAC 
mPrdm16  CCACCAGCGAGGACTTCAC GGAGGACTCTCGTAGCTCGAA 
~250 nm
~80 nm
TG clearance
TG clearance
-4h 
Food removal
0h
Injection
rec. TRLs
15 min
Cervical dislocation 
& Perfusion 
20 min
Necropsy
glycerol tri[3H]oleate (TRL FA) 
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B
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TG clearance test
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Day 0
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N = 7 per genotype
Supplemental Figure 1. 
(A & B) Schematic representation of  cold exposure experiment, followed by a triglyceride clearance experiment in which 
either radiolabelled VLDL-like particles or chylomicron-like particles were injected via the tail vein of  Angptl4-/-, wild-type 
and Angptl4-Tg mice. 20 min post-injection mice were sacrificed to analyze the distribution of  the radioactive labels.
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Supplemental Figure 2. 
(A & B) Plasma ANGPTL4 levels in 10 obese (A) and 10 lean (B) individuals before and after exposure to a mild cold (16˚C) 
for 48h (27). Differences between mild cold and baseline were statistically significant in the obese group (paired Student’s 
t-test (p<0.05)). n = 10 individuals per group.
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Supplemental Figure 3. 
(A) Total LPL activity levels, (B) Angptl4 mRNA, and (C) Lpl mRNA in inguinal WAT (iWAT) of  Angptl4-/-, wild-type and 
Angptl4-Tg mice exposed to 4˚C or 28˚C for 10 days. *Statistically significant compared to mice of  equal genotype at 28˚C 
or between groups as indicated by bars, according to two-way ANOVA followed by a post-hoc Tukey HSD test (p<0.05). 
Error bars represent ± SEM. n = 7-10 mice per group
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ABSTRACT 
Lipoprotein lipase (LPL) hydrolyzes triglycerides in triglyceride-rich lipoproteins 
along the capillaries of heart, skeletal muscle, and adipose tissue. The activity of 
LPL is repressed by angiopoietin-like 4 (ANGPTL4) but the underlying mechanisms 
have not been fully elucidated. Our objective was to study the cellular location and 
mechanism for LPL inhibition by ANGPTL4. We performed studies in transfect-
ed cells, ex vivo studies and in vivo studies with Angptl4–/– mice. Co-transfection of 
CHO pgsA-745 cells with ANGPTL4 and LPL reduced intracellular LPL protein 
levels, suggesting that ANGPTL4 promotes LPL degradation. This conclusion was 
supported by studies of primary adipocytes and adipose tissue explants from 
wild-type and Angptl4–/– mice. Absence of ANGPTL4 resulted in accumula-
tion of the mature-glycosylated form of LPL and increased secretion of LPL. 
Blocking ER–Golgi transport abolished differences in LPL abundance between wild-
type and Angptl4–/– adipocytes, suggesting that ANGPTL4 acts upon LPL after LPL 
processing in the ER. Finally, physiological changes in adipose tissue ANGPTL4 
expression during fasting and cold resulted in inverse changes in the amount of 
mature-glycosylated LPL in wild-type but not Angptl4–/– mice. We conclude that 
ANGPTL4 promotes loss of intracellular LPL by stimulating LPL degradation after 
LPL processing in the ER.
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INTRODUCTION 
Circulating triglyceride-rich lipoproteins, such as chylomicrons and very low-density 
lipoproteins (VLDL), supply tissues with lipid nutrients for storage or oxidation. Hy-
drolysis of circulating triglycerides is mediated by lipoprotein lipase (LPL), a glyco-
protein found in multiple tissues, including adipose tissue, brain, heart and skeletal 
muscle (1–4). LPL is produced by parenchymal cells and then transported to the lumi-
nal surface of capillaries by an endothelial cell protein, GPIHBP1 (glycosylphosphati-
dylinositol-anchored high density lipoprotein binding protein 1) (5).
 A critical step in the maturation of LPL is asparagine-linked glycosylation 
(6–8). LPL is glycosylated within the endoplasmic reticulum (ER) via co-translational 
transfer of oligosaccharide chains high in mannose residues (6–9). After being translo-
cated to the Golgi apparatus, the high-mannose oligosaccharides are trimmed and re-
placed by more complex oligosaccharides (6–9). Endoglycosidase H (EndoH) cleaves 
high-mannose oligosaccharides from proteins but not complex oligosaccharides (6, 
10), making it possible to distinguish LPL within the ER and Golgi compartments. 
 The catalytic activity of LPL along the capillary endothelium is considered 
rate-limiting for the lipolytic processing of plasma triglycerides and for the subsequent 
uptake of fatty acids by surrounding tissues (1, 4, 11). To ensure that supply of fatty 
acids to tissues matches metabolic demand, LPL activity is under tight regulatory 
control. Although it is possible to identify small f luctuations in Lpl mRNA levels, LPL 
activity appears to be regulated mainly at the post-translational level (1, 4). An im-
portant physiological regulator of LPL is angiopoietin-like 4 (ANGPTL4). ANGPTL4 
potently inhibits LPL activity in multiple tissues and regulates LPL activity during a 
variety of physiological conditions, including fasting, cold and exercise (12–14). For 
example, changes in the expression of ANGPTL4 (originally called fasting-induced 
adipose factor) allow for swift changes in adipose tissue LPL activity during fasting 
(13, 15). Expression of ANGPTL4 is induced by fatty acids via Peroxisome Prolifera-
tor-Activated Receptors (PPARs) as part of a feedback mechanism aimed at prevent-
ing lipid overload within cells (16, 17).
 Genetic studies strongly support a role for ANGPTL4 in determining plasma 
triglyceride levels in humans and have linked inactivating variants in the ANGPTL4 
gene to a reduced risk of coronary heart disease (18–20). However, cross-sectional stud-
ies have not revealed a clear correlation between the plasma levels of ANGPTL4 and 
triglycerides (21–24). These observations suggest that the plasma pool of ANGPTL4 
may not be primarily responsible for regulating plasma triglyceride levels and that 
the inhibitory effects of ANGPTL4 on LPL activity may not occur exclusively on 
the surface of capillaries. Indeed, Robciuc and coworkers proposed that ANGPTL4 
could inhibit LPL activity not only at the cell surface but also intracellularly, partly 
based on microscopy studies showing co-localization of LPL and ANGPTL4 within 
cells (25). At the same time, recent studies have raised the possibility that ANGPTL4 
regulation of LPL might occur within the subendothelial spaces rather than along 
the capillary lumen (26–28). Studies of 3T3-L1 adipocytes suggested that inhibition 
of LPL activity by ANGPTL4 begins only after these proteins arrive at the cell sur-
face (29). However, the extent to which the cultured cell studies are relevant to LPL 
activity in adipose tissue in vivo is uncertain. Accordingly, our objective in the current 
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studies was to investigate the cellular location and mechanism for LPL inhibition by 
ANGPTL4 in adipose tissue. To address this objective, we used a combination of cell 
culture studies, and ex vivo and in vivo studies of adipocytes and adipose tissue from 
wild-type and Angptl4–/– mice.
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MATERIALS AND METHODS
All animal experiments were performed in accordance with Directive 2010/63/EU 
from the European Union. All animal studies were reviewed and approved by the 
Animal Ethics Committee of Wageningen University.
Cell culture 
CHO pgsA-745 cells were cultured as described previously (30, 31). CHO pgsA-745 
cells were electroporated with an expression vector for Flag-tagged human ANGPTL4 
(either the full-length protein hANGPTL4[1–406] or the amino-terminal domain of 
hANGPTL4 [1–160]) or a vector for V5-tagged human LPL (or empty vector). After 
the cell transfections, the cells were mixed and co-plated in the same well of a 24-
well plate. After 24 h, the cell culture medium was collected for a LPL activity assay. 
After 48 h, the cell culture medium was collected and cell lysates were prepared for 
SDS-PAGE and western blotting. ANGPTL4 and LPL expression vectors were also 
co-transfected into CHO pgsA-745 cells. For those studies, the cells were co-electro-
porated with a vector for Flag-tagged human ANGPTL4 (either hANGPTL4[1–406] 
or hANGPTL4 [1–160]) and a vector for V5-tagged human LPL (or empty vector). 
After 24 h, the cell culture medium was collected for a LPL activity assay. After 48 h, 
the cell culture medium was collected and cell lysates were prepared for SDS-PAGE 
and western blotting.
Isolation and differentiation of stromal vascular fraction
Inguinal or gonadal WAT was removed from Angptl4–/– and wild-type mice and placed 
in DMEM (Lonza) supplemented with 1% penicillin/streptomycin (P/S) and 1% bo-
vine serum albumin (BSA) (Sigma-Aldrich, Houten, The Netherlands). Fat pads from 
2–3 mice were pooled, minced with scissors, and digested for 1 h at 37°C in colla-
genase-containing medium [DMEM with 3.2 mM CaCl2, 1.5 mg/mL collagenase 
type II (C6885, Sigma-Aldrich), 10% fetal calf serum (FCS), 0.5% BSA, and 15 mM 
HEPES]. Next, the cell suspension was f iltered through a 100 μm cell strainer (Fal-
con) and centrifuged at 1600 rpm for 10 min. The supernatant f luid was removed, and 
the pellet containing the stromal vascular fraction was resuspended in erythrocyte 
lysis buffer (155 mM NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA) and incubated for 
2–3 minutes at room temperature. After neutralization, cells were centrifuged at 1200 
rpm for 5 min. Pelleted cells were resuspended in DMEM containing 10% FCS and 
1% P/S and plated. After reaching conf luency, cells were differentiated according to 
standard protocol for 3T3-L1 cells with addition of 1 μM rosiglitazone (32). 
Mouse studies
Tissue samples from angiopoietin-like 4 knockout mice (Angptl4–/–), wild-type mice, 
and Angptl4-transgenic (Angptl4-Tg) mice from previously published studies were used 
for analyses of LPL glycosylation and mass (13, 14, 33–35). Angptl4–/– mice, wild-type 
mice, and Angptl4-Tg mice have been on a C56BL/6J background for > 10 genera-
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tions. Wild-type and Angptl4-Tg mice are littermates. In Angptl4–/– mice part of the 
Angptl4 gene was deleted by homologous recombination in embryonic stem cells, re-
sulting in a non-functional ANGPTL4 protein (33, 34). Angptl4-Tg mice over-express 
the Angptl4 gene in various tissues under the endogenous promoter (35). Brown adipose 
tissue samples from Angptl4–/– and wild-type mice exposed to cold or thermoneutral 
temperature for 10 days were from a study by Dijk et al. (14). Gonadal white adipose 
tissue (WAT) samples from fed, fasted and refed Angptl4–/– and wild-type mice were 
from a study described by Kroupa et al. (13). Hearts from fed and overnight-fasted 
Angptl4–/– and wild-type mice were collected and snap-frozen in liquid nitrogen. For 
“post-heparin” tissues, wild-type and Angptl4–/– mice were fed or fasted for 16 h. The 
mice were then anesthetized with isof lurane and injected with heparin (100 IU/kg in 
0.9% NaCl) through the jugular vein. After 5 min, the mice were killed by cervical 
dislocation. Gonadal WAT was dissected, frozen immediately in liquid nitrogen, and 
stored at –80°C for further analyses. 
LPL activity measurements 
LPL activity levels in culture medium and cell lysates of transfected cells was assessed 
in duplicate with a [3H]triolein substrate (PerkinElmer) as previously described (36). 
WAT explants 
Gonadal WAT was harvested from Angptl4–/– and wild-type mice and placed in DMEM 
supplemented with 1% P/S and 1% BSA. Fat pads were minced into small pieces, 
which were further divided to make small mounds of WAT (~50–100 mg of tissue). 
WAT explants were placed into wells containing medium (DMEM with 1% P/S and 
10% FCS) with or without heparin (50 IU/mL). Explants were incubated for different 
times (as indicated in the f igure legends), after which the medium was harvested and 
explant weights were determined. Explants were immediately lysed to prepare protein 
extracts. Protein concentrations in explants were determined and equal amounts of 
protein were used for SDS-PAGE and western blotting studies. 
NP40 solubilization of adipocytes 
Adipocytes that had been differentiated from the stromal vascular fractions of 
Angptl4–/– and wild-type mice were prepared as described earlier. Upon differenti-
ation, adipocytes were lysed in NP40 lysis buffer (50 mM Tris-HCl, pH 8.0, 0.5% 
NP40, 150 mM NaCl, 5 mM MgCl2) supplemented with protease and phosphatase 
inhibitors (Roche). After centrifugation, the supernatant f luid (NP40S) was mixed 
with 2x Laemmli sample buffer (LSB) and heated at 65°C for 15 min. The pellet was 
resuspended in PBS and 2x LSB and heated at 95°C for 30 min (NP40P). NP40S and 
NP40P fractions were then loaded onto SDS-PAGE for further analyses by western 
blotting. 
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Western blots 
Fat pads, explants and differentiated adipocytes were lysed in a mild RIPA-like lysis 
buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, and 5% 
glycerol; Thermo Scientif ic, Landsmeer, The Netherlands) containing protease and 
phosphatase inhibitors (Roche). Lysates were centrifuged 2–3 times at 13,000 rpm for 
10 min to remove fat droplets. Protein lysates (10–30 μg protein per lane), medium 
(10–15 μL), or plasma (0.75 μL) samples were diluted in Laemmli sample buffer, cooked 
for 5 minutes at 95˚C, and loaded onto pre-casted TGX gels (Bio-Rad, Veenendaal, 
The Netherlands). For Native PAGE, protein lysates were diluted in a SDS-free and 
DTT-free sample buffer, directly loaded onto pre-casted TGX gels, and run in a 
Tris-Glycine running buffer without SDS. The separated proteins were transferred 
onto a PVDF membrane with a Transblot Turbo System (Bio-Rad). Membranes were 
probed with a goat anti-mouse LPL antibody (37); a rabbit anti-mouse HSP90 anti-
body (Cell Signalling Technology, #4874); a rabbit anti-mouse H2A antibody (Ab-
cam, #ab18255); a rat anti-mouse ANGPTL4 antibody (Adipogen, #Kairos 142-2); 
or a rabbit anti-mouse ADIPOQ antibody (ThermoScientif ic, #PAI-054) at 1:5000 
(LPL), 1:2000 (HSP90, ANGPTL4) or 1:1000 (H2A, ADIPOQ ) dilution. All incuba-
tions were performed in Tris-buffered saline, pH 7.5, 0.1% Tween-20 (TBS-T), and 
5% nonfat dry milk. Membranes were washed in the Tris-buffered saline/Tween-20 
solution. Antibody signals were detected with the ChemiDoc MP system (Bio-Rad) 
and Clarity ECL substrate (Bio-Rad). Equal loading of medium and plasma samples 
was verif ied by Coomassie blue staining, H2A or HSP90 expression. 
 Proteins in culture supernatants and cell lysates from transfected CHO pgsA-
745 cells were separated on 12% Bis-Tris SDS-polyacrylamide gels (Life Technolo-
gies) and transferred to a nitrocellulose membrane for western blotting. The antibody 
dilutions were 1:500 for an IRdye800-conjugated mouse monoclonal against the V5-
tag; 1:500 for an IRdye680-conjugated mouse monoclonal against the Myc-tag; 1:500 
for IRdye680-conjugated mouse monoclonal 4-1a against human LPL (38); 1:500 for 
a mouse monoclonal against the Flag-tag (Sigma-Aldrich); 1:2000 for IRdye680-con-
jugated donkey anti-mouse IgG (LI-COR Biosciences); 2 µg/ml for a goat polyclonal 
against β-actin (Santa Cruz Biotechnology); 1:2000 for IRdye680-conjugated donkey 
anti-goat IgG (LI-COR); 2 µg/ml for a polyclonal antibody against human SLURP1 
(Novus Biologicals); 1:2000 for IRdye800-conjugated donkey anti-mouse IgG (LI-
COR).
EndoH and PNGase digestions 
Glycosylation of proteins was analyzed by western blotting after digestion of 10–20 
μg of protein with EndoH or PNGase (New England BioLabs) according to manufac-
turer’s instructions. 
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RESULTS
Secreted ANGPTL4 inactivates LPL outside of the cell 
To assess to what extent secreted angiopoietin-like 4 (ANGPTL4) affects the amount 
of lipoprotein lipase (LPL) and LPL activity in cells and cell culture medium, CHO 
pgsA-745 cells were transfected with either human ANGPTL4 (hANGPTL4) or hu-
man LPL (hLPL) expression vectors. The ANGPTL4-transfected cells were then 
mixed with the LPL-transfected cells and co-plated. Co-plating of hANGPTL4-ex-
pressing cells with hLPL-expressing cells did not change the amount of LPL in the cell 
extracts, but co-plating did reduce the amount of LPL in cell culture medium (Figure 
1A). A similar reduction in the amount of LPL in cell culture medium was found when 
hLPL-transfected cells were co-plated with cells expressing the amino-terminal 160 
residues of hANGPTL4 (Figure 1A). As expected, co-plating of hLPL-expressing 
cells with hANGPTL4-expressing cells resulted in a striking reduction in LPL activ-
ity levels in the cell culture medium (Figure 1B). Thus, the presence of ANGPTL4 
in the cell culture medium reduces the amount of LPL protein in the medium and 
markedly inhibits LPL activity in the medium. However, co-plating of hLPL- and 
hANGPTL4-expressing cells had no effect on intracellular levels of LPL. 
Figure 1. ANGPTL4 inactivates LPL outside of the cell. 
(A) Western blots of  cell culture media and cell lysates of  CHO pgsA-745 cells. Cells were transfected with either a Flag-
tagged ANGPTL4 expression vector or a vector for V5-tagged human LPL. The ANGPTL4- and LPL-transfected cells 
were then mixed and co-plated. A full-length ANGPTL4 expression vector (hANGPTL4[1–406]) or a vector encoding the 
amino-terminal domain of  ANGPTL4 (hANGPTL4 [1–160]) was used. Western blots were probed with an anti-Flag an-
tibody to detect ANGPTL4 (red); an anti-V5 antibody to detect LPL (green); and an anti-actin antibody (red) (as a loading 
control). LPL-CTD, carboxyl-terminal domain of  LPL; ANGPTL4-NTD, amino-terminal domain of  ANGPTL4. (B) Bar 
graph representing LPL activity levels in the media of  CHO pgsA-745 cells that had been transfected with empty vector 
(C); full-length ANGPTL4 alone (FL); the amino-terminal domain of  ANGPTL4 alone (NTD); human LPL alone (LPL); a 
mixture of  ANGPTL4 (full-length)-transfected cells and LPL-transfected cells (LPL + FL); a mixture of  ANGPTL4 (ami-
no-terminal domain)-transfected cells and LPL-transfected cells (LPL + NTD).
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Figure 2. ANGPTL4 inactivates LPL inside cells. 
(A) Western blots of  cell culture media and cell lysates of  CHO pgsA-745 cells that had been co-transfected with an expres-
sion vector for Flag-tagged human ANGPTL4 (hANGPTL4[1–406]) and a vector for V5-tagged human LPL (or empty 
vector). Western blots were probed with an anti-Flag antibody to detect ANGPTL4 (red); an anti-V5 antibody to detect LPL 
(green); and an anti-actin antibody (red) (as a loading control). LPL-CTD, carboxyl-terminal domain of  LPL; ANGPTL4-
CTD, carboxyl-terminal domain of  ANGPTL4. (B) Western blots of  cell culture media and cell lysates of  CHO pgsA-745 
cells co-transfected with an expression vector for myc-tagged human ANGPTL4 (hANGPTL4[1–160]) and a vector for 
V5-tagged human LPL (or empty vector). Western blots were probed with an anti-Myc antibody to detect ANGPTL4 (red); 
an anti-V5 tag antibody (green) or Mab 4-1a (red) to detect LPL; and an anti-actin antibody (red) (as a loading control). LPL-
CTD, carboxyl-terminal domain of  LPL; LPL-NTD, amino-terminal domain of  LPL; ANGPTL4-NTD, amino-terminal 
domain of  ANGPTL4. (C) LPL activity levels in the culture media and cell lysates of  CHO pgsA-745 cells that had been 
transfected with an empty vector alone (C); full-length hANGPTL4 alone (FL), amino-terminal domain of  hANGPTL4 
alone (NTD); full-length ANGPTL4 and LPL (LPL + FL); the amino-terminal domain of  ANGPTL4 and LPL (LPL + 
NTD).
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Co-expression of ANGPTL4 and LPL inactivates LPL within cells
ANGPTL4 and LPL are both secreted glycoproteins, and are expected to follow a 
similar route to the cell surface (6, 8, 39). To determine if ANGPTL4 expression af-
fects the levels of LPL protein inside cells, CHO pgsA-745 cells were simultaneously 
transfected with hLPL and hANGPTL4 expression vectors. Co-transfection of hLPL 
and hANGPTL4 markedly reduced the amount of LPL in both the cell extracts and 
the cell culture medium (Figure 2A). When we performed analogous studies with 
the amino-terminal portion of hANGPTL4 (residues 1–160), a similar reduction in 
the amounts of LPL in the medium and inside cells was found (Figure 2B). We also 
observed markedly reduced amounts of LPL catalytic activity, both within cells and 
in the cell culture medium (Figure 2C). Similar to hLPL, co-transfection of mLPL 
with hANGPTL4 reduced the amount and activity of mLPL within cells and in the 
cell culture medium (Figure 3A & 3B). The reduced amounts of intracellular LPL in 
the co-transfection studies could not be explained by lower levels of LPL transcripts 
(Figure 4A). Likewise, the reduced amounts of intracellular LPL in the ANGPTL4 
co-expression studies could not be explained by a global decrease in secreted proteins 
Figure 3. hANGPTL4 inactivates mouse LPL inside cells. 
(A) CHO pgsA-745 cells were co-transfected with an expression vector for Flag-tagged human ANGPTL4 
(hANGPTL4[1-406]), or the amino-terminus domain of  hANGPTL4 (hANGPTL4[1-160] and a vector for V5-tagged 
human LPL (hLPL) or mouse LPL (mLPL), or empty vector. 48 h later, cell culture media and cell lysates were examined 
by SDS-PAGE and Western blotting. Western blots were probed with an anti-Flag antibody to detect ANGPTL4 (red); an 
anti-V5 tag antibody was used to detect hLPL and mLPL (green). Actin (red) was used as a loading control. LPL-CTD, car-
boxyl-terminal domain of  LPL; ANGPTL4-CTD, carboxyl-terminal domain of  ANGPTL4; ANGPTL4-NTD, amino-ter-
minal domain of  ANGPTL4. (B) Bar graph representing LPL activity levels in cell culture media of  CHO pgsA-745 cells 
that were co-transfected with an expression vector for Flag-tagged human ANGPTL4 (hANGPTL4[1-406]) and a vector for 
V5-tagged human LPL (hLPL) or mouse LPL (mLPL), or empty vector. C; empty vector control; FL, full-length ANGPTL4.
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Figure 4. ANGPTL4 does not affect transcription of LPL or secretion of SLURP1. 
(A) Transcript levels for LPL and ANGPTL4 in CHO pgsA-745 cells that had been transfected with empty control vector 
(C); an expression vector for the Flag-tagged amino-terminal domain of  hANGPTL4 (NTD); a vector for V5-tagged hLPL 
(LPL); or amino-terminal hANGPTL4 and V5-tagged hLPL (LPL+NTD). (B) Western blots of  cell lysates of  CHO pgsA-
745 cells that had been co-transfected with an expression vector for Flag-tagged full-length hANGPTL4 and either a vector 
for V5-tagged hLPL or a vector for hSLURP1. Western blots were probed with an anti-Flag antibody to detect ANGPTL4 
(red); an anti-SLURP1 antiserum (green); an anti-V5 tag antibody to detect LPL (green); and an anti-Actin antibody (red) 
(as a loading control).
inside cells; co-expression of ANGPTL4 with SLURP1, another secreted protein, did 
not result in reduced amounts of intracellular SLURP1 (Figure 4B). 
Deletion of ANGPTL4 causes accumulation of EndoH-resistant LPL in adipo-
cytes
Adipose tissue displays robust expression of both ANGPTL4 and LPL (14). To deter-
mine if ANGPTL4 expression affects intracellular LPL levels in adipose tissue, we 
studied the effects of ANGPTL4 def iciency on LPL protein levels in mouse adipose 
tissue. A def iciency of ANGPTL4 resulted in a marked accumulation of full-length 
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LPL in adipose tissue explants and adipocytes from Angptl4–/– mice (Figure 5A & 
5B). The accumulation of LPL could not be attributed to higher Lpl expression levels 
because Lpl mRNA levels were similar in the explants and adipocytes of wild-type 
and Angptl4–/– mice (Figure 5C & 5D). 
 To determine the location of LPL accumulation in adipose tissue from 
Angptl4–/– mice, adipose tissue lysates were treated with endoglycosidase H (EndoH). 
These studies revealed that the accumulation of LPL in Angptl4–/– explants and ad-
ipocytes was mainly EndoH-resistant LPL (LPL in the Golgi or on the cell surface) 
rather than EndoH-sensitive LPL (LPL within the ER) (Figure 5A & 5B). Further 
studies revealed that the EndoH-resistant LPL could be removed from cells by hepa-
rin, suggesting that the EndoH-resistant LPL in Angptl4–/– adipose tissue explants and 
Angptl4–/– adipocytes represented LPL attached to the cell surface by heparin-sulphate 
proteoglycans (HSPGs) or LPL present in rapidly-releasable secretory vesicles (40, 41) 
(Figure 5A & 5B). 
 The accumulation of heparin-releasable EndoH-resistant LPL in Angptl4–/– 
adipose tissue was accompanied by a constitutively higher release of LPL from gWAT 
explants and adipocytes (Figure 6A & 6B). Treatment with heparin magnif ied these 
differences; signif icantly higher amounts of heparin-releasable LPL were detected in 
the medium of gWAT explants and adipocytes from Angptl4–/– mice as compared to 
wild-type mice (Figure 6A & 6B). By contrast, secretion of ADIPOQ was not altered 
in Angptl4–/– adipocytes, implying that a def iciency of ANGPTL4 did not have a gen-
eral effect on the secretion of adipocyte proteins (Figure 6A & 6B). 
Mechanism of ANGPTL4-mediated loss of LPL
To assess whether ANGPTL4 affects LPL present on the cell surface and/or intra-
cellularly, we treated differentiated adipocytes from Angptl4–/– and wild-type mice 
with heparin to remove cell-surface LPL. The cells were then washed and incubated 
for up to 180 min in the presence of heparin, followed by measurement of LPL levels 
in medium and cells. Heparin was included to prevent the sequestration of LPL on 
cell-surface HSPGs and to prevent its degradation in the medium (42). The accumu-
lation of LPL in the medium was much greater in Angptl4–/– adipocytes than in wild-
type adipocytes, implying increased LPL secretion from Angptl4–/– adipocytes (Fig-
ure 6C). These data suggest that ANGPTL4 promotes intracellular LPL degradation 
in adipocytes, leading to reduced LPL secretion. 
 We next explored the mechanism accounting for the effect of ANGPTL4 on 
specif ically EndoH-resistant LPL in adipocytes. Earlier studies revealed an accumu-
lation of EndoH-sensitive LPL in cld/cld (Lmf1–/–) and Sel1L –/– mice, characterized by 
aggregated LPL in the ER that was targeted for endoplasmic reticulum–associated 
degradation (ERAD) (6, 10, 43–45). To determine if LPL in ANGPTL4-expressing 
cells is targeted for degradation in the ER, we incubated primary adipocytes with 
brefeldin A, a fungal lactone antibiotic that is known to block protein transport from 
the ER and induce translocation of Golgi proteins to the ER. Brefeldin A–mediated 
inhibition of ER–Golgi transport abolished differences in the amounts of total LPL 
and EndoH-resistant LPL between wild-type and Angptl4–/– adipocytes, suggesting 
that ANGPTL4-mediated LPL degradation occurs in a post-ER compartment (Fig-
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Figure 5. ANGPTL4 lowers the amount of LPL on the adipocyte cell surface. 
(A) Western blot of  cell lysates of  gWAT explants from Angptl4–/– and wild-type mice incubated in the absence or presence 
of  heparin (50 IU/mL) for 3 h. Western blots were probed with antibodies against LPL and HSP90 (as loading control). (B) 
Western blot of  cell lysates of  adipocytes that had been differentiated from stromal vascular fractions of  WAT from Angptl4–/– 
and wild-type mice and incubated in the absence or presence of  heparin (10 IU/mL) for 20 min. Western blots were probed 
with antibodies against LPL and HSP90 (as loading control).  (C) Angptl4 and Lpl mRNA levels in gWAT explants from 
Angptl4–/– and wild-type mice. (D) Angptl4 and Lpl mRNA levels in adipocytes that had been differentiated from stromal 
vascular fractions of  WAT from Angptl4–/– and wild-type mice. EndoH-resistant LPL (complex oligosaccharides; Golgi and 
cell surface LPL) is indicated with R; EndoH-sensitive LPL (high-mannose oligosaccharides, ER LPL) is indicated with S.
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Figure 6. ANGPTL4 lowers LPL secretion. 
(A) Western blot of  media of  gWAT explants from Angptl4–/– and wild-type mice treated in the absence or presence of  
heparin (50 IU/mL) for 3 h. Western blots were probed with antibodies against LPL and ADIPOQ. Coomassie blue stain-
ing was used to assess loading. (B) Western blot of  media of  adipocytes that had been differentiated from stromal vascular 
fractions of  WAT from Angptl4–/– and wild-type mice and incubated in the absence or presence of  heparin (10 IU/mL) for 
20 min. Western blots were probed with antibodies against LPL and ADIPOQ. Coomassie blue staining was used to assess 
loading. (C) Western blot of  media of  adipocytes that had been differentiated from stromal vascular fractions of  WAT from 
Angptl4–/– and wild-type mice. Cells were pretreated for 20 min with heparin (10 IU/mL), washed with PBS, and incubated 
with heparin (10 IU/mL) for the indicated times. Western blots were probed with antibodies against LPL and ADIPOQ. 
EndoH-resistant LPL (complex oligosaccharides; Golgi and cell surface LPL) is indicated with R; EndoH-sensitive LPL 
(high-mannose oligosaccharides, ER LPL) is indicated with S.
ure 7A). In support of this notion, no differences in ERAD-associated LPL aggrega-
tion (NP40P ) were observed between adipocytes of wild-type and Angptl4–/– mice (Fig-
ure 7B). Also, incubation of adipocytes with monensin, an inhibitor of medial to the 
trans-Golgi protein transport, abolished differences between wild-type and Angptl4–/– 
adipocytes (Figure 7C). 
 A potential explanation for the effect of ANGPTL4 on EndoH-resistant LPL 
is that ANGPTL4 targets LPL from the trans-Golgi towards lysosomal degradation, 
which has been postulated to account for the removal of up to 80% of basal LPL pro-
duction (41, 42). Accordingly, we treated differentiated adipocytes from Angptl4–/– and 
wild-type mice with different inhibitors of autophagosomal and lysosomal degrada-
tion. Treatment of cells with 3-methyladenine (3MA), a PI3K inhibitor that blocks 
autophagy, as well as with the inhibitors of lysosomal proteases leupeptin and e64D, 
ANGPTL4 promotes intracellular degradation of LPL in adipocytes
107
5
Figure 7. ANGPTL4-mediated loss of LPL protein occurs in a post-ER compartment.
 (A) Western blot of  EndoH-treated cell lysates of  adipocytes that had been differentiated from stromal vascular fractions 
of  WAT from Angptl4–/– and wild-type mice. Cells were treated with 5 µg /mL Brefeldin A for 2 h. Western blots were 
probed with antibodies against LPL and HSP90 (as a loading control). (B) Western blot of  cell lysates of  adipocytes that 
had been differentiated from stromal vascular fractions from WAT of  Angptl4–/– and wild-type mice. Cells were lysed in 
NP-40 lysis buffer. Western blots were probed with antibodies against LPL, HSP90 (as a loading control), and H2A (as a 
loading control). NP40S, NP40-soluble LPL; NP40P, NP40-precipitated LPL; s.e., short exposure; l.e., long exposure. (C) 
Western blot of  EndoH-treated cell lysates of  adipocytes that had been differentiated from the stromal vascular fractions 
of  WAT from Angptl4–/– and wild-type mice. Cells were treated with 10 μM monensin (Mon.) for 3h. Western blots were 
probed with antibodies against LPL and HSP90 (as a loading control). (D) Western blot of  EndoH-treated cell lysates from 
adipocytes that had been differentiated from stromal vascular fractions of  WAT from Angptl4–/– and wild-type mice. The cells 
were treated with 20 µM E64D for 24 h. Western blots were probed with antibodies against LPL and HSP90 (as a loading 
control). (E) Western blot of  EndoH-treated cell lysates of  adipocytes that had been differentiated from stromal vascular 
fractions of  WAT from Angptl4–/– and wild-type mice. Cells were treated with 5 mM 3-methylamine for 10 h. Western blots 
were probed with antibodies against LPL and HSP90 (as a loading control). (F) Western blot of  EndoH-treated cell lysates 
of  adipocytes that had been differentiated from stromal vascular fractions from WAT of  Angptl4–/– and wild-type mice. The 
cells had been treated with 10 mM leupeptin (leup.) for 10 h. Western blots were probed with antibodies against LPL and 
HSP90 (as a loading control). EndoH-resistant LPL (complex oligosaccharides; Golgi and cell surface LPL) is indicated with 
R; EndoH-sensitive LPL (high-mannose oligosaccharides, ER LPL) is indicated with S.
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resulted in a pronounced accumulation of LPL but did not eliminate the differenc-
es in the amounts of EndoH-resistant LPL between Angptl4–/– and wild-type adipo-
cytes (Figure 7D-F ). Of note, 3MA consistently affected levels of the loading control 
HSP90 specif ically in Angptl4–/– adipocytes, despite equal protein loading (data not 
shown). These data suggest that LPL is degraded by lysosomes, but that inhibition of 
lysosomal degradation with e64D, 3MA or leupeptin cannot prevent ANGPTL4-me-
diated reduction in EndoH-resistant LPL. 
Physiological regulation of ANGPTL4 affects LPL quantity and glycosylation in 
vivo
To determine if the physiological regulation of Angptl4 expression affects intracellu-
lar degradation of LPL in vivo, we examined LPL quantity and LPL glycosylation in 
adipose tissue of fed and fasted wild-type and Angptl4–/– mice. Consistent with the ex 
vivo experimental data, the total LPL protein levels and levels of EndoH-resistant LPL 
were noticeably higher in Angptl4–/– adipose tissue than in wild-type adipose tissue 
(Figure 8A & 8B). Accumulation of LPL in Angptl4–/– adipose tissue was observed 
for dimeric LPL (~110 kDa) and multimeric LPL (~220 kDa) as determined by Na-
tive PAGE (Figure 8A). Interestingly, while total LPL protein in WAT of wild-type 
mice mirrored previously published Lpl mRNA levels during fasting and refeeding 
(13), the amount of EndoH-resistant LPL decreased with fasting and increased with 
refeeding (Figure 8C). These changes are in accordance with increased ANGPTL4 
mRNA and protein levels upon fasting and decreased ANGPTL4 mRNA and protein 
levels upon refeeding (Figure 8D) (13). By contrast, the amount of EndoH-resistant 
LPL in WAT of Angptl4–/– mice was not regulated by fasting and slightly increased by 
refeeding (Figure 8C). Together, these data imply that the reciprocal regulation of 
EndoH-resistant LPL levels upon fasting and feeding in wild-type mice is likely me-
diated by ANGPTL4.
 To determine whether the increased amount of EndoH-resistant LPL in adi-
pose tissue of Angptl4–/– mice ref lects the absence of ANGPTL4-mediated inhibition of 
LPL in capillaries, we detached LPL from the endothelium by perfusing tissues with 
heparin and injecting heparin intravenously. As expected, heparin reduced amounts 
of EndoH-resistant LPL in WAT lysates but did not eliminate the differences in En-
doH-resistant LPL between wild-type and Angptl4–/– mice (Figure 8E & 8F ). Togeth-
er, these data suggest that EndoH-resistant LPL was inside cells or was within the 
interstitial spaces (possibly on the surface of adipocytes). Interestingly, the levels of 
LPL in the pre-heparin plasma were higher in Angptl4–/– mice than in wild-type mice, 
suggesting that some of the LPL that accumulates in the setting of Angptl4 def iciency 
ends up in plasma (Figure 9A).
To exclude the possibility that the regulation of LPL by ANGPTL4 in adipocytes is 
an artefact related to the use of Angptl4–/– adipocytes (where ANGPTL4 is completely 
absent), we assessed total and EndoH-resistant LPL levels in mouse adipose tissue 
from Angptl4–/–, Angptl4+/–, wild-type, and Angptl4-Tg mice. A clear dose-dependent 
reduction of EndoH-resistant LPL was observed with increasing ANGPTL4 levels 
(Figure 9B & 9C). In addition, we tested whether inducing ANGPTL4 expression 
in 3T3-F442a and 3T3-L1 adipocytes with rosiglitazone leads to reduced amounts of 
ANGPTL4 promotes intracellular degradation of LPL in adipocytes
109
5
Figure 8. Physiological regulation of ANGPTL4 expression affects levels of EndoH-resistant LPL in vivo. 
(A) Western blot of  gWAT lysates of  Angptl4–/– and wild-type mice as analysed by SDS-PAGE and Native PAGE. Western 
blots were probed with antibodies against LPL and HSP90. Coomassie blue staining was used to assess loading. (B) Western 
blot of  EndoH-treated and PNGase-treated gWAT lysates of  Angptl4–/– and wild-type mice. Western blots were probed with 
antibodies against LPL and HSP90 (as a loading control). (C) Western blot of  EndoH-treated gWAT lysates prepared from 
ad libitum fed, overnight-fasted or refed Angptl4–/– and wild-type mice. The tissue samples were taken from an experiment 
described earlier (13). Western blots were probed with an antibody against LPL; Coomassie blue staining was used to assess 
loading. (D) Western blot of  gWAT lysates prepared from ad libitum fed, overnight-fasted, or refed wild-type mice. The 
tissue samples were taken from an experiment described earlier (13). Western blots were probed with an antibody against 
ANGPTL4; Coomassie blue staining was used to assess loading.  (E) Western blot of  EndoH-treated gWAT lysates from 
Angptl4–/– and wild-type mice that were either not perfused or perfused with PBS containing heparin (50 IU/mL). Western 
blots were probed with antibodies against LPL and HSP90 (as a loading control). (F) Western blot of  EndoH-treated gWAT 
lysates prepared from fed and overnight-fasted Angptl4–/– and wild-type mice that had been given an intravenous injection of  
heparin (100 IU/kg). Western blots were probed with antibodies against LPL and HSP90 (as a loading control). EndoH-re-
sistant LPL (complex oligosaccharides; Golgi and cell surface LPL) is indicated with R; EndoH-sensitive LPL (high-mannose 
oligosaccharides, ER LPL) is indicated with S.
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Figure 9. Levels of EndoH-resistant LPL are inversely related to Angptl4 expression. 
(A) Western blot on 0.75 µl of  plasma from Angptl4–/– and wild-type mice. Western blots were probed with an antibody 
against LPL; Coomassie blue staining was used to assess loading. (B) Western blot of  EndoH-treated WAT lysates prepared 
from Angptl4–/–, Angptl4+/–, and wild-type mice. Western blots were probed with an antibody against LPL; Coomassie blue 
staining was used to assess loading.  (C) Western blot of  EndoH-treated WAT lysates prepared from Angptl4–/–, wild-type, 
and Angptl4-Tg mice. Western blots were probed with an antibody against LPL; Coomassie blue staining was used to assess 
loading. (D) Western blot of  EndoH-treated lysates of  3T3-F442a adipocytes that had been treated with rosiglitazone (10 
µM) or DMSO control for 6 h. Western blots were probed with antibodies against LPL, ANGPTL4 and HSP90 (as a loading 
control). (E) Western blot of  EndoH-treated lysates of  3T3-L1 adipocytes that had been treated with rosiglitazone (10 µM) 
or DMSO control for 6 h. Western blots were probed with antibodies against LPL, ANGPTL4 and HSP90 (as a loading 
control). EndoH-resistant LPL (complex oligosaccharides; Golgi and cell surface LPL) is indicated with R; EndoH-sensitive 
LPL (high-mannose oligosaccharides, ER LPL) is indicated with S.
EndoH-resistant LPL. In rosiglitazone-treated adipocytes, ANGPTL4 expression was 
increased concomitant with a reduction in levels of EndoH-resistant LPL (Figure 9D 
& 9E). 
 A f inal question is whether physiological regulation of ANGPTL4 expres-
sion affects LPL abundance and LPL glycosylation in other tissues. Prolonged cold 
exposure markedly increases LPL activity in brown adipose tissue (BAT) as a result 
of reduced ANGPTL4 expression (14). As in WAT, the amount of EndoH-resistant 
LPL in BAT was noticeably higher in Angptl4–/– mice than in wild-type mice both at 
thermoneutral and cold temperatures (Figure 10A). Cold exposure mildly affected 
levels of multiple loading controls, despite an equal loading of protein (Figure 10A; 
data not shown). Consistent with reduced ANGPTL4 expression after prolonged cold 
exposure, the amount of EndoH-resistant LPL in BAT was markedly increased in 
wild-type mice but less so in Angptl4–/– mice (Figure 10B). In contrast, the amounts 
of total and EndoH-sensitive LPL in hearts of Angptl4–/– and wild-type mice during 
basal and fasting conditions were not different (Figure 10B). Thus, it appears that 
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ANGPTL4-mediated loss of EndoH-resistant LPL in vivo requires a high basal level 
of ANGPTL4 expression, which is characteristic of BAT and WAT but not heart (14).
Figure 10. ANGPTL4 regulates levels of EndoH-resistant LPL in adipose tissue but not heart. 
(A) Western blot of  EndoH-treated BAT lysates from Angptl4–/– and wild-type mice exposed to cold (4°C) or thermoneutral 
temperature (28°C) for 10 days. The tissue samples were taken from an experiment described earlier (14). Western blots were 
probed with antibodies against LPL and HSP90 (as a loading control). (B) Western blot on EndoH-treated heart lysates from 
Angptl4–/– and wild-type mice fed ad libitum or fasted overnight. Western blots were probed with antibodies against LPL and 
HSP90 (as a loading control). EndoH-resistant LPL (complex oligosaccharides; Golgi and cell surface LPL) is indicated with 
R; EndoH-sensitive LPL (high-mannose oligosaccharides, ER LPL) is indicated with S.
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DISCUSSION 
ANGPTL4 is known to inhibit LPL catalytic activity in a variety of tissues, including 
skeletal muscle and adipose tissue (17, 46). Here we show that ANGPTL4 reduces LPL 
protein in adipocytes by promoting intracellular degradation. Co-transfecting CHO 
pgsA-745 cells with ANGPTL4 and LPL expression vectors—but not co-plating of 
independently transfected cells—markedly reduced the amount of LPL within cells. 
Conversely, the absence of ANGPTL4 expression in adipocytes led to an accumula-
tion of heparin-releasable, EndoH-resistant LPL. The suppressive effect of ANGPTL4 
on total and EndoH-resistant LPL in adipose tissue was conf irmed in adipose tissue in 
vivo. Together, our f indings demonstrate that ANGPTL4 reduces the amount of LPL 
protein within adipocytes by promoting LPL degradation after its post-translational 
processing in the ER (see Figure 11 for a schematic model). 
 Inactivating variants in the human ANGPTL4 gene have been repeatedly 
linked to low plasma triglycerides and elevated HDL cholesterol, and have been asso-
ciated with a reduced risk of coronary heart disease (18–20). Given the marked impact 
of ANGPTL4-inactivating mutants on plasma triglycerides, it is somewhat surprising 
that no clear correlation between plasma ANGPTL4 and plasma triglyceride levels 
has been observed (21–24, 47–49). A possible explanation for this apparent discrep-
ancy is that ANGPTL4 regulates LPL via a local mechanism rather than via an endo-
crine mechanism—so as to match the uptake of fatty acids to the metabolic needs of 
underlying tissue. Our data strongly suggest that ANGPTL4 impacts LPL locally by 
acting on LPL intracellularly along the secretory pathway (25). An important action 
of ANGPTL4 inside the cell and in the subendothelial space rather than intravascu-
larly is consistent with the observation that both circulating triglyceride-rich lipopro-
teins and GPIHBP1 protect LPL from inhibition by ANGPTL4 (27, 28). It should be 
noted that our f indings per se do not argue against the ability of ANGPTL4 to act 
on extracellular and intravascular LPL. Indeed, secreted ANGPTL4, recombinant 
ANGPTL4, and anti-ANGPTL4 antibodies have all been shown to be able to im-
pact extracellular LPL activity (25, 28, 50). In addition, liver-specif ic Angptl4 overex-
pression or injection of mice with recombinant ANGPTL4 effectively lowers plasma 
triglycerides and plasma LPL activity levels, implying that circulating ANGPTL4 is 
able to target and inhibit intravascular LPL (33, 51). Similarly, monoclonal antibodies 
against ANGPTL4—which are expected to primarily affect intravascular ANGPTL4 
and to a lesser extent subendothelial ANGPTL4—have been shown to potently lower 
plasma triglyceride levels in hyperlipidaemic mice and monkeys (19, 52, 53). Future 
studies are necessary to assess the relative importance of intracellular, subendotheli-
al, and intravascular inhibition of LPL by ANGPTL4. It can be speculated that the 
importance of the three routes may differ between tissues and may depend on the 
physiological state of the organism.
 Our experiments show that EndoH-resistant LPL could be rapidly released 
by heparin, suggesting that the accumulated EndoH-resistant LPL in Angptl4–/– mice 
is either bound to HSPGs on the cell surface or located in rapidly-releasable secre-
tory vesicles (40, 41). The precise location for the interaction of ANGPTL4 and LPL 
within cells remains to be determined. However, both ANGPTL4 and LPL are se-
creted proteins that consequently are expected to be found at similar locations within 
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the cell, which limits the applicability of immunof luorescence studies. Makoveichuk 
and co-workers found that ANGPTL4-producing cells have lower LPL activity in 
cell culture medium but concluded that the inhibition of LPL by ANGPTL4 oc-
curred after both proteins arrived at the cell surface (29, 50). Our data suggest that 
ANGPTL4-mediated removal of LPL starts within cells—before LPL is secreted. In 
the presence of heparin, which is known to stabilize LPL (42), the secretion of LPL by 
Angptl4–/– adipocytes is higher than by wild-type adipocytes. Similarly, co-expression 
of ANGPTL4 and LPL in CHO pgsA-745 cells, which are def icient in cell-surface 
HSPGs (54), markedly reduced amounts of LPL within cells. Presently, we cannot 
fully exclude the possibility that the elimination of LPL occurs (partly) on the cell 
surface, as secreted LPL may be inactivated by ANGPTL4 on the cell surface and 
directly taken up by the cell for degradation. However, our data strongly suggest that 
ANGPTL4 eliminates the majority of LPL before the enzyme reaches the cell surface. 
ANGPTL4 could mediate intracellular degradation of LPL by stimulating endosomal 
transport of LPL from the (trans-)Golgi or cell surface to lysosomes (42, 55–58). Pulse-
chase experiments have shown that ~80% of newly synthesized LPL in adipocytes is 
degraded intracellularly, primarily by lysosomes (41, 42). Our data conf irmed that in-
hibition of the lysosomal pathway reduces intracellular degradation of LPL. However, 
inhibition of autophagosomal or lysosomal degradation did not abolish differences in 
the intracellular LPL levels between Angptl4–/– and wild-type adipocytes. It is possible 
that the use of chemical inhibitors may not permit us to detect the effect of ANGPTL4 
Figure 11. Schematic model. 
Within the ER, LPL acquires oligosaccharides side chains via co-translational transfer of  oligosaccharides high in mannose 
residues. Upon translocation to the Golgi apparatus, the high-mannose oligosaccharides are trimmed and replaced by more 
complex oligosaccharides. In the absence of  ANGPTL4 (i.e., Angptl4–/– adipocytes), LPL with complex oligosaccharide 
side chains is packaged in secretory vesicles and secreted. Secreted LPL accumulates on the cell surface of  adipocytes, 
mostly bound to heparin-sulphate proteoglycans (HSPGs). In ANGPTL4-expressing adipocytes (i.e. wild-type adipocytes), 
ANGPTL4 interacts with LPL in a post-ER compartment. This interaction leads, potentially via converting LPL homod-
imers to monomers, to degradation of  LPL. This results in a specific reduction of  LPL with complex oligosaccharide side 
chains in wild-type adipocytes versus Angptl4–/– adipocytes. Once secreted, ANGPTL4 also reduces levels and activity of  
secreted LPL.
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on lysosomal degradation of LPL or that ANGPTL4-induced removal of EndoH-re-
sistant LPL occurs, at least in part, in a compartment other than the lysosomes. One 
possibility is that ANGPTL4 alters LPL protein conformation and stability or inter-
feres with the addition of complex oligosaccharides. Biochemical studies have indicat-
ed that ANGPTL4 inactivates LPL by converting the catalytically active LPL dimers 
into catalytically inactive monomers (59). Accordingly, the degradation of LPL could 
be secondary to an effect of ANGPTL4 on dimer–monomer conversion and/or LPL 
protein stability. The exact mechanism by which ANGPTL4 promotes intracellular 
LPL degradation will be the subject of further investigation. 
 The fact that LPL might be regulated before secretion is not surprising giv-
en that other key players in lipid metabolism, illustrated by apolipoprotein B and 
the LDL receptor, are regulated along the secretory pathway (60–65). We propose 
that a multilevel regulation of LPL by ANGPTL4, along with tight regulation of 
ANGPTL4 expression, permits for rapid adjustments in local LPL activity in accord-
ance with the requirements of the tissue. To assure the appropriate distribution of 
lipid nutrients, ANGPTL4 may collaborate with its family members ANGPTL3 and 
ANGPTL8 to regulate LPL activity levels during different physiological conditions 
(66). While ANGPTL3 and ANGPTL8 have been proposed to mainly exert their ac-
tions via an endocrine mechanism, it would be of interest to study whether ANGPTL3 
and ANGPTL8 may also regulate LPL intracellularly and promote LPL degradation 
(66). In this context, it is interesting to mention that homozygous carriers of an inac-
tivating mutation in the ANGPTL3 gene have markedly higher levels of post-heparin 
LPL mass and activity as compared to non-carriers (67).
 In conclusion, our data indicate that ANGPTL4 interacts with LPL inside 
cells, both in CHO pgsA-745 cells and in adipocytes ex vivo and in vivo. ANGPTL4 pro-
motes intracellular degradation of LPL within adipocytes after LPL processing within 
the ER. Together, our studies reveal a novel site and mechanism for ANGPTL4-me-
diated regulation of LPL activity.
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ABSTRACT 
Lipoprotein lipase (LPL) hydrolyzes triglycerides from circulating triglyceride-rich 
lipoproteins at the capillary endothelium to yield fatty acids that are stored or ox-
idized in the underlying parenchymal cells. To assure the effective distribution of 
fatty acids, the activity of LPL is tightly regulated at the post-translational level. In 
vitro studies indicate that LPL is cleaved by members of the proprotein convertase 
subtilisin/kexin (PCSK) protein family. Our objective was to assess the relevance of 
PCSK-mediated cleavage of LPL in vivo and to clarify the underlying mechanisms. By 
treatment of different in vitro adipocyte models with the PCSK-inhibitor Dec-RVKR-
CMK, we demonstrate that LPL is cleaved by PCSKs in the adipose tissue. Treatment 
of mature 3T3-L1 adipocytes with heparin revealed that (part of ) the LPL cleavage 
occurs intracellularly, suggesting a role for the trans-Golgi located PCSK3. Indeed, 
siRNA-mediated knockdown of Pcsk3 signif icantly reduced the amount of LPL cleav-
age in cell culture medium and cell lysates of 3T3-L1 adipocytes. Finally, we show 
that PCSK-mediated cleavage of LPL is diminished in adipocytes of mice lacking 
angiopoietin-like 4 (ANGPTL4), a well-established inhibitor of LPL. In conclusion, 
cleavage of LPL by PCSKs is a physiological process in adipocytes that may be pro-
moted by ANGPTL4.
ANGPTL4 promotes the intracellular cleavage of LPL by PCSK3 
123
6
INTRODUCTION 
At the capillary endothelium, lipoprotein lipase (LPL) hydrolyzes triglycerides from 
circulating triglyceride-rich lipoproteins such as chylomicrons or very low-density li-
poproteins. LPL-mediated hydrolysis of circulating triglycerides yields free fatty acids 
and monoglycerides that are either stored or oxidized by the underlying parenchymal 
cells, including (cardio)myocytes and adipocytes (1). Expression of LPL is limited to 
the parenchymal cells and, accordingly, LPL requires active transport to the endothe-
lial cell surface by the enzyme GPIHBP1 (glycosylphosphatidylinositol-anchored high 
density lipoprotein binding protein 1) (2). To assure an effective distribution of fatty 
acids, the activity of LPL is tightly regulated, primarily at the post-translational level 
(3).  
 Three members of the angiopoietin-like (ANGPTL) protein family potent-
ly inhibit LPL activity at the post-translational level; ANGPTL3, ANGPTL4 and 
ANGPTL8 (4). ANGPTL3 and ANGPTL8 circulate in the blood and cooperate to 
inhibit the activity of LPL in oxidative tissues, such as the heart, upon refeeding (5, 
6). In contrast, tissue-specif ic changes in the expression of ANGPTL4 determine the 
changes in LPL activity that occur during physiological conditions such as exercise, 
fasting and cold exposure (7–9). ANGPTL4 inhibits LPL activity intracellularly, in 
the subendothelial spaces and at the endothelium (10–12). However, the exact mech-
anisms by which ANGPTL4 inhibits LPL remain debated. For example, ANGPTL4 
has been proposed to convert the LPL dimer into catalytically inactive monomers or 
to function as a non-competitive, reversible inhibitor of LPL (13, 14). 
 Members of the proprotein convertase subtilisin/kexin (PCSK) protein fam-
ily (PCSK1-7, SKI-1/S1P and PCSK9) are calcium-dependent serine endopeptidas-
es that convert proproteins into their active forms by cleavage (15, 16). PCSK1-7 
recognize and cleave substrates at specif ic lysine- and/or arginine-containing basic 
amino acid sequences (15). Despite overlap in substrate recognition, their functions 
are tissue-specif ic and dependent on their cellular localization. For example, PCSK3 
(FURIN) is primarily found in the trans-Golgi network, in the endosomes and on the 
cell surface, while PCSK5 (PC5/6) and PCSK6 (PACE4) are primarily present on the 
cell surface (16). Interestingly, several PCSKs have been implicated in the cleavage of 
proteins involved in intravascular lipolysis. For example, ANGPTL3 and ANGPTL4 
are potently cleaved by PCSKs in vitro and in vivo, whereas LPL is post-translationally 
cleaved by PCSKs in vitro (17–21).  
 Here, our objective was to assess whether PCSK-mediated cleavage of LPL 
also occurs in vivo in the adipose tissue, a tissue with a high expression of LPL. We 
show, for the f irst time, that cleavage of LPL by PCSKs takes place in the adipose tis-
sue and that this cleavage is mediated by PCSK3. Furthermore, our data suggest that 
ANGPTL4 promotes PCSK-mediated cleavage of LPL in adipocytes, an observation 
that may help to clarify how ANGPTL4 inhibits adipose tissue LPL activity. 
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MATERIALS AND METHODS
All animal experiments were performed in accordance with Directive 2010/63/EU 
from the European Union. All animal studies were reviewed and approved by the 
Animal Ethics Committee of Wageningen University.
Chemicals
AICAR, dexamethasone, IBMX, insulin, rosiglitazone, and intralipid were from Sig-
ma. Furin inhibitor I was from Cayman Chemicals (via Sanbio, Uden, The Nether-
lands). A769662 was from Tocris (Tocris Bioscience, Bristol, United Kingdom). 
Cell culture 
3T3-L1 f ibroblasts (P7-P16) were maintained in DMEM (Lonza, Verviers, Belgium) 
supplemented with 10% newborn calf serum (NCS) (Lonza) and 1% penicillin/strep-
tomycin (P/S) (Lonza). Two days post-conf luency, cells were switched to DMEM, 
supplemented with 10% fetal bovine serum (FBS), 1% P/S, 0.5 mM IBMX, 10 μM 
dexamethasone, 5 μg/mL insulin for 2 days. Subsequently, cells were maintained in 
DMEM supplemented with 10% FBS, 1% P/S, and 5 μg/mL insulin for 6 days and 
switched to DMEM with 10% FBS and 1% P/S for 3 days, after which experiments 
were performed  as indicated in f igure legends (22). To examine the accumulation of 
amino-terminal LPL on the cell surface, mature 3T3-L1 adipocytes were incubated 
with 10 IU/mL heparin for 20 minutes.
 For isolation and differentiation of primary adipocytes, inguinal WAT was 
removed from Angptl4–/– and wild-type mice and placed in DMEM supplemented with 
1% P/S and 1% bovine serum albumin (BSA) (Sigma-Aldrich) (10). Material from 
2–3 mice was pooled, minced with scissors, and digested in collagenase-containing 
medium [DMEM with 3.2 mM CaCl2, 1.5 mg/mL collagenase type II (C6885, Sig-
ma-Aldrich), 10% FBS, 0.5% BSA, and 15 mM HEPES] for 1 h at 37°C. Following 
digestion, the cells were f iltered through a 100 μm cell strainer (Falcon) to remove 
remaining cell clumps. The cell suspension was centrifuged at 1600 rpm for 10 min, 
after which the supernatant was removed and the pellet was resuspended in erythro-
cyte lysis buffer (155 mM NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA). Upon incubation 
for 2–3 minutes at room temperature, cells were centrifuged at 1200 rpm for 5 min 
and the pelleted cells were resuspended in DMEM supplemented with 10% FCS and 
1% P/S, and plated. Upon conf luency, the cells were differentiated according to the 
protocol as described above for 3T3-L1 cells, with the addition of 1 μM rosiglitazone 
during the initial differentiation step. 
 For WAT explants, gonadal WAT was taken from wild-type mice and 
Angptl4–/– mice and placed in DMEM supplemented with 1% P/S and 1% BSA. Fat 
pads were minced into small pieces and divided into small mounds of WAT (~50–100 
mg of tissue). WAT explants were placed into wells containing medium (DMEM with 
1% P/S and 10% FCS) and incubated as indicated in the f igure legends. Next, the 
medium was harvested and explant weights were determined. Explants were immedi-
ately lysed to prepare protein extracts. 
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siRNA knockdown 
Dharmacon ON-TARGETplus SMARTpool siRNAs against mouse Pcsk3 were pur-
chased from Thermo Fisher-Scientif ic. siRNAs were diluted in Dharmacon 1x siRNA 
buffer (f inal concentration 20 mM KCl, 6 mM HEPES pH 7.5, 0.2 mM MgCL2). 
Transfections were performed with Lipofectamine RNAiMAX transfection reagent 
(Life Technologies, Bleiswijk, The Netherlands) at a concentration of 10 nM siR-
NA and 1.5 µL transfection reagent for a 24-wells plate. To examine the impact of 
Pcsk3 knockdown on LPL cleavage, mature 3T3-L1 adipocytes were washed with 
PBS, trypsinized and collected in DMEM. Following centrifugation at 1250 rpm for 
5 minutes, pelleted cells were re-suspended and f iltered through a 70 µM cell strainer. 
Adipocytes were plated at 70% conf luency and two hours later siRNAs complexed to 
Lipofectamine were added. Cleavage of LPL was examined after 48 hours of incuba-
tion.
Mouse studies
Tissue samples from Angptl4 knockout mice (Angptl4–/–) and wild-type mice were taken 
to assess LPL cleavage. Angptl4–/– mice and wild-type mice have been on a C56BL/6J 
background for > 10 generations. To assess regulation of Pcsk3 during different phys-
iological conditions, WAT from previously published studies was used. WAT from 
wild-type mice exposed to cold or thermoneutral temperature for 10 days were from 
a study by Dijk et al. (8). WAT from fed and fasted mice were from a study by Kersten 
et al. (23). WAT from mice injected with 1 mg/kg CL316,243 were from a study by 
Dijk et al. (submitted for publication). For the tissue panel, wild-type mice (n=4) were 
euthanized and multiple tissues were harvested, snap-frozen in liquid nitrogen and 
stored at -80˚ C until further analyses. 
Western blots 
Fat pads, WAT explants and differentiated primary adipocytes were lysed in RIPA 
buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate 
and 1% SDS; Thermo Fisher-Scientif ic, Landsmeer, The Netherlands) supplemented 
with protease and phosphatase inhibitors (Roche Diagnostics, Almere, The Neth-
erlands). Following homogenization, lysates were placed on ice for 30 minutes and 
centrifuged 2–3 times at 13,000 rpm for 10 min at 4˚C to remove fat and cell debris. 
Concentration of protein lysates was determined by using a bicinchoninic acid (BCA) 
assay (Thermo Fisher-Scientif ic). Protein lysates (10–30 μg protein per lane) or me-
dium aliquots (10–15 μL) were loaded onto 8-16% or 10% Criterion gels (Bio-Rad, 
Veenendaal, The Netherlands). Next, proteins were transferred onto a PVDF mem-
brane using the Transblot Turbo System (Bio-Rad). Membranes were probed with a 
goat anti-mouse LPL antibody (24); a rabbit anti-mouse HSP90 antibody (Cell Signa-
ling Technology, #4874); a rat anti-mouse ANGPTL4 antibody (Kairos 142-2, Adipo-
gen); a mouse anti-mouse β-TUBULIN (sc-5274, Santa Cruz); or a rabbit anti-mouse 
PCSK3 (Abcam, ab183495) at 1:5000 (LPL), 1:2000 (HSP90) or 1:1000 (PCSK3) di-
lutions. Blocking, primary antibody incubations and secondary antibody incubations 
were all done in Tris-buffered saline, pH 7.5, 0.1% Tween-20 (TBS-T), and 5% w/v 
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skimmed milk. In between, membranes were washed in TBS-T. Quantif ication was 
performed with the ChemiDoc MP system (Bio-Rad) and Clarity ECL substrate (Bio-
Rad). Equal loading of medium samples was verif ied by Coomassie blue staining. 
RNA isolation and qPCR
To isolate RNA, tissues or cells were homogenized using TRIzol (Thermo Fisher-Sci-
entif ic) in a Qiagen Tissue lyser II (Qiagen, Venlo, The Netherlands) or by pipetting 
up and down. RNA was reverse transcribed using the First Strand cDNA synthesis kit 
(Thermo Fisher-Scientif ic). qPCR analyses were done on a CFX384 Real-Time PCR 
platform (Bio-Rad) with the SensiMix PCR mix from Bioline (GC biotech, Alphen 
aan de Rijn, The Netherlands).
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RESULTS 
LPL is cleaved in adipose tissue by PCSKs
Examination of western blots of LPL in different adipocyte and adipose tissue models 
consistently revealed a band of ~33 kDa below the band of full-length LPL of ~55 
kDa and corresponding to the amino-terminal domain of LPL (Figure 1A) (10, 25) 
(A. Beigneux, personal communications). Previously, members of the proprotein con-
vertase subtilisin/kexin (PCSK) family were suggested to cleave LPL at residues 321-
324 to yield nearly complete amino-terminal and carboxyl-terminal domains (21). To 
examine whether the observed amino-terminal LPL was the result of PCSK-mediated 
cleavage, mature 3T3-L1 and 3T3-F442a adipocytes, as well as primary adipocytes 
and WAT explants were treated with the inhibitor Dec-RVKR-CMK (dec-CMK) to 
block PCSK activity (26). In all adipose tissue models, incubation with dec-CMK 
consistently resulted in the almost complete disappearance of amino-terminal LPL 
in cell culture medium and cell lysates, indicating that LPL is cleaved by PCSKs in 
adipocytes (Figure 1A).  
PCSK3 is expressed in adipose tissue and cleaves adipocyte LPL
To assess whether adipocyte LPL is cleaved by PCSKs intracellularly or upon secre-
tion, we treated 3T3-L1 adipocytes with heparin to release LPL bound to heparin 
sulphate proteoglycans (HSPGs) from the cell surface. As expected, heparin treatment 
resulted in a pronounced increase of LPL in the cell culture medium, along with a 
concomitant reduction of LPL in the cell lysates (Figure 2A & Figure 2B). However, 
in line with the reported importance of carboxyl-terminal LPL for HSPG binding, the 
amount of amino-terminal LPL observed in cell culture medium and cell lysates was 
unaltered (Figure 2A & Figure 2B) (25, 27). These data indicate that no or little 
amino-terminal LPL is bound to HSPGs on the cell surface and that amino-terminal 
LPL in cell lysates must originate from intracellular LPL cleavage. 
 Given that LPL is cleaved by PCSKs intracellularly, a promising candidate 
for LPL cleavage in adipocytes is PCSK3, as it is activated and active intracellularly in 
the trans-Golgi (16). Expression prof iling showed that PCSK3 is most highly expressed 
in liver and kidney, with comparatively low but clearly detectable PCSK3 expression 
in adipose tissue and in adipocytes (Figure 3A & 3B). In the adipose tissue, PCSK3 
appears to be present in its mature ~98 kDa form and its proteolytically cleaved, 
shed ~90 kDa form (Figure 3A) (28). To assess whether PCSK3 might be involved in 
LPL cleavage in adipocytes, we knocked down Pcsk3 in mature 3T3-L1 adipocytes by 
means of siRNA. SiRNA-mediated knockdown resulted in a 90% reduction in Pcsk3 
expression levels and a near complete loss of the mature PCSK3 protein, as assessed 
by western blot (Figure 3C & Figure 3D). Surprisingly, however, knockdown of 
PCSK3 did not substantially impact protein levels of shed PCSK3 (Figure 3D). In 
line with a role for PCSK3 in LPL cleavage, the knockdown of Pcsk3 signif icantly 
reduced the amount of LPL cleavage in cell culture medium and cell lysates (Figure 
3D).  
Amino-terminal LPL is cleared by the lysosomes
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Figure 1. LPL is cleaved by PCSKs in adipocytes.
 (A) Western blots of  cell culture medium (upper panels) and cell lysates (lower panels) of  mature 3T3-L1 adipocytes, mature 
3T3-F442a adipocytes, primary adipocytes differentiated from the stromal vascular fraction of  WAT and WAT explants, 
that were treated with 50 μM Dec-RVKR-CMK (dec-CMK) for 9h. Western blots were probed with antibodies against LPL 
and HSP90 (as a loading control). Coomassie blue staining was performed as a loading control for cell culture medium, 
primary adipocytes and WAT explants. 
Previously, PCSK-mediated cleavage was shown to promote the inactivation of en-
dothelial lipase, a family member of LPL (21). Since the PCSK-cleavage site in LPL is 
situated in the middle of the protein, it may be suggested that PCSK-mediated cleav-
age might also serve to inactivate LPL (21). Since full-length LPL is known to be de-
graded in the lysosomes in adipocytes, we incubated mature 3T3-L1 adipocytes and 
primary adipocytes with baf ilomycin A1 (BafA1) and ammonium chloride (NH4Cl) to 
inhibit lysosomal degradation and to assess the fate of amino-terminal LPL (29). In 
agreement with previous studies, treatment of adipocytes with the lysosomal inhibi-
tors BafA1 and NH4Cl signif icantly increased proteins levels of full-length LPL in cell 
lysates and to a lesser extent in the cell culture medium (Figure 4A & Figure 4B). 
More surprisingly, both compounds also consistently increased the amount of ami-
no-terminal LPL in the cell lysates, suggesting that at least part of the amino-terminal 
LPL is cleared by the lysosomes (Figure 4A & Figure 4B). In contrast, BafA1 and 
NH4Cl differentially impacted the accumulation of amino-terminal LPL in the cell 
culture medium (Figure 4A & Figure 4B). 
ANGPTL4 promotes PCSK-mediated cleavage of adipocyte LPL 
The observation that amino-terminal LPL is cleared by the lysosomes suggests that 
PCSK-mediated cleavage might promote LPL degradation and thereby affect LPL 
activity levels. To explore whether regulation of PCSK3 might contribute to the phys-
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Figure 2. Amino-terminal LPL cannot be released from the cell surface by heparin. 
(A) Western blots of  cell culture medium of  mature 3T3-L1 adipocytes that were treated with 10 IU/ mL heparin for 20 
minutes. Western blot was probed with an antibody against LPL and a Coomassie blue staining was performed as a loading 
control. (B) Western blots of  cell lysates of  mature 3T3-L1 adipocytes that were treated with 10 IU/ mL heparin for 20 
minutes. Western blots were probed with antibodies against LPL and HSP90 (as a loading control).
iological changes in LPL activity observed in the adipose tissue, we assessed Pcsk3 
expression levels in adipose tissue of mice that were either fasted for 24h, treated with 
the β3-adrenergic agonist CL316,243 or cold-exposed for 10 days, conditions that are 
known to inf luence LPL activity (8, 9). Fasting and treatment with the β3-adrenergic 
agonist CL316,243 resulted in a signif icant reduction in the expression of Pcsk3, while 
cold exposure did not affect Pcsk3 expression (Figure 5A). However, the decrease in 
Pcsk3 expression upon fasting is in apparent conf lict with the reduction of adipose tis-
sue LPL activity during fasting (9). Similarly, treatment of mature 3T3-L1 adipocytes 
with a variety of compounds did not result in any signif icant changes in the expression 
of PCSK3 (Figure 5B). Together, these data suggest that the regulation of PCSK3 
is most likely not responsible for the variation in LPL activity levels during various 
physiological conditions. 
 From these data it cannot be inferred that cleavage of LPL by PCSK3 is 
relevant for the regulation of LPL activity. It may hypothesized that LPL needs to be 
destabilized to unmask the PCSK3 cleavage site and to enable cleavage. Recently, we 
identif ied ANGPTL4 as a protein that promotes the intracellular degradation of LPL 
(10). To investigate whether ANGPTL4 could promote PCSK3-mediated cleavage, we 
assessed the accumulation of amino-terminal LPL in adipose tissue and isolated adi-
pocytes from Angptl4 -/- and wild-type mice. Conf irming previous studies, we observed 
higher levels of full-length LPL in adipocytes and adipose tissue Angptl4 -/- mice (Fig-
ure 5D & Figure 5E) (10). More surprisingly, we detected signif icantly lower levels 
of amino-terminal LPL in adipocytes and adipose tissue of Angptl4 -/- mice (Figure 5D 
& Figure 5E). Treatment with the PCSK inhibitor dec-CMK fully abrogated these 
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Figure 3. PCSK3 is well expressed in adipose tissue and cleaves adipocyte LPL. 
(A) Pcsk3 mRNA levels (left) and PCSK3 protein levels (right) in different tissues from C57BL/6 mice (n=4 for mRNA levels, 
n=1 for protein levels). (B) Pcsk3 mRNA levels in WAT, isolated primary adipocytes and isolated stromal vascular fractions 
from WAT of  C57BL/6 mice (n=4). (C) Pcsk3 mRNA levels in fully differentiated 3T3-L1 adipocytes that were trypsinized, 
replated at 70% confluency, and treated with siPcsk3 or siCtrl for 48h. (D)  Western blots of  cell culture medium (upper pan-
els) and cell lysates (lower panels) of  fully differentiated 3T3-L1 adipocytes that were trypsinized, replated at 70% confluency, 
and treated with siPcsk3 or siCtrl for 48h. Western blots were probed with antibodies against LPL, PCSK3 and HSP90 (as 
a loading control). Coomassie blue staining was performed as a loading control for cell culture medium. Data are mean ± 
SEM. Asterisks indicate significant differences according to Student’s t-test; ** p<0.01, * p<0.05.
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differences, indicating that PCSK-mediated LPL cleavage mediates the differences in 
amino-terminal LPL between Angptl4 -/- and wild-type mice (Figure 5F ). Of interest, 
PCSKs might have a double function in the regulation of LPL activity, as ANGPTL4 
is also cleaved in the adipose tissue to yield an amino-terminal domain that is known 
to potently inhibit LPL activity (Figure 5G) (18, 19, 30).   
Figure 4. Amino-terminal LPL is cleared by the lysosomes. 
(A) Western blots of  cell culture medium (upper panels) and cell lysates (lower panels) of  mature 3T3-L1 adipocytes, that were 
treated with 100 nM Bafilomycin A1 (BafA1), a vaculaor-type H (+)-ATPase inhibitor, and 10 mM NH4Cl for 10h. Western 
blots were probed with antibodies against LPL and HSP90 (as a loading control). Coomassie blue staining was performed 
as a loading control for cell culture medium. (B)  Western blots of  cell culture medium (upper panels) and cell lysates (lower 
panels) of  primary adipocytes differentiated from the stromal vascular fraction of  WAT that were treated with 100 nM 
Bafilomycin A1 (BafA1), a vaculaor-type H (+)-ATPase inhibitor, and 10 mM NH4Cl for 12h. Western blots were probed 
with antibodies against LPL and HSP90 (as a loading control). Coomassie blue staining was performed as a loading control 
for cell culture medium.
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Figure 5. ANGPTL4 promotes PCSK-mediated cleavage of adipocyte LPL. 
(A) Pcsk3 mRNA levels in gonadal WAT of  three different mice experiments: 1) a 24h fast; 2) injection of  1 mg/kg 
CL316,243; 3) cold exposure to 4˚C for 10 days (B) Pcsk3 mRNA levels of  mature 3T3-L1 adipocytes that were treated with 
0.5 mM AICAR, 100 μM A769662, 10 μM rosiglitazone, 500 nM insulin, and 2 mM intralipid for 6h.  (C) Western blots of  
cell lysates of  mature 3T3-L1 adipocytes that were treated with 0.5 mM AICAR. Western blots were probed with antibodies 
against PCSK3 and HSP90 (as a loading control). (D) Western blots of  cell lysates of  gonadal WAT (gWAT) from Angptl4–/– 
and wild-type mice. Western blot was probed with an antibody against LPL and a Coomassie blue staining was performed 
as a loading control. (E) Western blots of  primary adipocytes differentiated from the stromal vascular fraction of  WAT from 
Angptl4–/– and wild-type mice. Western blots were probed with antibodies against LPL and HSP90 (as a loading control). (F) 
Western blots of  primary adipocytes differentiated from the stromal vascular fraction of  WAT from Angptl4–/– and wild-type 
mice that were treated with 50 μM dec-CMK for 9h. Western blots were probed with antibodies against LPL and HSP90 (as 
a loading control). (G) Western blots of  inguinal WAT (iWAT), gonadal WAT (gWAT) and brown adipose tissue (BAT) of  a 
C57BL/6 mouse. Western blots were probed with antibodies against ANGPTL4 and β-tubulin (as a loading control). Data 
are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test; ** p<0.01, * p<0.05
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DISCUSSION 
In this paper, we demonstrate that PCSK-mediated cleavage of LPL is a physiological 
process in adipocytes that may be promoted by the LPL inhibitor ANGPTL4. We 
show that treatment with the PCSK inhibitor dec-CMK prevents the appearance of 
amino-terminal LPL in various adipocyte models. At least part of the LPL cleavage 
occurs intracellularly and is mediated by PCSK3. We did not f ind evidence to sug-
gest that regulation of Pcsk3 expression explains the physiological regulation of LPL 
activity. However, loss of Angptl4 resulted in a signif icant reduction in the amount of 
amino-terminal LPL, suggesting a role for ANGPTL4 in the PCSK3-mediated cleav-
age of LPL in adipocytes. 
 Given that LPL cleavage occurs intracellularly and PCSK3 localizes to the 
trans-Golgi and the endosomes, we focused on PCSK3 as a potential mediator of LPL 
cleavage. Other PCSKs, such as PCSK5 (PC5/6) and PCSK6 (PACE4), are mainly 
activated and present on the cell surface, anchored to HSPGs (31). However, PCSK3, 
PCSK5 and PCSK6 are widely expressed, recognize similar target sequences and, 
hence, share multiple target proteins (16). Indeed, in vitro studies have indicated that 
LPL may also be cleaved by PCSK5 and PCSK6 (20, 21). It is likely, though, that the 
spatial and temporal separation of PCSKs, as well as other cell-specif ic factors make 
that differences exist between in vitro and in vivo studies (16). Nonetheless, we did ob-
serve LPL cleavage products in the cell culture medium of adipocytes and we cannot 
formally exclude that PCSK5 and PCSK6 cleave LPL extracellularly or on the cell 
surface.  
 An intriguing observation is that PCSK-mediated cleavage of LPL is promot-
ed by ANGPTL4. ANGPTL4 is a well-established inhibitor of LPL and changes in 
ANGPTL4 expression are responsible for the physiological regulation of LPL activity 
that is observed during exercise, fasting and cold exposure (7–9, 32). Interestingly, 
the liver-expressed family member ANGPTL3 has been demonstrated to enhance 
the cleavage of LPL, resulting in the inactivation of LPL and release of LPL from the 
endothelial cell surface (20). Based on these data, it was suggested that ANGPTL3 
functions as a co-factor for PCSKs and thereby inhibits LPL activity (20). In contrast, 
it has been proposed that ANGPTL4 inhibits LPL by binding to LPL and convert-
ing the catalytically active, dimeric form of LPL to catalytically inactive monomers 
(13). To what extent the ANGPTL4-mediated conversion of the LPL dimer to mon-
omers can be merged with our observations that ANGPTL4 promotes LPL cleav-
age by PCSKs remains to be determined. Hypothetically, ANGPTL4 and possibly 
ANGPTL3 bind to LPL and convert LPL to inactive monomers, thereby unmasking 
the PCSK cleavage site at residues 321-324 and rendering LPL more susceptible for 
cleavage and subsequent degradation (13, 21). Another interesting point is that both 
ANGPTL4 and ANGPTL3 are cleaved by PCSKs, liberating their amino-terminal 
domains (17–19, 33). Since the amino-terminal domain of ANGPTL4 inhibits LPL 
more potently than the full-length protein, the PCSKs might promote the loss of LPL 
activity by two complementary mechanisms  (19, 30). To further establish the link be-
tween ANGPTL4 and PCSK-mediated cleavage of LPL, future studies should assess 
the impact of ANGPTL4 on LPL cleavage and LPL activity through extensive in vitro 
studies, as were performed for ANGPTL3 (20). 
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 An interesting question concerns the rationale behind PCSK3-mediated 
cleavage of LPL. PCSK3 catalyzes the maturation of a variety of proproteins, in-
cluding growth factors and pathogen recognizing proteins (31). In fact, PCSK3 is 
essential for proper embryonal development with Pcsk3 deletion resulting in defective 
ventral closure and axial rotation (34). However, in contrast to the several propro-
teins, PCSK3-mediated cleavage of LPL likely does not serve to activate but rather 
to inactivate LPL, as was previously observed for endothelial lipase (20, 21). Indeed, 
cleaved LPL products that were found in human pre-heparin plasma had little LPL 
activity (35). Furthermore, mutations G409R or E410V in the human LPL gene that 
are characterized by enhanced cleavage of LPL in vitro cause a severe chylomicro-
naemia (36). Our data support this notion and indicate that amino-terminal LPL is 
eff iciently cleared by the lysosomes. An alternative explanation is that some degree of 
LPL cleavage may be required for the proper secretion of LPL, as inhibition of LPL 
cleavage resulted in the reduced secretion of total LPL (full-length and cleaved LPL) 
in an in vitro model (21). Similarly, in the setting of the human G409R or E410V mu-
tations, pharmacologic inhibition of cleavage increased the degradation of full-length 
LPL (36). Although these observations are counterintuitive, it may be speculated that 
cleaved amino-terminal LPL forms transient heterodimers with full-length LPL mon-
omers, thereby stabilizing and preventing the inactivation of LPL monomers (13). 
Indeed, a rapid exchange of subunits exists between LPL dimers, with the interme-
diate monomer being metastable and more easily acted upon by factors that impair 
monomer re-association (37). Furthermore, the rapid association/dissociation of the 
LPL dimer might be an important aspect of the intracellular transport of LPL, as co-
valently linked LPL homodimers were found to be less eff iciently secreted compared 
to unlinked homodimers (38). Evidently, more in-depth studies will need to reveal 
why some degree of LPL cleavage would be required for the effective secretion of LPL 
secretion.  
 Another explanation for the PCSK-mediated cleavage of LPL would be that 
the separate amino- and carboxyl-termini of LPL have specif ic physiological func-
tions that complement or go beyond LPL’s capacity to hydrolyze triglycerides from 
triglyceride-rich lipoproteins. For example, the carboxyl-terminal domain of LPL 
was previously found to mediate the margination of triglyceride-rich lipoproteins to 
the endothelium (39). However, it is questionable whether the carboxyl-terminal do-
main alone is capable of translocating onto the endothelium via GPIHBP1 (40). Like-
wise, the separate termini are unlikely to bind to HSPGs on the cell surface as both 
monomeric LPL and carboxyl-terminal LPL have a much lower aff inity for HSPGs 
compared to full-length dimeric LPL (41, 42). As brief ly mentioned above, however, 
cleaved LPL might hypothetically form a heterodimer with a full-length LPL mono-
mer. It has been postulated repeatedly that LPL may function as a functional heterod-
imer in that the two LPL monomers serve distinct roles when dimerized, although this 
hypothesis remains to be conf irmed experimentally (43, 44). As such, amino-terminal 
or carboxyl-terminal LPL might be transferred onto the endothelium to inf luence, for 
example, the margination of circulating triglyceride-rich lipoproteins. Alternatively, 
secreted amino-terminal or carboxyl-terminal domains may bind to circulating tri-
glyceride-rich lipoproteins to enhance the hepatic uptake of remnant particles (45). 
Possibly, future studies on the specif ic physiological functions of amino-terminal of 
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carboxyl-terminal LPL could employ adipose tissue-specif ic Pcsk3-/- knockout mice to 
investigate the functional consequences of loss of LPL cleavage.      
 In conclusion, we demonstrate that LPL is cleaved in adipocytes by PCSK3, 
a process that is promoted by the LPL inhibitor ANGPTL4. Our data suggest a novel 
pathway by which ANGPTL4 regulates LPL in the adipose tissue. Given the impor-
tance of LPL for the regulation of plasma triglyceride levels and the causal role of 
plasma triglyceride levels in the development of cardiovascular disease, future studies 
need to address the functional consequences of PCSK-mediated cleavage of LPL and 
should aim to further examine the link between ANGPTL4 and the PCSK-mediated 
cleavage of LPL.  
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ABSTRACT
An intricate relationship exists between the gut microbiota, the host and host bile 
acid (BA) metabolism. Angiopoietin-like 4 (ANGPTL4) is abundantly expressed in 
the intestine, is regulated by BAs and bacterial metabolites in intestinal cell lines, and 
potently inhibits the activity of pancreatic lipase. Here, our objective was to examine 
the impact of intestinal ANGPTL4 on gut microbial composition and host BA me-
tabolism. To that end, we fed wild-type and Angptl4−/− mice either a control diet or a 
diet enriched in taurocholic acid (TCA) for seven days. We found that total plasma BA 
concentrations were signif icantly lower while the faecal excretion of specif ically pri-
mary BAs was signif icantly higher in the Angptl4−/− mice fed TCA as compared to the 
wild-type mice fed TCA, suggesting that the loss of ANGPTL4 reduces BA re-absorp-
tion. The lower absorption of BAs in the Angptl4−/− mice signif icantly impacted BA 
signaling via FXR, as demonstrated by the reduced expression of multiple FXR-target 
genes in the ileum of the Angptl4 -/- mice fed TCA. Inasmuch as the gut microbiota con-
vert primary bile acids into secondary bile acids, the higher excretion of specif ically 
primary BAs in the faeces of Angptl4−/− mice indicated that loss of ANGPTL4 may 
impact gut microbial composition. Indeed, analysis of the colonic microbial com-
position by 16s rRNA gene sequencing revealed substantial differences between the 
Angptl4−/− mice and the wild-type mice on the control and the TCA-enriched diet. In 
conclusion, we demonstrate that loss of Angptl4 signif icantly reduces plasma BA levels 
and increases BA excretion in TCA-fed mice, which is associated with differences in 
gut microbial composition.
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INTRODUCTION 
The gastro-intestinal tract harbours a large community of micro-organisms of which 
the composition is inf luenced by numerous factors, including diet, environment, 
stress, geography and age  (1, 2). The gut microbial community has a mutualistic re-
lationship with the host. For example, intestinal bacteria play an essential role in the 
energy metabolism and the immune system of the host (3). As a result, disturbances in 
gut microbiota have been associated with diseases such as obesity-associated metabol-
ic disease, liver disease, inf lammatory bowel disease and cancer (1, 2). 
 An intricate relationship exists between the gut microbiota, the host and host 
bile acid (BA) metabolism. While the gut microbiota deconjugate BAs and transform 
primary BAs into secondary BAs, alterations in BA composition in turn affect the 
gut microbial composition (4–7). By shifting BA composition, the gut microbiota may 
signif icantly impact host metabolism, as BAs affect the emulsif ication and absorption 
of dietary lipids and fat-soluble vitamins, act as signalling molecules and impact host 
cholesterol and triglyceride metabolism (7–12). For example, dietary BA supplementa-
tion signif icantly reduces plasma triglyceride levels (8, 9, 12, 13). 
 Angiopoietin-like 4 (ANGPTL4) is a ubiquitously expressed protein that po-
tently inhibits the activity of lipoprotein lipase (LPL), the enzyme responsible for 
hydrolysis of fatty acids from circulating triglycerides (14). Accordingly, mice lacking 
Angptl4 have reduced plasma triglyceride levels, whereas mice overexpressing Angptl4 
have elevated plasma triglyceride levels as compared with wild-type mice (15–18). 
In addition, physiological regulation of ANGPTL4 is responsible for the changes in 
LPL activity observed in white adipose tissue during fasting, in brown adipose tissue 
during cold, and in muscle during exercise (16, 19, 20). Given the prominent role of 
ANGPTL4 in the regulation of plasma triglyceride levels and our previous observa-
tion that BAs potently lower ANGPTL4 secretion from the human duodenal cell line 
Hutu-80, we hypothesized that the triglyceride-lowering effect of BAs might perhaps 
be mediated via regulation of ANGPTL4 (21).  
 Several studies have also linked the expression of intestinal ANGPTL4 to 
the gut microbiota and host metabolism. For example, specif ic bacterial strains as 
well as the bacterial fermentation end products short-chain fatty acids potently stim-
ulate Angptl4 expression in colonic cell lines (21–24). Conversely, conventionalization 
of germ-free mice signif icantly suppressed the expression of Angptl4 in the intestine 
(25–27). More recently, intestinal ANGPTL4 was demonstrated to inhibit the ac-
tivity of pancreatic lipase, a family member of LPL responsible for the hydrolysis of 
dietary triglycerides in the gastro-intestinal tract (28). The effects of various micro-
biota strains and bacterial metabolites on intestinal Angptl4 expression, as well as the 
inhibitory effect of ANGPTL4 on pancreatic lipase activity suggest that intestinal 
ANGPTL4 might be part of the intricate cross-talk between gut microbiota and host. 
To test this hypothesis and to address whether the triglyceride-lowering effect of BAs 
might be mediated via ANGPTL4, we challenged Angptl4−/− and wild-type mice with 
a diet enriched in taurocholic acid (TCA) and assessed the differences in gut microbial 
composition and BA metabolism between Angptl4−/− and wild-type mice. 
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MATERIALS AND METHODS
Animals and diet
Animal studies were performed using pure-bred wild-type and Angptl4-/- mice on a 
C57BL/6 background. Angptl4-/- mice have been obtained via homologous recombina-
tion of embryonic stem cells and lack part of the Angptl4 gene, resulting in a non-func-
tional ANGPTL4 protein (17, 29). Mice were individually housed in temperature- and 
humidity-controlled conditions. 4 month-old male mice received either chow (control) 
or chow supplemented with 0.5% (wt/wt) taurocholic acid (TCA) (Calbiochem) for 7 
days. The mice had ad libitum access to food and water. Body weight and food intake 
were assessed daily. At the end of the study, mice were anesthetized using isof lurane 
and blood was collected by orbital puncture. Mice were sacrif iced via cervical disloca-
tion after which tissues were excised and weighed. The small intestine was divided in 
three equal parts along the distal-to-proximal axis and epithelial cells were obtained 
by scraping the mucosal lining. All animal experiments were approved by the local 
animal ethics committee of Wageningen University. 
Plasma parameters
Blood was collected in EDTA-coated tubes and centrifuged for 15 minutes at 3000 
rpm to obtain plasma. Plasma free fatty acid and triglyceride concentrations were 
determined according to manufacturer’s instructions using commercially available 
kits (Wako chemicals, Neuss, Germany and HUMAN Diagnostics, Wiesbaden, Ger-
many). Plasma cholesterol was quantif ied using a kit from Elitech (Sees, France). Plas-
ma concentrations of total bile acids were determined using a colorimetric assay kit 
(Diazyme Laboratories, Poway, USA). Free and conjugated bile acid subspecies were 
quantif ied by liquid chromatography tandem MS (LC-MS/MS) using a SHIMADZU 
liquid chromatography system (SHIMADZU, Kyoto, Japan) and tandem AB SCIEX 
API-3200 triple quadrupole mass spectrometry (AB SCIEX, Framingham, USA) as 
previously described (30). 
RNA isolation and qPCR
Total RNA was extracted from scrapings of the distal small intestine and liver us-
ing TRIzol reagent (Life technologies, Bleiswijk, Netherlands). Subsequently, 500 ng 
RNA was used to synthesize cDNA using the iScript cDNA synthesis kit (Bio-Rad 
Laboratories, Veenendaal, the Netherlands). Changes in gene expression were deter-
mined by real-time PCR on a CFX384 Real-Time PCR detection system (Bio-Rad) 
by using SensiMix (Bioline, GC biotech, Alphen aan den Rijn, the Netherlands). The 
housekeeping genes 36b4 and β-actin were used for normalization. Sequences of the 
used primers are listed in Table 1. 
Faecal measurements
Prior to sacrif ice, faeces were collected over a period of 48 hours. Total lipids and 
free fatty acids were measured in the faecal samples as described by Govers et al (31). 
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Brief ly, 100 mg of faecal samples were weighed, dried and acidif ied using HCl. Fatty 
acids were then extracted using petroleum and diethyl ether. The ether fraction was 
collected, evaporated and total lipids were weighed. Lipids were re-solubilised in eth-
anol and, next, the free fatty acid concentration was determined using a commercially 
available kit (Wako chemicals, Neuss, Germany). Faecal bile salt composition and fae-
cal neutral sterols were determined by capillary gas chromatography (Agilent 6890, 
Amstelveen, the Netherlands) as described previously (32, 33). 
Bacterial DNA extraction and Library preparation for 16S rRNA pyrosequenc-
ing
DNA was extracted from the freeze-dried luminal content of the colon as described 
previously (34). Universal primers were used for initial amplif ication of part of the 16S 
rRNA gene: forward primer, ‘5-TCGTCGGCAGCGTCAGATGTGTATAAGAGA-
CAGCCTACGGGAGGCAGCAG-3’ (broadly conserved bacterial primer 357F) and 
reverse primer, ‘5-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTACN-
VGGGTATCTAAKCC’ (broadly conserved bacterial primer 802R). To the purif ied 
PCR product, Illumina sequencing adapters were added and the 16S rRNA gene was 
subsequently sequenced on the Illumina MiSeq (PE300 cycles run) platform.
 
16s rRNA gene sequencing
Sequences were analyzed using a workf low based on QIIME 1.8 (35). OTU cluster-
ing, taxonomic assignment and reference alignment were done with the pick_open_
reference_otus.py workf low script of QIIME, using uclust as clustering method (97% 
identity) and GreenGenes v13.8 as reference database for taxonomic assignment. Ref-
erence-based chimera removal was done with uchime. Redundancy analysis (RDA) 
was performed in Canoco version 5. 
Statistical analysis
Data are presented as mean ± SEM. Statistical signif icant differences were deter-
mined with two-way analysis of variance with Bonferroni post hoc tests or by Stu-
dent’s t-test where appropriate using GraphPad Prism (GraphPad Software, Inc., La 
Jolla, USA).  P<0.05 was considered as statistically signif icant. For microbiota anal-
ysis, false discovery rate (FDR)-corrected P-values were estimated for each taxon to 
correct for multiple testing. Bacterial taxa with a FDR-corrected P-value < 0.20 were 
considered signif icant.
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RESULTS
ANGPTL4 is not implicated in the triglyceride-lowering effects of BAs
To investigate the role of ANGPTL4 in the lowering of plasma triglycerides by BAs, 
we fed wild-type and Angptl4−/− mice either a control diet or a diet enriched in tau-
rocholic acid (TCA) for seven days (Figure 1A). The TCA-enriched diet slightly 
reduced food intake and body weight. However, no differences were observed be-
tween the genotypes (Supp. Figure 1). In contrast to our hypothesis that BAs may 
down-regulate Angptl4 expression, mRNA levels of Angptl4 were either unchanged 
(liver; Figure 1B) or increased (ileum; Figure 1C) by TCA feeding. Furthermore, 
although the TCA treatment effectively lowered plasma TG levels, the reduction was 
similar in the wild-type and Angptl4−/− mice (Figure 1D). Other plasma parameters, 
including plasma free fatty acids (Figure 1E) and plasma cholesterol (Figure 1F ) 
were also not different between the genotypes. These data indicate that ANGPTL4 is 
not responsible for the plasma triglyceride-lowering effect of BAs. 
Figure 1: ANGPTL4 is not part of the triglyceride-lowering effects of BAs.
 (A) Schematic representation of  dietary intervention with 0.5% w/w taurocholic acid (TCA) in wild-type and Angptl4-/- mice. 
Relative gene expression of  (B) hepatic Angptl4, (C) ileal Angptl4 in the liver and ileum of  wild-type and Angptl4-/- mice fed 
(control) CTRL or TCA diet for 7 days. Gene expression levels in wild-type mice fed the control diet were set at 1. (D) Plasma 
triglycerides, (E) plasma free fatty acids (FFA), and (F) plasma cholesterol concentration of  wild-type and Angptl4-/- mice fed a 
control (CTRL) or TCA diet for 7 days. Data are presented as mean ± SEM. Statistically significant differences were assessed 
using two-way ANOVA for diet (D), genotype (G) or interaction between both parameters (X), as indicated at the top of  each 
figure. Asterisks represent significant differences compared with WT mice. *p<0.05, **p<0.001. 
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Figure 2: ANGPTL4 promotes an increase in BA re-absorption upon TCA feeding. 
(A) Total plasma bile acid concentration of  WT and Angptl4-/- mice fed control (CTRL) or TCA diet for 7 days. Statistically 
significant differences were observed using two-way ANOVA for diet (D), genotype (G) or interaction between both parame-
ters (X), as indicated at the top of  the figure. (B) Total bile acid excretion of  wild-type and Angptl4-/- mice fed control (CTRL) 
or TCA diet for 7 days. Statistically significant differences were observed using two-way ANOVA for diet (D), genotype (G) 
or interaction between both parameters (X), as indicated at the top of  the figure. (C) Concentration of  free and conjugated 
bile acid subspecies in the plasma of  wild-type and Angptl4-/- mice fed a TCA diet for 7 days. (D-F) Mean excretion of  (D) 
free and conjugated bile acid subspecies, (E) neutral sterols and (F) fatty acid excretion of  WT and Angptl4-/- mice fed TCA 
diet for 7 days. Data are presented as mean ± SEM. Asterisks represent significant differences compared with WT mice. 
*p<0.05, **p<0.001. 
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Figure 3: Differences in BA re-absorption between wild-type and Angptl4-/- mice translate into differences in ileal 
and hepatic gene expression. 
(A) Relative expression of  ileal BA transporters and BA-responsive genes, Fgf15, Fxr, Slc51a, Slc51b and Slc10a2, in wild-type 
and Angptl4-/- mice fed TCA diet for 7 days. Gene expression levels in WT mice fed TCA diet were set at 1. (B) Relative he-
patic expression of  genes involved in BA synthesis in wild-type and Angptl4-/- mice fed TCA diet for 7 days. Gene expression 
levels in WT mice fed TCA diet were set at 1. Data are presented as mean ± SEM. Asterisks represent significant differences 
compared with WT mice. *p<0.05, **p≤0.001.
ANGPTL4 promotes an increase in BA re-absorption upon TCA feeding
As expected, the TCA-enriched diet signif icantly increased total BA levels in plasma 
and total BA excretion in the faeces (Figure 2A & 2B). Interestingly, total plasma BA 
concentrations were signif icantly lower while the faecal BA excretion was signif icant-
ly higher in the Angptl4−/− mice fed TCA as compared to the wild-type mice fed TCA 
(Figure 2A & 2B). These observations suggest that the loss of ANGPTL4 reduces the 
absorption of BAs. To study this potential effect of Angptl4 deletion on BA absorption 
in more detail, we measured the levels of individual BAs in plasma and faeces. The 
analysis revealed that the lower levels of total plasma BAs in the Angptl4−/− mice as 
compared to the wild-type mice were primarily accounted for by lower plasma lev-
els of cholic acid and deoxycholic acid, and to a lesser extent chenodeoxycholic acid 
and lithocholic acids (Figure 2C). In the faeces, the excretion of the primary BAs 
cholic acid and β-muricholic acid was signif icantly higher in the Angptl4−/− mice as 
compared to wild-type mice fed the TCA-containing diet, whereas faecal excretion 
of the secondary BAs deoxycholic acid and α-muricholic acid, as well as excretion of 
neutral sterols and fatty acids was not different between the genotypes (Figure 2D – 
2F ). Overall, these data indicate that the loss of Angptl4 in mice fed TCA reduces BA 
absorption, leading to lower levels of BAs in the plasma and higher excretion of BAs 
in the faeces.
 The lower absorption of BAs in the Angptl4−/− mice is expected to signif icantly 
impact BA signaling via FXR. Consistent with this notion, the expression in the ileum 
of several target genes of FXR, including Fg f15, Slc51a (Ostα) and Slc51b (Ostβ), as well 
as expression of Fxr itself, was signif icantly lower in the Angptl4−/− mice than the wild-
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type mice (Figure 3A , Supp. Figure 2). The lower expression of Fg f15 in the ileum 
of Angptl4−/− mice was associated with markedly higher hepatic expression of genes 
involved in bile acid synthesis, including Cyp7a1, Cyp27a1 and Cyp8b1, whereas hepatic 
expression of other genes involved in BA metabolism was not or only slightly different 
between the Angptl4−/− and wild-type mice (Figure 3B, Supp. Figure 2). Interest-
ingly, expression of the BA transporter Slc10a2 (Asbt) in the ileum was markedly lower 
in the Angptl4−/− than in the wild-type mice, potentially contributing to the lower BA 
absorption (Figure 3A).
ANGPTL4 affects changes in gut microbial composition upon bile acid feeding
As pointed out above, the excretion of the primary BAs cholic acid and β-muricholic 
acid was signif icantly higher in Angptl4−/− mice, whereas the excretion of secondary 
BAs and neutral sterols was not different between the genotypes. Inasmuch as the 
conversion of primary BAs into secondary BAs is mediated by the gut microbiota, the 
higher excretion of specif ically primary BAs in the faeces of Angptl4−/− mice indicates 
that loss of ANGPTL4 may impact gut microbial composition. Analysis of the colonic 
microbial composition by 16s rRNA gene sequencing revealed substantial differences 
between the Angptl4−/− mice and the wild-type mice on the control diet and on the 
Figure 4:  TCA feeding and Angptl4 genotype affect gut microbial composition.
 (A) Redundancy analysis (RDA) correlation biplot describing the relationship between colonic luminal microbiota composi-
tion and the differences induced by genotype and diet. The explanatory variables diet and genotype explained 34.9% of  the 
total variation in the microbiota composition.
Chapter 7
150
TCA-enriched diet. Redundancy analysis (RDA) indicated that the explanatory var-
iables diet and genotype explained 34.9% of the total variation in the colonic micro-
biota composition (Figure 4A). To determine which variable was the most important 
determinant of colonic microbial composition, a partial RDA was performed. While 
genotype explained 10.9% of the total variation in microbial composition, diet was 
more important and explained 25.1% of the microbial variation (Figure 5A & 5B). 
 Although Angptl4 genotype also affected gut microbial composition on the 
control diet (Supp. Figure 3), differences in BA metabolism between Angptl4−/− and 
wild-type mice were only observed upon TCA feeding, suggesting that microbial 
changes occurring upon a TCA diet might be important for the observed differences. 
To that end, the composition of the colonic microbiota of wild-type and Angptl4−/− 
mice fed the TCA diet was compared in more detail. At the phylum level, the relative 
abundance of Actinobacteria was higher in the Angptl4−/− mice fed TCA, whereas the 
relative abundance of Bacteroidetes and Cyanobacteria was lower as compared with 
the wild-type mice fed TCA (Figure 6). An increase within the genus Adlercreutzia 
largely explained the increased abundance of the phylum Actinobacteria, whereas a 
decrease in the genus Prevotella mainly accounted for the decrease within the phylum 
Bacteroidetes (Figure 6). Interestingly, while the relative abundance of the phylum 
Proteobacteria was comparable between the genotypes, the family of Enterobacte-
riaceae was, with a relative proportion of 3.6%, 158-fold more abundant in the colon 
of the Angptl4−/− mice as compared with wild-type mice fed the TCA diet (Figure 6). 
Conversely, the abundance of Bilophila was signif icantly higher in the colon of wild-
type mice as compared with the Angptl4−/− mice fed the TCA diet. Finally, the species 
Lactobacillus reuteri was present in the colon of wild-type mice, whereas it was almost 
absent in the Angptl4−/− mice fed (Figure 6).
Figure 5: Bile acid feeding has more impact on gut microbial composition than Angptl4 genotype 
(A-B) Partial RDA correlation biplot describing the relationship between colonic luminal microbiota composition and ex-
planatory variables (A) genotype and (B) diet. Genotype explained 10.9% and diet 25.1% of  total variation in microbiota 
composition.
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Figure 6: Differences in microbial composition between wild-type and Angptl4-/- mice upon TCA feeding. 
Nodes represent taxa and the edges link the different taxonomic levels. The fold increase is calculated as the 2log of  the ratio 
of  the relative abundance in Angptl4-/- and wild-type mice upon TCA feeding. Significance is expressed as the FDR-corrected 
p-valu
Chapter 7
152
DISCUSSION 
In the present paper, we examined the impact of ANGPTL4 on gut microbial com-
position and host BA metabolism. We demonstrate that TCA feeding dramatically 
increased plasma BA levels in the wild-type but not the Angptl4−/− mice, which may 
be explained by lower ileal BA re-absorption in Angptl4-/- mice (see Figure 7 for an 
overview). The higher plasma BA levels found in the wild-type mice are likely respon-
sible for the reduction in genes involved in BA synthesis via the well-known feedback 
mechanism mediated by FXR. Although causality remains to be proven, we believe 
that the differences in gut microbial composition between the Angptl4−/− mice and 
the wild-type mice fed TCA provide a reasonable explanation for the lower ileal BA 
re-absorption.  
 We initially hypothesized that the well-established triglyceride-lowering ef-
fect of BAs might be mediated by ANGPTL4 (14, 21). Although TCA feeding effec-
tively lowered plasma triglyceride levels, the reduction in plasma triglyceride levels 
was similar between the wild-type and the Angptl4−/− mice, indicating that ANGPTL4 
does not mediate the triglyceride-lowering effect of BAs. Instead, it is probable that 
another circulating factor that impacts LPL activity, such as ANGPTL3 or APOCII, 
mediates the triglyceride-lowering effect of BAs (12, 36). Our data indicate that it is 
unlikely that circulating BAs directly impact LPL activity in peripheral tissues, as the 
pronounced differences in plasma BA levels between wild-type and Angptl4-/- mice fed 
TCA did not translate into differences in plasma triglyceride levels. 
 A potential explanation for the higher plasma BA levels as observed in the 
wild-type mice fed TCA may lie in the increased expression of Slc10a2, the main 
active transporter for BA re-absorption, in the ileum of wild-type mice fed TCA com-
pared to the Angptl4−/− mice fed TCA (37). Expression of Slc10a2 in the ileum is tightly 
controlled by FXR via a negative feedback mechanism that involves activation of the 
small heterodimer partner (SHP) and subsequent repression of liver related homolog-1 
(LRH-1) (37–39). Various BAs activate intestinal FXR, but their potency to activate 
FXR varies greatly (38, 40). Indeed, a recent study demonstrated that the expres-
sion levels of Fxr and FXR-target genes such as Fg f15 and Slc10a2 were differentially 
regulated in ileum and liver upon feeding of different BA species (41). Furthermore, 
more hydrophilic BAs such as tauro-β-muricholic acid may in fact act as antagonists 
of FXR (42). Since Angptl4−/− mice had a signif icantly higher excretion of specif ically 
primary BAs, our studies suggest that the differences in intestinal BA composition 
between wild-type and Angptl4−/− mice might explain the differences in ileal Slc10a2 
expression and BA re-absorption. 
 Gut microbial composition potently inf luences intestinal BA composition and 
BA metabolism. Indeed, the gut microbiota convert primary BAs to secondary BAs 
by 7α-dehydroxylation, thereby increasing the hydrophobicity of BAs, and decon-
jugate BAs, thereby preventing the active re-absorption of BAs by SLC10A2 (4, 7, 
43). As a result, alterations in gut microbial composition, for example by treatment 
with antibiotics, probiotics or a high-fat diet, signif icantly impact the abundance of 
secondary BAs and BA homeostasis (6, 41, 42, 44, 45). The gut microbiota may also 
directly impact BA metabolism, as recent studies demonstrate that bacterial metabo-
lites modulate FXR activity and that conventionalization of germ-free mice increases 
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Figure 7: Schematic overview of differences in gene expression between wild-type and Angptl4-/- mice in liver and 
intestine. 
Compared to wild-type mice, TCA feeding in Angptl4-/- mice significantly increased faecal primary BA levels and changed 
gut microbial composition. A reduction in the ileal expression of  Slc10a2 may have resulted in the reduced reuptake of  BAs 
into the ileum and a decrease in plasma BA levels in the Angptl4-/- mice fed the TCA-enriched diet as compared to wild-type 
mice. The lower plasma BA levels, as well as the lower expression of  Fgf15 as observed in the Angptl4-/- mice fed the TCA-en-
riched diet might have stimulated the expression of  Cyp7a1 and Cyp8b1 and might have increased hepatic BA synthesis in the 
Angptl4-/- mice as compared to the wild-type mice.
the expression of FXR-target genes (42, 46). More specif ically, suppression of the gut 
microbiota by antibiotics treatment reduced activation of GATA4, a transcription 
factor that negatively regulates the expression of the Slc10a2 transporter, resulting in 
the increased expression of Slc10a2 and increased BA re-absorption, while conven-
tionalization of germ-free mice lowered Slc10a2 expression (47, 48). Given the intricate 
relationship between the gut microbiota and BA metabolism, it may be hypothesized 
that the microbial changes that occur specif ically upon a TCA diet signif icantly con-
tribute to the differences in BA metabolism observed between the Angptl4−/−  fed TCA 
and the wild-type mice fed TCA. For example, we detected a higher abundance of 
the Enterobacteriaceae, a family that includes several pathogenic strains such as Sal-
monella and E.Coli, and a lower abundance of bile-loving, sulphite-reducing Bilophila 
in the colon of Angptl4−/− mice fed TCA compared with the wild-type mice fed TCA 
(49). In human subjects, Enterobacteriaceae have been associated with the presence 
of primary BAs in the faeces and have been linked to pathologies such as hepatic 
encephalopathy and Crohn’s disease (50–52). It remains to be investigated, however, 
if and what microbial changes that occur upon TCA feeding are responsible for the 
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differences in intestinal BA composition and BA re-absorption between the wild-type 
and the Angptl4−/− mice fed TCA. 
 The origin of the differences in gut microbial composition between Angptl4−/− 
mice and wild-type mice is currently unclear, which is partially due to the uncertain-
ty about the function(s) of intestinal ANGPTL4. Levels of intestinal ANGPTL4 are 
comparatively high and numerous studies have demonstrated that BAs, bacteria and 
bacterial metabolites potently inf luence intestinal ANGPTL4 expression (21–24, 28). 
In contrast, what intestinal cells produce and secrete ANGPTL4 and whether intesti-
nal ANGPTL4 is secreted into the blood stream and/or into the intestinal tract is un-
known (21, 28). For example, conventionalization of germ-free mice was associated in 
some, yet not all studies with enhanced peripheral adiposity in wild-type mice but not 
Angptl4−/− mice via the purported loss of endocrine inhibition on adipose tissue LPL 
activity (25, 27, 53). In contrast, in line with observations that suggest a local instead 
of endocrine function for ANGPTL4, a recent study demonstrated that intestinal 
ANGPTL4 has the capacity to inhibit pancreatic lipase, the main enzyme responsible 
for the hydrolysis of dietary triglycerides in the gastro-intestinal tract (14, 28, 54). In 
agreement with this study, we observed a tendency towards increased fat excretion in 
Angptl4−/− mice. Multiple studies indicate that elevated levels of lipids in the ileum and 
colon signif icantly impact the gut microbial composition, indicating that the differ-
ences in dietary fat metabolism might possibly explain the differences in gut microbial 
composition between wild-type and Angptl4−/− mice (55, 56). In fact, the origin of the 
differences in gut microbial composition between wild-type and Angptl4−/− mice might 
lie during suckling, when pups receive a high amount of lipid-containing milk. Future 
studies employing an intestine-specif ic knock-out of ANGPTL4 should conf irm that 
inhibition of pancreatic lipase is the primary function of intestinal ANGPTL4 and 
should clarify what cells are responsible for secretion of ANGPTL4 into the intestinal 
tract.  
  In conclusion, we demonstrate that loss of Angptl4 signif icantly reduces plas-
ma BA levels and increases BA excretion in TCA-fed mice. Although causality re-
mains to be proven, these differences are associated with signif icant differences in 
gut microbial composition between the wild-type mice and the Angptl4−/− mice. Our 
observations further underline the importance of the gut microbiota for BA homeo-
stasis. 
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SUPPLEMENTAL FIGURES 
Supplemental Figure 1: TCA feeding affect body weight and food intake. 
(A) Final body weight of  wild-type and Angptl4-/- mice fed control (CTRL) or TCA diet for 7 days. (B) Mean food intake per 
day during dietary intervention. Data are presented as mean ± SEM.
Supplemental Figure 2: Ileal and hepatic gene expression in wild-type and Angptl4-/- mice fed the TCA diet. 
(A-C) Relative gene expression of  (A) ileal BA transporters,  (B) portal BA transporters, (C) genes involved in canalicular bile 
acid, cholesterol and phosphatidylcholine export in the ileum (A) or liver (B &C) of  wild-type and Angptl4-/- mice fed TCA 
diet for 7 days. Gene expression levels in WT mice fed TCA diet were set at 1. Data are presented as mean ± SEM. Asterisks 
represent significant differences compared with WT mice. *p<0.05, **p≤0.001.
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Supplemental Figure 3: Differences in microbial composition between wild-type and Angptl4-/- mice fed the con-
trol diet. 
Nodes represent taxa and the edges link the different taxonomic levels. The fold increase is calculated as 
the 2log of  the ratio of  the relative abundance in Angptl4-/- and wild-type mice fed the control (CTRL) 
diet. Significance is expressed as the FDR-corrected p-value
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ABSTRACT  
Triglycerides are stored in specialized organelles called lipid droplets. Numerous pro-
teins have been shown to be physically associated with lipid droplets and to govern 
their function. Previously, hypoxia-inducible lipid droplet-associated (HILPDA) was 
localized to lipid droplets in HeLa cells and hepatocytes. Studies in hepatocytes sug-
gested that HILPDA may inhibit triglyceride lipolysis. Here, our aim was to explore 
the regulation and possible function of HILPDA in adipose tissue. We found that 
HILPDA is abundant in adipose tissue and is associated with lipid droplets. Expres-
sion of HILPDA in adipocytes was controlled by the peroxisome proliferator-acti-
vated receptor γ and by β-adrenergic stimulation. Expression of HILPDA marked-
ly increased during 3T3-L1 adipocyte differentiation. Nevertheless, knockdown of 
HILPDA using siRNA or overexpression of HILPDA using adenovirus did not inf lu-
ence 3T3-L1 adipogenesis. Knockdown of HILPDA in adipocytes did not signif icant-
ly alter the release of NEFAs following β-adrenergic stimulation. By contrast, adeno-
viral-mediated overexpression of HILPDA modestly attenuated the release of NEFAs 
from adipocytes following β-adrenergic stimulation. In mice, however, adipocyte-spe-
cif ic deletion of HILPDA had no effect on plasma levels of NEFAs and glycerol after 
fasting, cold exposure or pharmacological β-adrenergic stimulation. In addition, oth-
er relevant metabolic parameters were unchanged by adipocyte-specif ic deletion of 
HILPDA. Taken together, we f ind that HILPDA is highly abundant in adipose tissue, 
where its expression is regulated by PPARγ and β-adrenergic stimulation. In contrast 
to the purported inhibition of lipolysis by HILPDA in hepatocytes, our data do not 
support a major role of HILPDA in the regulation of lipolysis in adipose tissue.
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INTRODUCTION 
In humans and many other animal species, excess energy is eff iciently stored in white 
adipose tissue as triglycerides, providing a buffer against periods of low energy intake. 
Triglycerides are stored in the adipose tissue in lipid droplets, which are dynamic 
intracellular organelles that are regulated by the organism’s nutritional status. Lipid 
droplets consist of a core of triglycerides and cholesteryl esters surrounded by a mon-
olayer of phospholipids and proteins (1). Many lipid droplet-associated proteins are 
involved in the release of non-esterif ied fatty acids (NEFAs) from lipid droplets or the 
incorporation of triglycerides into lipid droplets (1–4). Other lipid droplet-associated 
proteins include regulatory proteins such as members of the perilipin (PLIN) family, 
and proteins that affect lipid droplet size such as members of the cell death–inducing 
DFF45-like effector (CIDE) protein family (5, 6). For example, CIDEC was suggested 
to promote the enlargement of lipid droplets by facilitating lipid transfer from small to 
larger lipid droplets and/or by acting as a barrier for adipose triglyceride lipase, the 
rate-limiting enzyme of lipolysis (5, 7–9). A better understanding of the function of 
lipid droplet-associated proteins is important to gain more insight into the regulation 
of lipid storage and mobilization.
 Peroxisome Proliferator Activated Receptors (PPARs) represent an important 
subgroup within the nuclear receptor superfamily, consisting of PPARα, PPARδ and 
PPARγ. An intricate relationship exists between lipid storage and PPARs. On the one 
hand, changes in intra- and extracellular lipid metabolism impact the activation of 
PPARs by inf luencing the availability of ligands in the form of fatty acids and fatty 
acid derivatives (10–13). On the other hand, PPARs inf luence lipid metabolism by 
activating the transcription of numerous target genes, including many genes encoding 
lipid droplet-associated proteins such as adipose triglyceride lipase (ATGL/PNPLA2), 
G0/G1 switch gene 2 (G0S2), PLIN2 and CIDEC  (11, 14–16). Functional studies of 
(novel) PPAR-target genes may help to further uncover the intricate regulation of lipid 
storage and mobilization in adipose tissue. 
 Recently, hypoxia-inducible lipid droplet-associated (HILPDA) was identi-
f ied as a novel lipid droplet-associated protein in HeLa cells and hepatocytes (17, 18). 
We and others have identif ied Hilpda as a novel target gene of PPARα in liver involved 
in hepatic triglyceride metabolism (17, 19). HILPDA overexpression resulted in a fatty 
liver due to a reduction in very-low density lipoprotein (VLDL) triglyceride secretion, 
whereas Hilpda deletion lowered hepatic lipid accumulation (17, 19). More specif ically, 
loss of HILPDA was found to lead to enhanced triglyceride lipolysis and triglyceride 
turnover in isolated primary hepatocytes (17). Considering the reported localization 
of HILPDA to lipid droplets and the importance of lipolysis in adipocytes, we exam-
ined the role and regulation of HILPDA in adipose tissue (18, 19). In particular, we 
investigated the potential role for HILPDA in adipocyte lipolysis using in vitro and 
in vivo tools of HILPDA overexpression and inactivation. We f ind that HILPDA is a 
sensitive PPARγ target gene in adipocytes and is highly responsive to β-adrenergic 
stimulation. In contrast to the purported inhibition of lipolysis by HILPDA in hepat-
ocytes, our data do not support a major role of HILPDA in the regulation of lipolysis 
in adipose tissue.
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MATERIALS AND METHODS 
All animal experiments were performed in accordance with Directive 2010/63/EU 
from the European Union. All animal studies were reviewed and approved by the 
Animal Ethics Committee of Wageningen University.
Animal experiments
Mice were housed in temperature- and humidity-controlled specif ic pathogen-free 
conditions. Mice had ad libitum access to food (chow) and water, except where spec-
if ied otherwise. To generate mice with adipocyte-specif ic deletion of Hilpda, hete-
rozygous f loxed Hilpda animals on a mixed C57BL/6 and Sv129 background were 
purchased from The Jackson Laboratory (Bar Harbor, ME, USA). LoxP sites were 
introduced to f lank the second exon of Hilpda followed by the open reading frame for 
membrane-tethered human placental alkaline phosphatase (ALPP ) after the second 
loxP site. Following Cre-recombination, ALPP is expressed under control of the Hilpda 
promoter. Floxed Hilpda mice were crossed with Adiponectin-Cre mice (The Jackson 
Laboratory) on a C57BL/6 background. After initial crosses, Hilpdaf lox/f lox mice were 
crossed with Hilpdaf lox/f lox mice heterozygous for Adiponectin-Cre, yielding 50% wild-
type and 50% adipocyte-specif ic Hilpda null animals (HilpdaΔAT), equally distributed 
among males and females. For experiment 1, in which the adipocyte-specif ic dele-
tion of HILPDA was verif ied by separation of the adipose tissue into adipocytes and 
stromal vascular fractions, four 20-week old female Hilpdaf lox/f lox and four 20-week old 
female HilpdaΔAT mice were sacrif iced by cervical dislocation and epididymal adi-
pose tissue depots were excised and placed in Dulbecco’s modif ied Eagle’s medium 
(DMEM) (Lonza, Verviers, Belgium) supplemented with 1% fatty acid-free bovine 
serum albumin (BSA) until further isolation as described below. For the CL316,243 
experiment (2), 15- to 18-week old male Hilpdaf lox/f lox (n=16) and HilpdaΔAT (n=16) litter-
mates were fasted for 3h and subcutaneously injected with 1 mg/kg CL316,243 (n=8 
per genotype) or saline solution (n=8 per genotype). During the experiment, all mice 
were housed individually. At 10 minutes, 30 minutes, and 60 minutes after injection, 
blood was drawn via the tail vein. 3h after injection, the animals were anesthesized 
with isof lurane, blood was collected and following cervical dislocation several tissues 
were excised and snap-frozen or placed in DMEM + 1% BSA for separation into 
adipocytes and stromal vascular fractions. The animals remained fasted until sac-
rif ice. For the fasting experiment (3), 9- to 13-week old male Hilpdaf lox/f lox (n=6) and 
HilpdaΔAT (n=8) littermates were fasted for 24 hours and killed by cervical dislocation, 
after which several tissues were excised and snap-frozen. During the fasting period, 
all mice were housed individually. For the in vitro lipolysis experiment with explants 
(4), adipose tissue of male Hilpdaf lox/f lox (n=3) and HilpdaΔAT (n=3) mice was excised 
and minced with scissors. Adipose tissue explants were plated, serum-starved for 30 
minutes in DMEM (Lonza, Verviers, Belgium) with 1% fatty acid-free BSA, and sub-
sequently treated with 10 μM isoproterenol for 3h. Medium samples were assayed for 
NEFAs as described below and corrected for total protein. For the in vitro lipolysis 
experiment with primary adipocytes (5), inguinal adipose tissue of male Hilpdaf lox/
f lox (n=3) and HilpdaΔAT (n=3) mice was excised and minced with scissors. Stromal vas-
Role and regulation of HILPDA in adipose tissue 
167
8
cular fractions were isolated and differentiated to mature adipocytes as described 
previously (20). Mature adipocytes were serum-starved for 2h in DMEM with 1% 
fatty acid-free BSA, and subsequently treated with 10 μM isoproterenol or 10 μM 
CL316,243 for 3h. Medium samples were assayed for NEFAs as described below and 
corrected for total protein.
Recombinant adenoviruses
Adenoviruses (AV) were generated by cloning GFP or Hilpda cDNA in human ade-
novirus type 5 (dE1/E3). Expression was under the control of the CMV promotor. 
Viruses were produced and titrated by Vector Biolabs (Philadelphia, PA, USA).
Chemicals 
Isoproterenol, norepinephrine, 3-isobutyl-1-methylxanthine (IBMX), insulin, dexa-
methasone, fatty acid-free BSA and rosiglitazone were purchased from Sigma-Aldrich 
(Schnelldorf, Germany). Forskolin, procaterol and CL316,243 were from Tocris (Toc-
ris Bioscience, Bristol, United Kingdom). 
Separation SVF & Adipocytes
Dissected adipose tissue depots from the different experiments were kept on ice in 
DMEM supplemented with 1% fatty acid-free BSA (Sigma-Aldrich). Samples were 
minced into small 1-2 mm3 pieces and incubated with collagenase solution (DMEM, 
3.2 mM CaCl2, 15 mM HEPES, 0.5% BSA, 10% fetal calf serum (FCS), 1.5 mg/
mL collagenase type II (Sigma-Aldrich #C6885)) at 37˚C for 45 minutes. Mixtures 
were strained through a 100 µm cell strainer and centrifuged at 300*g for 10 minutes 
at room temperature. Floating adipocytes were collected and snap-frozen for RNA 
isolation. The pelleted stromal vascular fractions (SVF) were re-suspended in Trizol 
(Thermo Fisher-Scientif ic, Landsmeer, the Netherlands) and snap-frozen for RNA 
isolation. 
Cell Culture
3T3-L1 f ibroblasts were maintained in DMEM supplemented with 10% newborn calf 
serum (NCS) (Lonza) and 1% penicillin/streptomycin (P/S) (Lonza) and differentiat-
ed as described previously (21). The day at which differentiation was started is indi-
cated as day 0. Dharmacon ON-TARGETplus SMARTpool siRNAs were purchased 
from Thermo Fisher-Scientif ic. siRNAs were diluted in Dharmacon 1x siRNA buffer 
(f inal concentration 20 mM KCl, 6 mM HEPES pH 7.5, 0.2 mM MgCL2). Trans-
fections were performed with Lipofectamine RNAiMAX transfection reagent (Life 
Technologies, Bleiswijk, The Netherlands). All siRNA transfections were carried out 
at a concentration of 40 nM siRNA and 2 µL of transfection reagent for a 12-wells 
plate. To study the effect of HILPDA knockdown on 3T3-L1 differentiation, siRNAs 
were added two days before initiation of differentiation, at the start of differentiation 
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and subsequently every 3rd day. To knock down HILPDA, G0S2 or PPARγ in mature 
3T3-L1 adipocytes, cells were washed with PBS, trypsinized and collected in PBS or 
DMEM. After centrifugation at 400*g for 5 minutes cells were strained over a 70 µM 
cell strainer and plated to 70% conf luency. siRNAs were added two hours later, and 
experiments were carried out after an additional 48-72 hours of incubation. siCtrl-, 
siHILPDA- and siG0S2-treated adipocytes were incubated in DMEM with 1% fatty 
acid-free BSA for 2 hours and subsequently exposed as described in f igure legends. 
Medium samples were assayed for NEFAs as described below. 
 For overexpression experiments in differentiating 3T3-L1 adipocytes, recom-
binant viruses were diluted in DMEM (low glucose, 1 g/L) supplemented with 0.5 
µg/mL poly-L-lysine and incubated at room temperature for 100 minutes. Mixtures 
were added to cells and allowed to incubate for 90 minutes followed by the addition 
of normal culture medium. Differentiation was initiated two days later. Adenovirus-
es were used at a multiplicity of infection (MOI) of 500. To study isoproterenol-in-
duced NEFA release, mature 3T3-L1 adipocytes were re-plated at 70% conf luency 
as described above and subsequently starved in DMEM (low glucose) + 1% FCS for 
12 hours followed by DMEM (low glucose) + 0.1% FCS for an additional 12 hours. 
Adenoviruses diluted in 0.5 µg/mL poly-L-lysine were added to serum starved cells 
at an MOI of 750. Regular culture medium containing 10% FCS was added after 90 
minutes. Three days later cells were incubated in DMEM + 1% BSA for 2 hours and 
subsequently exposed as described in f igure legends. Medium samples were assayed 
for NEFA as described below. 
 Stromal vascular fractions derived from eWAT or iWAT of wild-type male 
C57BL/6 mice (n=3/type of WAT) were differentiated as described previously and 
treated as described in f igure legends (20). SGBS cells and hMADs cells were cultured 
and differentiated according to published methods (22, 23). For microarray analysis, 
cells were exposed to 0.5 μM rosiglitazone or DMSO control for 6 hours as described 
previously (24). 
Serum analyses 
Triglycerides were determined using a triglyceride liquicolor mono kit (Human, Wies-
baden, Germany). NEFA was measured with the NEFA-HR(2) kit (Wako, Neuss, Ger-
many). Cholesterol and glucose were measured with commercially available kits from 
Diasys (Holzheim, Germany). Glycerol was measured with a kit from Sigma-Aldrich. 
Plasma adiponectin was determined using the Mouse Ultrasensitive Insulin ELISA 
(ALPCO Diagnostics, Salem, NH, USA). Plasma insulin levels were quantif ied using 
the Quantikine ELISA (R&D Systems, Abingdon, United Kingdom).
Oil-red-O staining
3T3-L1 adipocytes were f ixed with 4% formaldehyde in PBS for 20 minutes at room 
temperature. Cells were subsequently washed with PBS and incubated with f iltered 
Oil-red-O solution (30 mg/mL in 60% isopropanol) for 10 minutes. Cells were washed 
2-3 times with ddH2O twice before taking pictures.  
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ChIP-seq data
ChIP-seq data sets from 3T3-L1 cells (GSE13511) (25), hMADS cells (GSE59703) (26) 
and mouse eWAT and BAT, either whole tissue (GSE43763) (27) or primary in vitro dif-
ferentiated adipocytes (GSE41481) (28) were obtained from the Gene Expression Om-
nibus database. PPARγ peaks in mouse and human adipocytes were identif ied with 
default settings and scanned for the presence of known motifs using HOMER (29). 
The location of PPARγ super-enhancers was identif ied using annotatePeaks.pl–style 
super in HOMER. Conservation of PPARγ binding sites was determined using the 
University of California at Santa Cruz (UCSC) LiftOver tool from the mm9 to hg19 
genome assemblies. The UCSC genome browser (30) was used for visualization. 
Western Blot 
Proteins were extracted from adipose tissue using homogenization buffer (50 mM Tris, 
pH 8.0, 150 mM NaCl, 1% v/v/ NP-40, 0.5% v/v sodium deoxycholate, 0.1% SDS) 
supplemented with Complete EDTA-free protease inhibitor cocktail and phosSTOP 
tablets (Roche Diagnostics, Almere, The Netherlands), and the Qiagen Tissuelyser II 
(Qiagen, Venlo, The Netherlands). Lysates were rotated for 15 minutes at 4 ˚C and 
subsequently centrifuged at 11.000*g for 15 minutes at 4 ˚C. For extraction of protein 
from cells, homogenization buffer was added to PBS-washed cells and the cells were 
subsequently scraped. Equal amounts of protein were diluted with 2x or 5x Laemmli 
sample buffer, boiled, and separated on 8-16% or 4-20% Criterion gradient gels (Bio-
Rad, Veenendaal, The Netherlands). Proteins were transferred to PVDF membrane 
using a Transblot turbo system (Bio-Rad). Antibodies to detect HILPDA (1:1000, 
Santa Cruz Biotechnology, #sc-137518), β-TUBULIN (1:1000, Santa Cruz Biotech-
nology, #sc-23949), ACTIN (1:2000, Sigma-Aldrich #A2066), HSP90 (1:2000-4000, 
Cell Signaling Technology #4874), HSL (1:5000, Cell Signaling Technology #4107), 
ATGL (1:1000, Cell Signaling Technology #2138), phospho-HSL ser660 (1:2000, Cell 
Signaling Technology #4126) and corresponding secondary antibodies were diluted 
in PBS-T or TBS-T containing 5% w/v skimmed milk powder. Quantif ication of 
western blots was performed with the ChemiDoc MP system (Bio-Rad) and either 
Pierce ECL plus (Thermo Fisher-Scientif ic) or Clarity ECL substrate (Bio-Rad). 
RNA isolation and qPCR
RNA was isolated from tissues and cells using TRIzol (Thermo Fisher-Scientif ic). 
Homogenization of tissues was performed using a Qiagen Tissue lyser II, whereas 
cells were lysed by pipetting up and down several times. Isolated RNA and RNA from 
the FirstChoice Human Total RNA Survey Panel (Ambion, via Thermo Fisher-Sci-
entif ic) was reverse transcribed using the First Strand cDNA synthesis kit (Thermo 
Fisher-Scientif ic) or iScript cDNA Synthesis Kit (Bio-Rad). Gene expression analysis 
was performed on a CFX384 Real-Time PCR platform (Bio-Rad). SensiMix PCR 
mix was purchased from Bioline (GC biotech, Alphen aan de Rijn, The Netherlands). 
Gene expression values were normalized with expression values for 36B4 (housekeep-
ing gene). 
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Microarray analysis
RNA from SGBS and hMADS (24) cells was purif ied with an RNAeasy Minikit (Qia-
gen). RNA quality was verif ied with the RNA 6000 Nano assay on an Agilent 2100 
Bioanalyzer (Agilent Technologies, Amsterdam, The Netherlands). Hybridization, 
washing and scanning of the Affymetrix Human Gene 1.1 ST array plate was per-
formed according to standard protocols on an Affymetrix GeneTitan platform. Bio-
conductor packages were used to analyse the scans of the arrays (31). Robust multiar-
ray normalization was applied to obtain raw signal intensities. Probe sets were def ined 
using remapped chip def inition f ile (CDF) based on the Entrez gene database. Fold 
changes were calculated by dividing expression values of rosiglitazone-treated adipo-
cytes by expression values of DMSO-treated adipocytes.
Confocal Microscopy 
A HILPDA-Turquoise2 plasmid and a HILPDA-mCherry plasmid were constructed 
by fusing full-length HILPDA DNA with the 3′ end of eGFP in pEGFP-N2 (CLON-
TECH). A CIDEB-mCherry plasmid was constructed by fusing full-length CIDEB 
cDNA with 3′ end of eGFP in pEGFP-N2 (CLONTECH). Next, the eGFP region was 
substituted with cDNA encoding the f luorescent protein mTurquoise2 or the f luores-
cent protein mCherry (32). 3T3-L1 f ibroblasts were transfected with HILPDA-mTur-
quoise2 plasmid DNA and CIDEB-mCherry plasmid DNA or HILPDA-mCherry 
plasmid DNA with Fugene (Promega). 24 hours post-transfection, 3T3-L1 cells were 
lipid-loaded with 400 µM oleic acid. Lipid droplets were stained with BODIPY® 
493/503(4,4-Dif luoro-1,3,5,7,8-Pentamethyl-4-Bora-3a,4a-Diaza-s-Indacene) (Mo-
lecular Probes, Leiden, The Netherlands). BODIPY was diluted in PBS at a concen-
tration of 1 mg/mL and incubated for 45 mins. Confocal laser scanning microscopy 
imaging was performed using a confocal laser scanning microscope (LSM510 Carl 
Zeiss, Jena, Germany). Cells were maintained in medium for cellular imaging (20 
mM HEPES pH=7.4, 137 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4, 
20 mM D-Glucose). For mTurquoise2, an excitation light of 458 nm was used and a 
band-pass f ilter of 470-500 nm was used for detection. mCherry was excited using a 
He/Ne diode laser (543nm) and and a band-pass f ilter 560-615 nm was used for de-
tection. A PlanNeof luar 63x oil immersion objective with a numeric aperture of 1.25 
was used. The pinhole setting was set at 1 to 1.3 Airy units. Images were collected 
as 2048×2048 pixel scans at 12-bit intensity resolution. Pixel saturation was avoided 
using the range indicator view during acquisition.
Statistical analyses 
Student’s t-tests or two-way ANOVAs with Tukey’s post-hoc test were performed in 
GraphPad Prism (GraphPad Software, La Jolla, CA, USA). The signif icance level was 
set at p < 0.05.
Role and regulation of HILPDA in adipose tissue 
171
8
RESULTS 
HILPDA is highly expressed in adipose tissue and localizes to lipid droplets  
First, we determined the distribution of hypoxia-inducible lipid droplet-associated 
(HILPDA) mRNA and protein expression across various mouse and human tissues 
and found that HILPDA protein is highly abundant in adipose tissue (Figure 1A & 
Figure 1B). In agreement with previous reports, f luorescently labelled HILPDA lo-
calized primarily, though not exclusively, to the lipid droplets in lipid-loaded 3T3-L1 
pre-adipocytes, as demonstrated by the co-localization with BODIPY and CIDEB, an 
established lipid droplet protein (Figure 1C & Figure 1D) (17, 18, 33). 
Figure 1. HILPDA is highly expressed in adipose tissue and localizes to lipid droplets.
 (A) HILPDA mRNA levels in human (n=1) and mouse (n=4) tissues. (B) Immunoblot for HILPDA in various mouse tissues 
(n=1). (C) 3T3-L1 pre-adipocytes were transfected with HILPDA-mCherry plasmid, loaded with 400 μM of  oleic acid, and 
48h post-transfection stained with BODIPY and analysed by confocal microscopy. (D) 3T3-L1 pre-adipocytes were trans-
fected with HILPDA-Turquoise2 plasmid and CIDEB-mCherry plasmid, loaded with 400 μM of  oleic acid, and analysed 
by confocal microscopy 48h post-transfection. Data are mean ± SEM.
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Figure 2. HILPDA is a PPARγ target gene in adipocytes. 
(A & B) Top 20 of  most highly induced genes following gene expression profiling of  SGBS (A) and hMADS adipocytes (B) 
treated with 0.5 μM rosiglitazone or DMSO control for 6h. Fold change was calculated by dividing gene expression values of  
rosiglitazone-treated adipocytes by values of  control-treated adipocytes. (C) Undifferentiated (fibroblasts) and fully differentiat-
ed 3T3-L1 adipocytes (adipocytes) were exposed to 10 μM rosiglitazone or DMSO control for 24h and subsequently analysed 
for HILPDA mRNA (left) and protein (right). Gene expression levels of  control-treated fibroblasts were set at 1. ACTIN was 
used as a loading control. (D) Fully differentiated 3T3-L1 adipocytes were trypsinized, re-plated at 70% confluency, and in-
cubated with control siRNA (siCtrl) or siRNA against PPARγ (siPPARγ) and analysed for expression of  PPARγ and HILPDA 
after 72h. Gene expression levels of  siCtrl-treated adipocytes were set at 1 (E) Fully differentiated SGBS adipocytes were 
trypsinzed, re-plated at 70% confluency, and incubated with control siRNA (siCtrl) or siRNA against PPARγ (siPPARγ) and 
analysed for expression of  PPARγ and HILPDA after 72h. Gene expression levels of  siCtrl-treated adipocytes were set at 
1. Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test relative to control-treated 
fibroblasts or adipocytes (Figure 2C) or relative to siCtrl-treated adipocytes (Figure 2D & Figure 2E); ** p<0.01, * p<0.05.
(B) Screenshot of  the human HILPDA locus showing RNA-seq and PPARγ ChIP-seq profiles in hMADS preadipocytes 
and adipocytes. PPARγ binding sites that are conserved between mouse and human and the position of  PPREs within the 
PPARγ binding sites are highlighted. The sequences indicate conserved PPREs in the respective binding sites. The red bar 
indicates the position of  adipocyte-specific PPARγ super-enhancers in 3T3-L1 and hMADS adipocytes. The PPARγ bind-
ing site thathas been reported to bind PPARα in liver and that harbors a highly conserved PPRE is marked by an asterisk. 
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Figure 3. PPARγ is associated with the HILPDA locus in mouse and human adipocytes. 
(A) Screenshot of  the mouse Hilpda locus showing ChIP-seq profiles of  RXR, PPARγ, and RNA polymerase II in 3T3-L1 
preadipocytes and adipocytes, and PPARγ ChIP-seq profiles from eWAT and BAT (primary adipocytes and whole tissue). 
See previous page for continuation. 
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HILPDA is a PPARγ target gene in adipocytes
Hilpda was recently identif ied as a target gene of peroxisome proliferator-activated re-
ceptor (PPAR) α in liver (19). To explore whether PPARγ impacts HILPDA expression 
in adipocytes, we treated different types of adipocytes with the PPARγ agonist rosigl-
itazone. Interestingly, microarray analyses indicated that HILPDA was among the 
20 most signif icantly upregulated genes by rosiglitazone in differentiated SGBS adi-
pocytes and differentiated human multipotent adipose-derived stem cells (hMADS), 
together with the well-known PPARγ targets PCK1, PDK4 and LPL (Figure 2A & 
Figure 2B). Rosiglitazone also signif icantly induced HILPDA mRNA and protein in 
mature 3T3-L1 adipocytes, but not 3T3-L1 pre-adipocytes (Figure 2C). Consistent 
with PPARγ-dependent regulation, HILPDA expression in 3T3-L1 and human SGBS 
adipocytes was markedly decreased upon knockdown of PPARγ (Figure 2D & Fig-
ure 2E). 
Figure 4. SiRNA-mediated knockdown or adenoviral-mediated overexpression of HILPDA does not affect adipo-
genesis. 
(A) HILPDA mRNA (top) and protein (bottom) levels during 3T3-L1 adipogenesis. Cells were harvested at indicated days, 
with day 0 as the day at which differentiation was started. Gene expression levels of  Day -3 were set at 1. ACTIN was used 
as a loading control. (B) HILPDA mRNA (top) and protein (bottom) levels during 3T3-L1 adipogenesis. Control (siCtrl) and 
HILPDA siRNAs (siHILPDA) were added two days before initiation of  adipogenesis, at the start of  differentiation and on 
day 3 and day 6 of  differentiation. Cells were harvested at indicated days, with day 0 as the day at which differentiation 
was started. Gene expression levels of  siCtrl-treated adipocytes at day 3 of  differentiation were set at 1. ACTIN was used 
as a loading control. (C) Oil-Red-O staining of  of  3T3-L1 adipocytes treated with control (siCtrl) and HILPDA siRNA 
(siHILPDA). siCtrl and siHILPDA were added two days before initiation of  adipogenesis, at the start of  differentiation and 
on day 3 and day 6 of  differentiation. Cells were harvested at indicated days, with day 0 as the day at which differentiation 
was started. (D) FABP4, G0S2, and PPARγ mRNA levels during adipogenesis of  3T3-L1 adipocytes treated with control 
(Ctrl) and HILPDA siRNA. siCtrl and siHILPDA were added two days before initiation of  adipogenesis, at the start of  dif-
ferentiation and on day 3 and day 6 of  differentiation. Cells were harvested at indicated days, with day 0 as the day at which 
differentiation was started. Gene expression levels of  siCtrl-treated adipocytes at day 3 of  differentiation were set at 1. (E) 
HILPDA mRNA (top) and protein (bottom) during 3T3-L1 adipogenesis of  AV-gfp- or AV-Hilpda-treated cells. Recombinant 
adenoviruses expressing gfp or Hilpda were added at an MOI of  500 two days before initiation of  differentiation. Cells were 
harvested at indicated days, with day 0 as the day at which differentiation was started. Gene expression levels of  AV-gfp-
treated adipocytes at day 3 of  differentiation were set at 1. ACTIN was used as a loading control. (F) Oil-Red-O staining 
of  AV-gfp or AV-Hilpda treated cells at indicated days during the process of  differentiation. Recombinant adenoviruses 
expressing gfp or Hilpda were added at an MOI of  500 two days before initiation of  differentiation. Cells were harvested 
at indicated days, with day 0 as the day at which differentiation was started. (G) FABP4, G0S2, and PPARγ mRNA levels 
during adipogenesis of  3T3-L1 adipocytes treated with AV-gfp or AV-Hilpda. Recombinant adenoviruses expressing gfp or 
Hilpda were added at an MOI of  500 two days before initiation of  differentiation. Cells were harvested at indicated days, 
with day 0 as the day at which differentiation was started. Gene expression levels of  AV-gfp-treated adipocytes at day 3 of  
differentiation were set at 1. Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test 
relative to Day -3 (Figure 4A), relative to siCtrl-treated adipocytes (Figure 4B, 4D), or relative to AV-gfp-treated adipocytes 
(Figure 4E, 4G); ** p<0.01, * p<0.05.
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Figure 4. 
See previous page for figure legend.
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Figure 5. HILPDA is highly induced upon activation of β-adrenergic signaling. 
(A) HILPDA mRNA (left) and protein (right) levels in fully differentiated 3T3-L1 cells exposed to control medium, 10 
μM isoproterenol, 5 μM forskolin, 10 μM CL316,243, 10 μM procaterol, 10 μM norepinephrine for 3h. Protein levels of  
HILPDA were assessed on a regular gel and on a Phos-tag gel to assess HILPDA phosphorylation. Gene expression levels 
of  control-treated adipocytes were set at 1. TUBULIN was used as a loading control. (B) HILPDA mRNA (top) and protein 
(bottom) levels in fully differentiated 3T3-L1 cells exposed to 10 μM isoproterenol for indicated time points. Gene expression 
levels at time point 0h were set at 1. ACTIN was used as a loading control. (C) HILPDA mRNA (top) and protein (bottom) 
levels in fully differentiated 3T3-L1 cells incubated with control medium or indicated concentrations of  isoproterenol for 
6h. Gene expression levels of  control-treated adipocytes were set at 1. ACTIN was used as a loading control. (D) HILPDA 
mRNA levels in primary adipocytes differentiated from the stromal vascular fractions of  epididymal or inguinal white adi-
pose tissue and exposed to 10 μM isoproterenol for 3h. Gene expression levels of  control-treated epididymal adipocytes and 
inguinal adipocytes were set at 1. Data are mean ± SEM. Asterisks indicate significant differences according to Student’s 
t-test relative to control-treated adipocytes (all figures); ** p<0.01, * p<0.05.  
  Previously, a functional PPAR response element (PPRE) was identif ied 
around 1200 base pairs upstream of the transcriptional start site (TSS) of the Hilpda 
gene (19). Investigation of PPARγ ChIP-seq data from 3T3-L1, primary epididymal 
WAT- and brown adipose tissue (BAT)-derived adipocytes, and hMADS adipocytes 
demonstrated that PPARγ binds to three conserved sites upstream of the TSS (Figu-
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 re 3A & Figure 3B). The PPARγ binding site closest to the TSS overlaps with the lo-
cation of a highly conserved PPRE that was previously shown to mediate PPARγ-de-
pendent transcriptional activation in vitro (Figure 3A & Figure 3B) (19). Since pre-
vious studies have shown that clusters of nearby enhancers (i.e. super-enhancers) (34) 
control important cell type-def ining genes, we next asked whether the Hilpda locus 
is associated with a PPARγ super-enhancer. Interestingly, in both mouse and human 
adipocytes a prominent PPARγ super-enhancer is located near Hilpda (Figure 3A & 
Figure 3B), suggesting that Hilpda is an important PPARγ target gene that might 
control key adipocyte functions.   
HILPDA does not affect 3T3-L1 adipogenesis
With Hilpda being a PPARγ target gene, we explored a potential role for HILPDA 
in adipocyte differentiation. Expression of HILPDA mRNA signif icantly increased 
during mouse 3T3-L1 adipocyte differentiation, which was conf irmed at the protein 
level (Figure 4A). To assess the role of HILPDA in 3T3-L1 adipocyte differentiation, 
we employed siRNA-mediated knockdown of HILPDA. When compared with control 
siRNA, siRNA targeting HILPDA effectively reduced HILPDA mRNA and protein 
levels (Figure 4B). However, knockdown of HILPDA did not substantially inf luence 
3T3-L1 adipogenesis, as shown by Oil-Red-O staining and expression of adipogenic 
marker genes (Figure 4C & Figure 4D). Similarly, adenoviral-mediated overexpres-
sion of HILPDA did not inf luence 3T3-L1 adipogenesis, as revealed by Oil-Red-O 
staining, and the expression of adipogenic marker genes (Figure 4E-G). Together, 
these data suggest that HILPDA does not regulate 3T3-L1 adipogenesis.
HILPDA is highly induced upon activation of β-adrenergic signaling
Several lipid droplet proteins are responsive to β-adrenergic signaling, the key sign-
aling pathway that activates adipocyte lipolysis (35, 36). To assess whether β-adren-
ergic signaling regulates HILPDA expression, 3T3-L1 adipocytes were treated with 
various β-adrenergic receptor agonists. HILPDA mRNA and protein expression were 
signif icantly induced upon treatment with the non-selective β-receptor agonist isopro-
terenol, the β3-receptor agonist CL316,243, the β2-receptor agonist procaterol, the 
non-selective adrenergic receptor agonist norepinephrine and the adenylate cyclase 
activator forskolin, suggesting that HILPDA is responsive to β-adrenergic stimulation 
(Figure 5A). The remainder of the experiments was performed with isoproterenol. 
HILPDA mRNA and protein levels were induced by isoproterenol in a time- and con-
centration-dependent manner, with HILPDA levels peaking after 3 hours of stimula-
tion and an isoproterenol concentration of 1 μM (Figure 5B & Figure 5C). Induc-
tion of HILPDA mRNA by isoproterenol was conf irmed in primary mouse gonadal 
and inguinal adipocytes, as well as in brown adipocytes (Figure 5D, Supplemental 
Figure 1). 
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SiRNA-mediated knockdown of HILPDA in adipocytes does not affect lipolysis
Loss of HILPDA was previously shown to increase triglyceride hydrolysis in primary 
hepatocytes (17). Also, the protein that shares the highest sequence homology with 
HILPDA is G0S2, an inhibitor of intracellular lipolysis (17) (unpublished observa-
tions). To explore a possible role of HILPDA in adipose tissue lipolysis, we studied 
the effect of siRNA-mediated HILPDA knockdown on intracellular lipolysis in dif-
ferentiated 3T3-L1 adipocytes. Although treatment with siRNA targeting HILPDA 
effectively reduced HILPDA mRNA and protein levels in the adipocytes, it did not 
inf luence the release of NEFA upon stimulation with isoproterenol (Figure 6A & 
Figure 6B). To determine whether loss of HILPDA may be functionally compensated 
by G0S2, we assessed the impact of siRNA-mediated knockdown of HILPDA and/
or G0S2 on intracellular lipolysis in 3T3-L1 adipocytes. Again, while treatment with 
siRNA targeting HILPDA and/or G0S2 effectively reduced RNA levels of HILPDA 
Figure 6. Overexpression of HILPDA in adipocytes inhibits lipolysis. 
(A) HILPDA mRNA (left) and protein levels (right) in fully differentiated 3T3-L1 adipocytes that were trypsinized, replated 
at 70% confluency, and treated with siHILPDA or siCtrl for 48h. Gene expression levels of  siCtrl-treated adipocytes were set 
at 1. ACTIN was used as a loading control. (B) NEFA release in medium of  fully differentiated 3T3-L1 adipocytes that were 
trypsinized, replated at 70% confluency, and treated with siHILPDA or siCtrl for 48h. After 48h, adipocytes were serum 
starved for 2h and incubated with 5 µM isoproterenol or control medium for 2h. NEFA levels were corrected for protein 
levels in cell lysates. (C) HILPDA and G0S2 mRNA levels in fully differentiated 3T3-L1 adipocytes that were trypsinized, 
replated at 70% confluency, and treated with siCtrl, siHILPDA or siG0S2 for 48h. Gene expression levels of  siCtrl-treated 
adipocytes were set at 1. (D) NEFA release in medium of  fully differentiated 3T3-L1 adipocytes that were trypsinized, replat-
ed at 70% confluency, and treated with siCtrl, siHILPDA or siG0S2 for 48h. After 48h, adipocytes were serum starved for 
2h and incubated with 5 µM isoproterenol or control medium for 2h. NEFA levels were corrected for protein levels in cell 
lysates. (E) HILPDA mRNA (left) and protein levels (right) in fully differentiated 3T3-L1 adipocytes transduced with AV-gfp 
or AV-Hilpda. Fully differentiated 3T3-L1 adipocytes were trypsinized, re-plated at 70% confluency, serum starved for 24h 
and transduced with recombinant adenoviruses expressing gfp or Hilpda at an MOI of  750 for 72h. Gene expression levels 
of  AV-gfp- treated adipocytes were set at 1. HSP90 was used as a loading control. s.e., short exposure; l.e., long exposure. 
(F) NEFA release in fully differentiated 3T3-L1 adipocytes that were trypsinized, re-plated at 70% confluency, serum starved 
for 24h and transduced with recombinant adenoviruses expressing gfp or Hilpda at an MOI of  750 for 72h. Transduced 
differentiated 3T3-L1 adipocytes were serum starved for 2h, and incubated with 5 µM isoproterenol for 3h. (G) NEFA re-
lease in fully differentiated 3T3-L1 adipocytes that were trypsinized, re-plated at 70% confluency, serum starved for 24h and 
transduced with recombinant adenoviruses expressing gfp or Hilpda at an MOI of  750 for 72h. Transduced differentiated 
3T3-L1 adipocytes were serum starved for 2h, and incubated either with 10 µM isoproterenol, 5 mM 3-methyladenine or 
10 µM CL316,243 for 3h. (H) Representative immunoblots for HSL (LIPE), phospho-HSL, ATGL (PNPLA2), PLIN1 and 
HILPDA in fully differentiated 3T3-L1 adipocytes that were trypsinized, re-plated at 70% confluency, serum starved for 
24h and transduced with recombinant adenoviruses expressing gfp or Hilpda at an MOI of  750 for 72h. Transduced 3T3-
L1 adipocytes were serum starved for 2h, and incubated with 10 µM isoproterenol for 3h. HSP90 was used as a loading 
control. s.e., short exposure; l.e., long exposure. Data are mean ± SEM. Asterisks indicate significant differences according 
to student’s t-test relative to siCtrl-treated or AV-gfp-treated adipocytes (Figure 6A, 6C, 6E). Asteriks or hashtags indicate 
significant differences according to two-way ANOVA (#) followed by Tukey’s HD post-hoc test (*) relative to control-treated 
adipocytes (#) or relative to siCtrl- or AV-gfp-treated adipocytes (*); ** or ## p<0.01, * or # p<0.05.
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and G0S2 (Figure 6C), it did not affect NEFA release upon stimulation with isopro-
terenol (Figure 6D). Together, these results indicate that knockdown of HILPDA in 
adipocytes—alone or in combination with G0S2—does not have a major impact on 
the in vitro lipolytic response to pharmacologic β3-adrenergic stimulation.
Overexpression of HILPDA in adipocytes in vitro reduces lipolysis 
We reasoned that a possible effect of HILPDA on lipolysis might be more evident when 
HILPDA is overexpressed as opposed to knocked down. Accordingly, we studied the 
effect of adenoviral-mediated HILPDA overexpression on lipolysis in differentiated 
3T3-L1 adipocytes (Figure 6E). Remarkably, HILPDA overexpression modestly but 
signif icantly reduced NEFA release induced by isoproterenol (Figure 6F ). The in-
hibitory effect of HILPDA overexpression on NEFA release was reproduced with the 
β3-adrenergic agonist CL316,243 and the PI3K inhibitor 3-methyladenine (Figure 
6G). To explore the potential mechanism underlying the observed anti-lipolytic effect 
of HILPDA, we studied the effect of AV-mediated HILPDA overexpression on the 
relative abundance and activation status of key lipolytic enzymes, including adipose 
triglyceride lipase (ATGL/PNPLA2) and hormone sensitive lipase (HSL/LIPE). In-
terestingly, HILPDA overexpression modestly decreased the abundance of phospho-
rylated HSL following isoproterenol induction and, to a lesser extent, ATGL (Figure 
6H ). These data suggest that overexpression of HILPDA has a mild attenuating effect 
on isoproterenol-induced lipolysis in 3T3-L1 adipocytes.
Figure 7. Adipocyte-specific knockdown of HILPDA has no effect on indicators of lipolysis in mice injected with 
CL316,243. 
(A) HILPDA mRNA levels in whole adipose tissue, and in freshly separated adipocytes and stromal vascular fractions (SVF) 
of  Hilpdaflox/flox (n=4) and HilpdaΔAT mice (n=4). Gene expression levels of  adipose tissue from Hilpdaflox/flox mice were set at 
1. (B) NEFA release in medium of  primary adipocytes differentiated from the stromal vascular fraction of  inguinal white 
adipose tissue from  HilpdaΔAT mice (n=3) and Hilpdaflox/flox (n=3)  mice, serum starved for 2h, and incubated with 10 µM 
isoproterenol or 10 µM CL316,243 for 3h.  (C) NEFA release in medium of  WAT explants of  HilpdaΔAT mice (n=3) and 
Hilpdaflox/flox (n=3) mice, serum starved for 30 min, and incubated with 10 µM isoproterenol for 3h. (D) HILPDA mRNA 
levels in epididymal WAT of  Hilpdaflox/flox (n=8/treatment) and HilpdaΔAT (n=8/treatment) mice excised and snap-frozen 3h 
after subcutaneous injection with 1 mg/kg CL316,243 or saline control. Gene expression levels of  saline-treated Hilpdaflox/
flox mice were set at 1.  (E) HILPDA mRNA levels in freshly isolated adipocytes or stromal vascular fraction isolated from 
epididymal WAT of  Hilpdaflox/flox (n=8/treatment) and HilpdaΔAT mice (n=8/treatment) excised and snap-frozen 3h after 
subcutaneous injection with 1 mg/kg CL316,243 or saline control. Gene expression levels of  the stromal vascular fractions 
of  saline-treated Hilpdaflox/flox mice were set at 1. (F) Plasma levels of  NEFAs, glycerol, triglycerides and glucose of  Hilpdaflox/
flox (n=8/treatment) and HilpdaΔAT (n=8/treatment) mice 3h after subcutaneous injection with 1 mg/kg CL316,243 or saline 
control. (G) Tissue weights of  inguinal WAT and epididymal WAT of  Hilpdaflox/flox (n=8/treatment) and HilpdaΔAT mice 
(n=8/treatment) 3h after subcutaneous injection with 1 mg/kg CL316,243 or saline control. Data are mean ± SEM. Aster-
isks indicate significant differences according to student’s t-test (*) relative to adipose tissue or SVF of  saline-treated Hilpdaflox/
flox mice (Figure 7A, 7E). Asteriks or hashtags indicate significant differences according to two-way ANOVA (#) followed by 
Tukey’s HD post-hoc test (*) relative to control-treated adipocytes (Figure 7B, 7C) or saline-treated mice (Figure 7D, 7F, 7G) 
(#) and relative to Hilpdaflox/flox mice (Figure 7D, 7F, 7G) (*); ** or ## p<0.01, * or # p<0.05.  
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Adipocyte-specific knockdown of HILPDA has minimal effects on metabolic 
parameters following pharmacological β-adrenergic stimulation and fasting 
To examine a potential role for HILPDA in adipocyte lipolysis in vivo, we generat-
ed adipocyte-specif ic Hilpda mutant mice (HilpdaΔAT) by crossing f loxed Hilpda mice 
(Hilpdaf lox/f lox) with Adiponectin-Cre mice. HILPDA expression was about 50% lower 
in adipose tissue of HilpdaΔAT mice as compared to Hilpdaf lox/f lox mice, which was ac-
counted for by an almost complete loss of Hilpda expression in adipocytes (Figure 
7A). Upon examination of the ex vivo NEFA release from primary adipocytes or ad-
ipose tissue explants stimulated with isoproterenol, we found that NEFA levels were 
comparable between adipocytes and adipose tissue explants of HilpdaΔAT mice and 
Hilpdaf lox/f lox mice, in line with our data of in vitro knockdown of HILPDA (Figure 7B 
& Figure 7C). To examine a potential role of HILPDA in the in vivo lipid metabol-
ic response to β-adrenergic stimulation, we injected HilpdaΔAT and Hilpdaf lox/f lox with 
the β3-adrenergic agonist CL316,243 to induce lipolysis. In agreement with our in 
vitro data, injection with CL316,243 potently induced HILPDA expression in white 
adipose tissue of Hilpdaf lox/f lox mice (Figure 7D). Induction of HILPDA expression 
upon CL316,243 injection was specif ically observed in the adipocytes and not in the 
stromal vascular fraction (Figure 7E). While injection with CL316,243 signif icantly 
increased plasma NEFA and glycerol levels—suggesting that CL316,243 effectively 
induced lipolysis—no differences were observed between HilpdaΔAT and Hilpdaf lox/f lox 
mice (Figure 7F ). Weight of inguinal and epididymal WAT (Figure 7G) and plasma 
levels of other metabolites (Figure 7F ) were also not different between HilpdaΔAT and 
Hilpdaf lox/f lox mice. 
 More physiological conditions that are associated with the activation of 
β-adrenergic signaling and adipose tissue lipolysis are fasting and cold exposure. In-
deed, fasting caused a marked increase in HILPDA mRNA and protein in WAT of 
wild-type mice (Figure 8A). After a 24h fast, however, WAT weight was not different 
between HilpdaΔAT and Hilpdaf lox/f lox mice (Figure 8B). No major differences in plasma 
NEFA and glycerol, as well as other metabolites were observed between the two gen-
otypes (Figure 8C). Also, plasma insulin and adiponectin levels and adipose tissue 
morphology were not different between HilpdaΔAT and Hilpdaf lox/f lox mice (Figure 8D, 
Supplemental Figure 2). Similarly, cold exposure of HilpdaΔAT and Hilpdaf lox/f lox 
mice did not result in signif icant differences in plasma NEFA levels or other metabolic 
parameters (Supplemental Figure 3). We did, however, observe a small but consist-
ent increase in the expression of several genes involved in lipolysis and lipid droplet 
morphology in WAT of HilpdaΔAT compared to Hilpdaf lox/f lox mice (Figure 8E).
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Figure 8. Adipocyte-specific knockdown of HILPDA has no effect on tissue weights or plasma parameters follow-
ing a 24h fast. 
(A) HILPDA mRNA (left) and protein levels (right) in epididymal WAT from C57BL/6 mice fed or fasted for 18h (n=6/
group). Gene expression levels of  fed mice were set at 1. ACTIN was used as a loading control. (B) Weight of  epididymal 
WAT of  male Hilpdaflox/flox (n=6) and HilpdaΔAT (n=8) fasted for 24h (in grams). (C) Plasma levels of  non-esterified fatty acids 
(NEFAs), glycerol, triglycerides, glucose and ketone bodies of  male Hilpdaflox/flox (n=6) and HilpdaΔAT (n=8) mice fasted for 
24h. (D) Plasma levels of  insulin and adiponectin of  Hilpdaflox/flox (n=6) and HilpdaΔAT (n=8) mice fasted for 24h. (E) mRNA 
levels of  genes involved in lipolysis or lipid droplet morphology (PNPLA2, LIPE, ABHD5, G0S2, PLIN1, PLIN2, PLIN4) in 
epididymal WAT of  Hilpdaflox/flox (n=6) and HilpdaΔAT (n=8) mice fasted for 24h. Gene expression levels for Hilpdaflox/flox mice 
were set at 1 for each gene. Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test 
relative to fed mice (Figure 8A) or Hilpdaflox/flox mice; ** p<0.01, * p<0.05.  
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DISCUSSION
Our paper shows that HILPDA is abundant in adipocytes, where its expression is 
stimulated by PPARγ and β-adrenergic signaling. Whereas adenoviral overexpression 
of HILPDA modestly lowered NEFA release from adipocytes, the absence of an effect 
of Hilpda deletion on NEFA release in vitro and plasma NEFA and glycerol levels in 
vivo suggest that HILPDA is not a physiological regulator of lipolysis in adipocytes, at 
least under conditions of β-adrenergic stimulation, cold exposure or fasting. It should 
be mentioned, though, that based on our data, we cannot exclude that HILPDA may 
inf luence adipose tissue lipolysis under different conditions, such as obesity or phys-
ical exercise. 
 The reason for the apparent discrepancy between the effect on lipolysis of 
in vitro HILPDA overexpression versus in vivo/in vitro Hilpda deletion or knockdown 
remains unclear. It can be hypothesized that the lack of effect of HILPDA deletion 
or knockdown on any of the parameters studied may be because the loss of HILPDA 
is functionally compensated by other genes. One protein that might be suspected to 
be able to functionally compensate for HILPDA is G0S2, a small ~11 kDa protein 
that is known to inhibit ATGL activity and inf luence ATGL localization (35, 37). 
Remarkable similarities exist between HILPDA and G0S2: HILPDA and G0S2 are 
both highly sensitive PPAR targets, share striking sequence homology in their N-ter-
minal domains, and increase hepatic lipid accumulation when overexpressed in liver 
(14, 17, 19, 35, 38). In our studies, however, knockdown of G0s2 did not signif icantly 
alter isoproterenol-induced NEFA release in 3T3-L1 adipocytes, whether alone or in 
combination with knockdown of HILPDA, suggesting that G0S2 does not functional-
ly compensate for HILPDA upon HILPDA knockdown. 
 Since HILPDA does not seem to be a direct inhibitor of adipocyte lipolysis—
which is supported by our previous studies indicating that HILPDA does not directly 
inhibit HSL or ATGL—the modest inhibitory effect of HILPDA overexpression on 
NEFA release by adipocytes might ref lect an indirect mechanism [19]. It may be 
speculated that HILPDA, similar to other lipid droplet-associated PPAR targets such 
as CIDEC and PLIN2, plays a role in lipid droplet coating, lipid droplet growth or in 
the regulation of interactions of lipid droplets with other organelles, such as the ER 
(5, 6, 39, 40). An important future research strategy should be to further examine 
the exact localization of HILPDA in adipocytes and hepatocytes and to study the 
potential inf luence of relevant stimuli on HILPDA localization. Also, efforts should 
be undertaken to identify binding partners of HILPDA. One possible binding partner 
for HILPDA is PLIN2, as PLIN2 and HILPDA are both sensitive PPAR targets, have 
a similar tissue expression prof ile, and co-localize on the surface of some, but not all 
lipid droplets (16, 18, 19). 
 Our data on the role of HILPDA in adipocytes add to the current literature 
on HILDA function. The observation that HILPDA is physically associated with lipid 
droplets in 3T3-L1 cells is in line with previous f indings in lipid-loaded HeLa cells 
and primary hepatocytes (17, 18). In those studies, overexpression of Hilpda in HeLa 
cells promoted cellular lipid accumulation, whereas loss of Hilpda in hepatocytes re-
duced lipid accumulation and resulted in more yet smaller lipid droplets (17, 18). The 
reduced lipid accumulation was attributed to increased triglyceride lipolysis and tri-
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glyceride turnover (17). Similarly, hepatic overexpression of HILPDA in vivo increased 
hepatic lipid accumulation, whereas liver-specif ic deletion of Hilpda lowered hepatic 
lipid accumulation, which was observed specif ically in mice fed a chow diet but not 
in mice fed a high fat diet (17, 19). By contrast, we did not observe any effect of adipo-
cyte-specif ic deletion of Hilpda in mice on adipocyte lipolysis, weight of adipose tissue 
depots or other relevant parameters. While the collective data thus point toward a role 
for HILPDA in lipid droplet morphology and lipid storage/mobilization, the exact 
molecular function of HILPDA remains to be elucidated. 
 An intriguing observation is that HILPDA is rapidly and very potently up-
regulated upon β-adrenergic stimulation. β-adrenergic signaling generally leads to 
activation of proteins that promote lipolysis (36). As discussed above, our data do not 
support such a function for HILPDA. The exact biological rationale and mechanisms 
underlying the upregulation of HILPDA mRNA by β-adrenergic stimulation require 
further investigation. Besides β-adrenergic stimulation, our data show that HILPDA 
expression is potently stimulated by treatment with PPARγ agonists. Previously, we 
demonstrated that HILPDA expression in liver is under transcriptional control of 
PPARα (19). In the current paper we show the presence of several conserved PPARγ 
binding sites in the vicinity of HILPDA, indicating that HILPDA is a bona-f ide PPARγ 
target gene in mouse and human adipocytes. The preservation of three conserved 
PPARγ sites, one of which is also conserved at the sequence level, is remarkable given 
that only approximately 17% of all mouse adipocyte PPARγ binding sites (and 28% 
of PPARγ sites in the vicinity of adipocyte selective genes) are preserved in human 
adipocytes (41). Furthermore, we demonstrate the existence of a conserved PPARγ 
super-enhancer in association with the HILPDA locus in both mouse and human adi-
pocytes. 
 Only a few genes and pathways are induced by both β-adrenergic signal-
ing and PPARγ. Interestingly, a shared downstream effect of activation of PPARγ 
and β-adrenergic signaling is stimulation of adipocyte lipolysis (36, 42). Whereas 
β-adrenergic signaling stimulates lipolysis mainly by promoting the phosphorylation 
of key lipolytic proteins, PPARγ induces lipolysis at the level of gene transcription 
(36, 42–44). Whether β-adrenergic signaling and PPARγ interact in the regulation of 
HILPDA mRNA remains unclear. Using Phos-tag gels, we did not f ind any evidence 
that HILPDA becomes phosphorylated upon β-adrenergic stimulation. Overall, the 
combined regulation of HILPDA by β-adrenergic signaling and PPARγ in adipocytes 
hints at an important yet not fully understood role of HILPDA in adipocyte biology.
 In conclusion, we demonstrate that HILPDA is well-expressed in adipocytes, 
where it is potently induced by PPARγ and β-adrenergic signaling. While overexpres-
sion of HILPDA modestly inhibited lipolysis in adipocytes, adipocyte-specif ic knock-
down of HILPDA had minimal effects on intracellular lipolysis and other relevant 
metabolic parameters upon pharmacological β-adrenergic stimulation, cold exposure 
and fasting. Taken together, our data indicate that HILPDA does not appear to be a 
major physiological regulator of adipocyte lipolysis. Future studies should reveal the 
exact molecular function of HILPDA in adipocytes.  
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SUPPLEMENTAL MATERIALS & METHODS
Animal experiments
For the cold exposure experiment (Supp. Figure 3), 15- to 18-week old male Hilpda-
f lox/f lox and HilpdaΔAT littermates were exposed to a cold environmental temperature (4 
˚C) (n=10 per genotype) or a thermoneutral temperature (28 ˚C) (n=8 per genotype) 
for 10 days. After 10 days animals were anesthesized with isof lurane, blood was col-
lected and following cervical dislocation several tissues were excised and snap-frozen. 
Food intake, body weight and body temperature were monitored daily. Body temper-
ature of cold-exposed mice was monitored via read-out of transponders (IPTT-300) 
that were injected subcutaneously prior to the experiment (Bio Medic Data Systems, 
Seaford, USA).
Cell culture 
T37i cells (P31-36; kind gift of Marc Lombès) were cultured in DMEM/F-12 (Gibco, 
Life Technologies, Blijswijk, the Netherlands), supplemented with 10% FBS and 1% 
P/S. Two days post-conf luency, cell culture medium was supplemented with 112 ng/
mL insulin and 2 nM T3 (Sigma-Aldrich) to induce differentiation. After 7 days of 
differentiation, cells were switched back to regular medium and used for experiments 
2/3 days after (1).
 For isolation of primary brown adipocytes, BAT from 1-month-old pups was 
used. Tissues of 5-10 pups were pooled, minced with scissors and digested for 30 
min in collagenase-containing medium at 37˚C (DMEM w/o serum, 2 mg/mL Colla-
genase type II, 2% BSA, 25 mM HEPES). After digestion, cells were passed through 
a 70 or 100 μM f ilter, mature adipocytes were discarded and cells were centrifuged 
at 800g for 5 min. Cells were re-suspended in differentiation medium (DMEM, 10% 
FBS, 20 nM insulin, 1 nM T3) and plated. Upon conf luence, cells were treated with 
induction medium (differentiation medium supplemented with 0.5 mM IBMX, 0.5 
μM dexamethasone, 0.125 mM indomethacin) for two days. After washing, cells were 
incubated in differentiation medium for another 5 to 7 days.
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SUPPLEMENTAL FIGURES
Supplemental Figure 1. 
(A) HILPDA mRNA levels in fully differentiated T37i adipocytes (left) and primary brown adipocytes (right) exposed to con-
trol medium or 10 μM isoproterenol. Gene expression levels of  control-treated adipocytes were set at 1. Data are mean ± 
SEM. Asterisks indicate significant differences according to Student’s t-test relative to control-treated adipocytes (all figures); 
** p<0.01, * p<0.05.
Supplemental Figure 2. 
(A) Representative H&E stainings of  epididymal WAT and BAT (7 μM) of  male Hilpdaflox/flox (n=6) and HilpdaΔAT (n=8) fasted 
for 24h.
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Supplemental Figure 3. 
(A) HILPDA mRNA levels in BAT, epididymal WAT and inguinal WAT of  C57BL/6 mice exposed to 4 °C or 28 °C for 10 
days (n=8-10 animals per group). Gene expression levels of  mice exposed to 28 °C were set at 1. (B) Body weight of  Hilpdaflox/
flox and HilpdaΔAT mice exposed to 4 °C or 28 °C for 10 days (n=8-10 animals per group). (C) Body temperature of  Hilpdaflox/
flox and HilpdaΔAT mice exposed to 4 °C or 28 °C for 10 days (n=10 animals per group). (D) HILPDA mRNA levels in BAT  of  
Hilpdaflox/flox and HilpdaΔAT mice exposed to 4 °C or 28 °C for 10 days (n=8-10 animals per group). Gene expression levels of  
Hilpdaflox/flox mice exposed to 28 °C were set at 1. (E) Tissue weights of  BAT, epididymal WAT and inguinal WAT of  Hilpdaflox/
flox and HilpdaΔAT mice exposed to 4 °C or 28 °C for 10 days (n=8-10 animals per group) (in grams). 
See next page for continuation.
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(F) Triglycerides, non-esterified fatty acids (NEFA), glucose and glycerol levels in plasma of  Hilpdaflox/flox and HilpdaΔAT mice 
exposed to 4 °C or 28 °C for 10 days (n=8-10 animals per group). (G) Representative H&E stainings of  eWAT and BAT of  
Hilpdaflox/flox and HilpdaΔAT mice exposed to 4°C or 28°C for 10 days. Data are mean ± SEM. Asterisks indicate significant 
differences according to student’s t-test (*) relative to mice exposed to thermoneutrality (Supp. Figure 3A). Asteriks or hash-
tags indicate significant differences according to two-way ANOVA (#) followed by Tukey’s HD post-hoc test (*) relative to 
mice exposed to thermoneutrality (Supp. Figure 3D, 3E, 3F) (#) and relative to Hilpdaflox/flox mice (Supp. Figure 3D, 3E, 3F) 
(*); ** or ## p<0.01, * or # p<0.05.
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Over a century ago, Whitehead’s observation that triglycerides are unable to cross 
cellular membranes in their unhydrolyzed form highlighted the crucial role of lipol-
ysis for general metabolism (1). Since then, considerable progress has been made in 
identifying the key players of gastro-intestinal lipolysis, intravascular lipolysis and in-
tracellular lipolysis (2–5). Notwithstanding the signif icant advances made, this thesis 
highlights that many of the molecular mechanisms underlying the physiological regu-
lation of lipolysis had and have not been fully characterized. In the previous chapters, 
we have unveiled and clarif ied the functions of the peroxisomal-proliferator activated 
receptor (PPAR)-target genes angiopoietin-like 4 (ANGPTL4 ) and hypoxia-inducible 
lipid droplet-associated (HILPDA) in the regulation of extracellular and intracellular 
lipolysis, respectively. We uncover ANGPTL4 as the main regulator of lipoprotein 
lipase (LPL) activity in the brown adipose tissue (BAT) during sustained cold and es-
tablish a novel mechanism by which ANGPTL4 inhibits LPL activity in adipocytes. 
In contrast, our data do not support a major role for HILPDA in the regulation of 
intracellular lipolysis in adipocytes, in apparent contrast to a study that identif ied a 
role for HILPDA in intracellular lipolysis in the liver (6). 
EXTRACELLULAR LIPOLYSIS 
ANGPTL4 regulates lipid partitioning during sustained cold
Upon cold exposure, the sympathetic nervous system activates BAT to promote the 
combustion of large amounts of fatty acids to generate heat (7). To replenish intra-
cellular lipid stores and to provide fatty acids for combustion, lipid fuel is specif ically 
directed towards BAT and away from other metabolic organs following cold exposure. 
Indeed, cold exposure promotes the release of fatty acids from the white adipose tissue 
(WAT) and enhances the production of very low-density lipoproteins (VLDLs) by the 
liver (8, 9). At the same time, the activity of LPL in BAT is dramatically increased 
upon cold exposure, enabling the uptake of fatty acids derived from triglyceride-rich 
lipoproteins (TRLs) such as VLDLs into BAT (10–14). In Chapter 4, we show that 
the increase in LPL activity and associated TRL-derived fatty acid uptake is pri-
marily mediated by the marked downregulation of the LPL inhibitor ANGPTL4 in 
BAT upon sustained cold. By contrast, the expression of ANGPTL4 in the white 
adipose tissue (WAT) was increased rather than decreased following cold exposure, 
thereby limiting WAT LPL activity and the uptake of TRL-derived fatty acids into 
WAT (Figure 1). Our data thus identify ANGPTL4 as an integral component of the 
physiological response that directs lipid fuel towards BAT during sustained cold, as 
ANGPTL4 promotes the uptake of TRL-derived fatty acids into BAT and prevents 
their uptake into WAT. However, several aspects merit further investigation.
 First of all, the mechanisms that underlie the opposite regulation of ANGPTL4 
in BAT and WAT in response to sustained cold are of great interest. Many of the met-
abolic changes in response to cold exposure are directly orchestrated by the sympa-
thetic nervous system via the activation of adrenergic receptors by noradrenaline (15, 
16). Indeed, repeated injections with the β3-adrenergic agonist CL316,243 potently 
activate BAT and promote TRL-derived fatty acid uptake into BAT (15). Our in vitro 
studies, however, surprisingly indicated that treatment with β-adrenergic agonists in-
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creased the expression of ANGPTL4 in both white and brown adipocytes (Chapter 
4). Instead, we propose that the opposite regulation of ANGPTL4 in BAT and WAT 
upon sustained cold exposure is mediated by the differential activation of AMP-acti-
vated protein kinase (AMPK) in BAT and WAT (Chapter 4). AMPK is a well-con-
served energy sensing kinase that is composed of a catalytic α subunit and regulatory 
β and γ subunits that together form a heterotrimeric complex (17). AMPK is activated 
upon a reduction in cellular energy status and phosphorylates downstream targets 
that inhibit energy-consuming processes and/or stimulate energy-generating path-
ways such as fatty acid oxidation and the uptake of TRL-derived fatty acids from the 
circulation (17–19). Indeed, AMPK activation has been linked to a local increase in 
Figure 1. Schematic model of the role of ANGPTL4 in the shuttling of lipids towards BAT during sustained cold. 
Regulation of  ANGPTL4 in BAT and WAT is an integral part of  the physiological response that re-directs fatty acids from 
circulating TRLs, such as VLDL and chylomicrons, preferentially to the BAT during cold exposure. Down-regulation of  
ANGPTL4 in BAT upon cold exposure facilitates the increase in BAT LPL activity, which results in an increased uptake of  
TRL-derived fatty acids. Down-regulation of  ANGPTL4 in BAT is likely due to specific activation of  AMPK in BAT, but not 
WAT. On the other hand, the up-regulation of  ANGPTL4 in WAT upon cold exposure limits LPL activity in WAT and the 
concomitant uptake of  TRL-derived fatty acids into WAT. The increase in ANGPTL4 expression in WAT is likely mediated 
via activation of  the β-adrenergic signalling pathway
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LPL activity via the repression of ANGPTL4 expression (20, 21) (Chapter 4). Given 
AMPK’s function as an energy sensor, it is perhaps not surprising that we and oth-
ers have found that AMPK is progressively activated in the energy-combusting BAT 
and only to a lesser extent in WAT during sustained cold (18, 22, 23) (Chapter 4). 
The underlying mechanisms for the specif ic activation of AMPK in BAT upon cold 
exposure remain, however, unclear; AMPK in BAT may be either directly activated 
by β-adrenergic signaling or indirectly activated due to a decrease in cellular energy 
status (24). Possibly, the elevated expression of the catalytic AMPKα2 isoform in BAT 
but not WAT may explain part of the tissue-specif ic activation of AMPK in BAT 
upon cold exposure (Chapter 4). In any case, our f indings highlight that the cold-in-
duced activation of AMPK in BAT is indispensable for the effective shuttling of lipid 
fuel towards BAT during cold exposure via the negative regulation of ANGPTL4 in 
BAT. Future studies should further clarify the role of AMPK in the uptake of lipid 
fuel into BAT and investigate the relative contributions of the catalytic AMPKα1 and 
AMPKα2 isoforms (22). Also, the mechanisms by which AMPK represses ANGPTL4 
expression require further study. 
 A second point of importance is the moderate increase in LPL activity levels 
that we observed in BAT of Angptl4-/- mice in response to sustained cold. This ob-
servation implies that besides ANGPTL4 additional mechanisms contribute to the 
cold-induced increase in BAT LPL activity levels. Possibly, changes in BAT LPL ac-
tivity upon cold exposure are regulated by ANGPTL3 and ANGPTL8, two proteins 
that share a common structure with ANGPTL4 and are known to potently inhibit 
LPL activity (25–29). However, literature indicates that the physiological regulation 
of ANGPTL3 is limited, which likely precludes a functional role for ANGPTL3 in the 
cold-induced increase of BAT LPL activity levels in Angptl4-/- mice (27, 30). Similarly, 
the reported induction of ANGPTL8 expression upon cold exposure in BAT is in 
seeming conf lict with the increased activity of LPL in BAT (31). A more reasonable 
explanation is that BAT LPL activity is regulated at the transcriptional level during 
sustained cold, as we observed a signif icant increase in Lpl mRNA levels in BAT in 
all cold-exposed mice (Chapter 4). Indeed, several studies suggest that BAT LPL 
mRNA levels are directly induced by the cold-induced, noradrenaline-mediated ac-
tivation of β3-adrenergic receptors in BAT (32–34). In support, short-term cold expo-
sure signif icantly increases BAT LPL activity levels via an increase in LPL mRNA 
expression and independent of changes in ANGPTL4 expression (Chapter 4) (12, 
13, 34–36). Currently, the relative contributions of transcriptional regulation and 
ANGPTL4-mediated post-translational regulation to the dynamic changes in BAT 
LPL activity during specif ic periods of cold exposure are not clear. To gain further 
insight, ideally, an elaborate cold exposure time-course experiment with wild-type 
and Angptl4 -/- mice should be performed.  
 Besides TRL-derived fatty acids, circulating glucose and fatty acids repre-
sent an important energy source for BAT during cold exposure (7). In fact, we pro-
pose in Chapter 4 that the lower uptake of TRL-derived fatty acids into BAT of 
Angptl4-transgenic mice may be compensated by the increased uptake of free fatty 
acids and glucose. This suggestion implies that glucose and fatty acids should also be 
preferentially shuttled to and/or taken up by BAT during cold exposure, similar to 
TRL-derived fatty acids. However, as opposed to TRLs, glucose and fatty acids can 
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directly cross cellular membranes and their uptake is therefore largely determined 
by the localization and abundance of transporters that shuttle between intracellular 
compartments and the cell membrane (37–39). Yet, there is some data to suggest that 
mechanisms promoting the specif ic uptake of glucose and fatty acids into BAT fol-
lowing cold exposure exist. For example, the expression of the glucose transporters 
GLUT1 and GLUT4 signif icantly increases in BAT upon cold exposure, which to-
gether with the purported cold-induced insulin resistance in peripheral tissues might 
promote the uptake of glucose specif ically into BAT (13, 40). Furthermore, the glucose 
transporter GLUT1 (but not GLUT4) translocates to the brown adipocyte cell surface 
upon β-adrenergic stimulation, although no inhibitory or stimulatory protein akin to 
ANGPTL4 has currently been identif ied to regulate this translocation (38, 41). The 
uptake of the circulating free fatty acids released from WAT and of the TRL-derived 
fatty acids is primarily mediated by the fatty acid transporter cluster of differentiation 
36 (CD36) in BAT (13, 42). Similar to GLUT1 and GLUT4, the expression of CD36 in 
BAT rapidly increases upon cold exposure (13). The impact of cold exposure on CD36 
translocation, as well as on the expression levels of CD36 in other tissues remains, 
however, unclear. Given the crucial role of CD36 in the uptake of (TRL-derived) 
fatty acids, it would be of great interest to identify the regulatory mechanisms driv-
ing the expression of CD36 in endothelial cells and brown adipocytes, as well as the 
mechanisms underlying a possible translocation of CD36 to the cell surface upon cold 
exposure (43). Similarly, the potential changes in the expression and translocation of 
glucose and fatty acid transporters in other metabolically active tissues during cold 
exposure would merit further investigation.  
ANGPTL4 as the master regulator of intravascular lipolysis  
The identif ication of ANGPTL4 as the main regulator of LPL activity in BAT during 
sustained cold further establishes ANGPTL4 as the master regulator of tissue LPL 
activity during different physiological conditions. Indeed, recent studies convincing-
ly demonstrated that the decrease in LPL activity in WAT observed during fasting 
is mediated by the increased expression of ANGPTL4 (originally called fasting-in-
duced adipose factor) in WAT (44–46). Similarly, changes in the expression of mus-
cle ANGPTL4 coordinate LPL-dependent uptake of fatty acids into exercising and 
nonexercising skeletal muscle during acute exercise (21). Together, these data point 
to a scenario wherein local ANGPTL4 coordinates local LPL-mediated hydrolysis of 
plasma TRLs and subsequent fatty acid uptake in response to changes in cellular fuel 
demand and lipid availability (21, 44, 47) (Chapter 4). By safeguarding the proper 
distribution of plasma triglycerides over various tissues during different physiological 
states, ANGPTL4 assures that tissues take up adequate amounts of fatty acids for rap-
id oxidation or storage, while preventing excess lipid uptake and cellular lipotoxicity. 
Several key questions regarding the physiology of ANGPTL4 remain, however, to be 
answered. 
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A local versus circulatory function for ANGPTL4 
An intriguing question is how the local, tissue-specif ic regulation of LPL activity by 
ANGPTL4 can be reconciled with the non-specif ic regulation of endothelial LPL 
activity by circulating ANGPTL4. Indeed, on the one hand, multiple in vitro exper-
iments that investigated the effects of secreted ANGPTL4, recombinant ANGPTL4 
and anti-ANGPTL4 antibodies on extracellular LPL activity suggest that freshly se-
creted ANGPTL4 may act on LPL within the subendothelial spaces (48–50). More-
over, we propose in Chapter 5 that ANGPTL4 inhibits LPL intracellularly in the 
adipose tissue. On the other hand, ANGPTL4 is abundantly present in the circulation 
where it can potently inhibit endothelial-bound LPL, as illustrated by the impact of 
either anti-ANGPTL4 antibodies or recombinant ANGPTL4 on plasma triglycerides 
and plasma LPL activity levels in experimental animals (26, 51–53). Most conceiva-
bly, the endocrine and local functions of ANGPTL4 are complementary and together 
assure that LPL activity is effectively regulated in a variety of tissues that differ in 
their overall physiology and energy requirements. Such complementary mechanisms 
are not uncommon in lipid metabolism, as illustrated by the hepatic protein pro-
protein convertase subtilisin/kexin 9 (PCSK9). PCSK9 promotes the degradation of 
the low-density lipoprotein receptor (LDLR) in the liver by acting upon the LDLR 
within the hepatocyte and on the cell surface, but also promotes the degradation of 
the related VLDL receptor in distal tissues upon secretion into the circulation (54). 
For ANGPTL4, its function (local or endocrine) may be determined by the relative 
expression levels of ANGPTL4 and LPL in a particular tissue (Figure 2). The low 
expression of LPL in the liver makes it conceivable that liver-expressed ANGPTL4 is 
primarily secreted into the circulation to act upon LPL that is either captured on the 
liver endothelium or bound to the endothelium in distal tissues (46, 55, 56). It should 
be noted, however, that a recent paper suggested that liver-expressed LPL might sig-
nif icantly impact triglyceride metabolism (57) (Chapter 4). By contrast, in the adi-
pose tissue the expression levels of  LPL and ANGPTL4 are high and ample data from 
our lab as well as others indicate that the physiological regulation of adipose tissue 
ANGPTL4 controls adipose tissue LPL activity during cold exposure and fasting 
(44, 58) (Chapter 4, Chapter 5). To what extent ANGPTL4 is secreted from the 
adipose tissue is, however, not clear. In the heart, the expression of ANGPTL4 is low 
compared to the expression of LPL (Chapter 4). Given that the energy requirements 
of the heart are primarily met by the oxidation of (TRL-derived) fatty acids, the 
physiological changes in the activity of heart LPL are tightly regulated by the binding 
aff inity of LPL to the heart endothelium as well as a transcription-regulated factor 
(58–61). This transcription-regulated factor is, however, unlikely to be ANGPTL4, as 
during fasting the increase in cardiac LPL activity is accompagnied by an increase 
in cardiac ANGPTL4 expression (46, 58–61). By contrast, ANGPTL4 is capable of 
regulating LPL activity in the heart, as highlighted by the reduced LPL activity in the 
heart of mice with cardiac-specif ic over-expression of Angptl4 (62). Similarly, follow-
ing a post-prandial lipid challenge, cardiac ANGPTL4 expression was signif icantly 
increased and protected the heart from fatty acid-induced oxidative stress (47). Col-
lectively, these data suggest that depending on the tissue, a) ANGPTL4 is secreted 
into the circulation, where it inhibits endothelial LPL (liver), b) ANGPTL4 regulates 
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the physiological changes in LPL activity (BAT, WAT), c) a signif icant induction of 
ANGPTL4 expression prevents lipotoxicity during specif ic conditions (heart, muscle, 
macrophages) (see Figure 2 for further details). The overall picture is, however, far 
from complete and many aspects warrant further study. For example, it is currently 
unclear what the exact physiological function of circulating ANGPTL4 is and what 
tissues contribute to circulating ANGPTL4. Also, the extent to which ANGPTL4’s 
function depends on inherent differences in tissue LPL biology remains to be deter-
mined. Turnover of LPL protein in the heart is, for example, slower than in adipo-
cytes and LPL mRNA species differ between heart and adipocytes (63, 64). Similarly, 
a study that compared LPL secretion from muscle and adipose tissue indicated that 
muscle mostly released active LPL into plasma, while adipose tissue mainly released 
inactive LPL (65). Future studies would greatly benef it from more in-depth knowl-
edge on tissue-specif ic differences in LPL biology, as well as the generation of cell 
type-specif ic Angptl4 knockout mice. Cell type-specif ic Angptl4 knockout mice could 
Figure 2. Model of the local versus circulatory role of ANGPTL4. 
Dependent on the relative expression levels of  ANGPTL4 and LPL in the different tissues, the function of  ANGPTL4 may 
differ. In liver, which has a comparatively low expression of  LPL, it conceivable that liver-expressed ANGPTL4 is primarily 
secreted into the circulation to act upon LPL that is either captured on the liver endothelium or bound to the endothelium in 
distal tissues (46, 55, 56). By contrast, in the adipose tissue (brown and white) the expression levels of   LPL and ANGPTL4 
are comparatively high, and multiple lines of  evidence suggest that ANGPTL4 regulates the physiological changes in LPL 
activity in BAT and WAT following cold exposure or fasting, respectively. In heart, but also muscle and macrophages, the 
expression of  ANGPTL4 is low compared to the expression of  LPL. In these tissues, it is unlikely that ANGPTL4 is respon-
sible for the physiological regulation of  LPL. However, the expression of  ANGPTL4 may be rapidly induced in these tissues 
upon fatty acid overload or another physiological stressor to prevent, for example, lipotoxicity (47, 203).
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also resolve other burning questions related to ANGPTL4 physiology, including what 
cells are responsible for the severe ascites observed in full-body Angptl4 knockout mice 
fed a saturated fat diet (66). 
The respective functions of ANGPTL3, ANGPTL4 and ANGPTL8
Another important question is how the physiological function of ANGPTL4 relates 
to the functions of its family members ANGPTL3 and ANGPTL8. ANGPTL3, 
ANGPTL4 and ANGPTL8 share a common architecture and inf luence plasma tri-
glyceride levels by impacting LPL activity, yet their tissue distribution, regulation and 
mode of action differ substantially (25–27). ANGPTL3 is mainly expressed in liver 
and is abundantly secreted into the circulation, whereas ANGPTL4 and ANGPTL8 
are more ubiquitously expressed (25, 27, 46) (Chapter 4). Similarly, while physio-
logical regulation of ANGPTL3 is limited, the expression levels of ANGPTL4 and 
ANGPTL8 are potently, although oppositely, regulated during physiological condi-
tions such as fasting/refeeding and cold exposure (30, 31, 67) (Chapter 4). These 
data suggest that ANGPTL3, ANGPTL4 and ANGPTL8 regulate LPL activity dur-
ing different physiological situations and/or in different tissues. Indeed, the impact of 
ANGPTL3 and ANGPTL8 ( feeding-induced ) on plasma triglyceride levels is most pro-
nounced upon refeeding, while the impact of ANGPTL4 ( fasting-induced ) on plasma 
triglyceride levels is more pronounced during fasting (30, 52, 67). Given the limited 
physiological regulation of ANGPTL3, it has been proposed that ANGPTL3 collab-
orates with ANGPTL8 during refeeding to inhibit LPL activity and TRL-derived 
fatty acid uptake specif ically in oxidative tissues and to promote the replenishment of 
WAT (25, 30, 67, 68) (Chapter 2). Such a role for ANGPTL3 and ANGPTL8 would 
f it with the model wherein ANGPTL4 is responsible for the physiological regulation 
of LPL activity in the adipose tissue depots, but not in oxidative tissues (Figure 2). 
Intriguingly, it had already been suggested in 1983 that the physiological regulation 
of adipose tissue and heart LPL activity is under independent genetic control (69). 
Together, these data suggest that ANGPTL4 and ANGPTL3/ANGPTL8 have com-
plementary functions that ensure the adequate distrubtion of circulating triglycerides 
during different physiological conditions. However, the circulating nature ANGPTL3 
and ANGPTL8 questions how these proteins are able to specif ically inhibit LPL in 
oxidative tissues during refeeding. Similarly, the model is challenged by the obser-
vation that the expression of ANGPTL8 and the activity of LPL in oxidative tissues 
simultaneously increase upon cold exposure (9, 70, 71) (unpublished observations). 
Evidently, further studies are needed to clarify the respective functions ANGPTL3, 
ANGPTL4 and ANGPTL8 in the regulation of LPL activity. Such investigations 
would be helped by the generation of mice knockout for multiple ANGPTL proteins 
and/or tissue-specif ic knockout mice. 
Mechanism of ANGPTL4-mediated inhibition of LPL 
In line with a more local regulatory role for ANGPTL4 in the adipose tissue, we pro-
pose in Chapter 5 that ANGPTL4 inhibits the activity of LPL intracellularly in ad-
ipocytes. Intracellular regulation of LPL by ANGPTL4 complements the established 
regulation of LPL by ANGPTL4 on the endothelium and in the subendothelial spaces 
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and may account for a substantial part of the physiological regulation of LPL activ-
ity upon fasting and cold exposure in WAT and BAT (44, 51, 52, 72) (Chapter 5). 
ANGPTL4 inhibits LPL activity intracellularly by promoting the degradation of LPL, 
possibly via the lysosomes (Chapter 5). Indeed, lysosomal degradation may account 
for the rapid degradation of up to 80% of the newly synthesized LPL in adipocytes 
(73, 74). The degradation of LPL is most likely initiated in the trans-Golgi or beyond, 
as ANGPTL4 solely impacts mature-glycosylated LPL (Chapter 5). From the (trans-)
Golgi, inactivated LPL may be send towards the endosomes to eventually end up in 
the lysosomes, possibly as part of the so-called Golgi protein quality control system. 
This quality control system is initiated upon protein aggregation, oligomerization 
and maturation, depends on nutrient availability and surveys secreted proteins, such 
as LPL, whose mature conformation is acquired following post-translational modif i-
cations or assembly in the Golgi (75, 76). Indeed, a mutant form of human LPL that 
failed to be secreted was eff iciently targeted directly from the Golgi to the lysosomes 
(77). Moreover, the endosomal sorting receptor Sortilin has been demonstrated to 
target LPL for degradation (78). Alternative pathways by which LPL may be targeted 
to the lysosomes include the endocytosis of cell surface-bound LPL or (chaperone-me-
diated) autophagy of inactivated LPL (73, 79–81). Lastly, we cannot formally exclude 
the involvement of proteasomal degradation, although we and others did not observe 
any impact of proteasomal inhibitors on LPL degradation (unpublished observations) 
(82). Future studies into the fate of the LPL molecules targeted by ANGPTL4 could 
employ advanced microscopy techniques, such as f luorescence resonance energy 
transfer (FRET), f luorescence time-lapse imaging and cellular co-localization of LPL 
with markers of the Golgi (GM130), early endosomes (RAB5), late endosomes (RAB7) 
and/or autophagosomes (LC3) (83). Alternatively, one could knock down key compo-
nents of the different degradatory pathways in adipocytes, alone or in combination 
with ANGPTL4 (e.g. ATG5 and ATG7 (autophag y), RAB5 and RAB7 (endosomes), or the 
sorting receptors SORLA and Sortilin) (78, 79, 81). Another question that should be 
addressed is whether the intracellular degradation of LPL by ANGPTL4 is limited 
to the adipose tissue or occurs also in other tissues. Possibly, a high expression level 
of ANGPTL4, such as in the adipose tissue, is required for intracellular degradation 
of LPL to occur, a level that may only be reached in other tissues upon a signif icant 
increase in ANGPTL4 expression (Figure 2). In support, we did not observe intra-
cellular regulation of LPL in the hearts of fed and fasted wild-type and Angptl4 -/- mice 
(Chapter 5).
 Most likely, the ANGPTL4-mediated intracellular degradation of LPL is 
secondary to the main action of ANGPTL4. It is surprising to note that, although 
ANGPTL4 has been known to inhibit LPL for nearly 15 years, the exact biochemical 
mechanism by which ANGPTL4 acts upon LPL remains hotly debated (26). A relative-
ly short amino acid sequence close to the amino-terminal of ANGPTL4 inhibits LPL 
and, as a consequence, only amino-terminal ANGPTL4 and full-length ANGPTL4 
impact LPL activity (28, 84–87). In contrast, carboxyl-terminal ANGPTL4 does 
not appear to impact lipid metabolism (88). In 2006, Sukonina and colleagues pro-
posed the now widely accepted dimer-dissociation model in which amino-terminal 
ANGPTL4 converts the catalytically active, dimeric form of LPL to catalytically in-
active monomers in an irreversible manner (89). This model was recently challenged 
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by the observation that LPL could regain activity upon detachment of ANGPTL4, 
suggesting that ANGPTL4 is a reversible, non-competitive inhibitor of LPL (90). 
These purported mechanisms are, however, based on data from biochemical in vitro 
techniques and the exact mechanisms by which ANGPTL4 destabilizes/inhibits LPL 
in vivo remain to be elucidated. One possible consequence of the destabilization of 
LPL by ANGPTL4 in vivo may be that LPL’s binding aff inity towards LPL-stabilizing 
proteins becomes altered. It is well-established that LPL rapidly loses its catalytic 
activity unless stabilized by lipase maturation factor 1 (LMF1) in the endoplasmic 
reticulum (ER), by heparan sulphate proteoglycans (HSPGs) on the cell surface, and 
by glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 
(GPIHBP1) on the endothelium (91, 92). Indeed, ANGPTL4 has been proposed to 
lower the aff inity of LPL to GPIHBP1 (93). Of note, no (chaperoning) protein has 
so far been identif ied for stabilization of LPL during its intracellular transport to-
wards the cell surface. Another potential consequence of the destabilization of LPL by 
ANGPTL4 in vivo is proposed in Chapter 6, where ANGPTL4 is shown to promote 
the cleavage of LPL by members of the PCSK family, serine endopeptidases that ei-
ther activate or inactivate proteins (94, 95). Most conceivably, destabilization of LPL 
by ANGPTL4 renders LPL more susceptible for PCSK-mediated cleavage, which 
likely ensues the inactivation and subsequent degradation of LPL, as was previously 
observed for the related endothelial lipase (96, 97). In support, mutations in the hu-
man LPL gene that are characterized by enhanced PCSK-mediated cleavage of LPL 
result in severe chylomicronaemia (98). However, to better understand the impact of 
ANGPTL4 on either LPL’s interaction with stabilizing proteins or on PCSK-mediat-
ed cleavage of LPL, the exact biochemical mechanism by which ANGPTL4 acts on 
LPL f irst needs to be clarif ied. Possibly, techniques similar to those used to study the 
impact of GPIHBP1 on LPL stability may be employed (99).  
 An intriguing analogy between the multi-level regulation of LPL by 
ANGPTL4 and the mechanisms of regulation of other key proteins in lipid metabo-
lism can be made. To regulate plasma cholesterol levels, the amount of LDLR on the 
hepatocyte surface is tightly controlled by the protein PCSK9. PCSK9 prevents the 
recycling of internalized LDLR from the endosomes to the cell surface by binding 
to cell surface LDLR, thereby targeting LDLR for lysosomal degradation. However, 
PCSK9 acts also on the LDLR in the trans-Golgi from where the LDLR can be di-
rectly targeted for degradation in the lysosomes (100–102). Similarly, apolipoprotein 
B (APOB), the major non-exchangeable apolipoprotein on VLDL, is subjected to ex-
tensive post-translational regulation that includes a late-stage degradatory process in 
a post-ER compartment (103–105). Conceivably, the induction of intracellular degra-
dation via a post-ER, post-translational mechanism is a common mechanism by which 
levels of proteins crucial for lipid metabolism are controlled. 
Clinical perspectives of ANGPTL4
Risk for cardiovascular disease, the current leading cause of death worldwide, is de-
termined by a plethora of factors, including plasma lipoprotein levels (106). The view 
on the role of TRLs in the development of cardiovascular disease has f luctuated over 
the past decades, but recent epidemiological and genetic studies unequivocally indi-
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cate that elevated plasma TRLs strongly predict the risk for cardiovascular disease 
and all-cause mortality (106–109). In order to promote cardiovascular disease, TRLs 
must enter the arterial intima, the location of atherosclerotic plaque development. 
Inf lux of lipoproteins into the arterial wall is largely determined by lipoprotein size 
and, as a result, large TRL particles such as chylomicrons are incapable of entering 
the intima (explaining why LPL-def icient individuals with severe chylomicronaemia 
are largely protected against cardiovascular disease) (110–112). In contrast, medi-
um-sized TRLs that are generated upon LPL-mediated hydrolysis (e.g. chylomicron 
remnants) are capable of entering the arterial wall, albeit at lower speed than smaller 
lipoproteins such as low-density lipoproteins (LDLs) (110). Upon entrance and possi-
ble trapping of TRLs in the arterial wall, LPL at the endothelial surface or within 
the arterial wall may hydrolyse the incorporated triglycerides to yield fatty acids that 
can promote local and possibly systemic inf lammation (107, 113). Alternatively, TRL 
particles may be directly taken up by macrophages in the arterial wall via the VLDL 
receptor in concert with LPL, resulting in foam cell formation ̶ a hallmark of the de-
velopment of atherosclerosis (114–116). Given the postulated roles of LPL in TRL-me-
diated atherosclerotic plaque development, it is perhaps not suprising that mendelian 
randomization studies revealed that deleterious or loss-of-function variants in either 
the LPL gene itself or in genes that encode regulators of LPL, such as APOA5, APOC3, 
ANGPTL3 and ANGPTL4, impact risk for cardiovascular disease (106, 117–120). More 
specif ically, these genetic data suggest that a reduced clearance rate of TRLs pro-
motes the risk for cardiovascular disease (e.g. due to deleterious variants in APOA5 
and LPL), whereas the increased clearance of TRLs protects against cardiovascular 
disease (e.g. due to inactivating variants in ANGPTL3, ANGPTL4 and APOC3) (106, 
117–120). 
 The re-appreciation of TRLs as contributors to cardiovascular disease risk 
has renewed the interest of pharmaceutical companies in regulators of LPL, such as 
ANGPTL4, as potential therapeutic targets to reduce cardiovascular disease risk. 
Currently, ample data support a role for ANGPTL4 in the inhibition of LPL ac-
tivity in humans: 1) the E40K inactivating variant of ANGPTL4 lowers circulating 
triglyceride levels (68, 118, 121–124), 2) in vitro human ANGPTL4 inhibits human 
LPL activity (50, 86, 125), 3) treatment of mice and non-primate monkeys with an 
antibody against human ANGPTL4 potently lowers plasma triglyceride levels (53). In 
contrast, no positive association has been found between plasma ANGPTL4 and plas-
ma triglycerides in human subjects, possibly because the employed ELISAs detect car-
boxyl-terminal ANGPTL4 and not the LPL-inhibiting amino-terminal domain (50, 
126–128). More detailed physiological studies on the role of ANGPTL4 in humans 
are, however, scarce. Indeed, it is unclear whether the high expression of ANGPTL4 
in the liver of humans as compared to mouse liver signif ies a more prominent circu-
latory function for human ANGPTL4 (46, 55). Similarly, no studies have investigated 
the association of the expression of ANGPTL4 in human adipose tissue and adipose 
tissue LPL activity upon fasting and refeeding (44, 129). From a clinical perspective, 
however, the most important question to resolve is whether the loss or inhibition of 
ANGPTL4 in humans will result in the lymphadenopathy and severe ascites that was 
observed in Angptl4 -/- mice fed a diet high in saturated fat (51, 53, 66). So far, there are 
no indications that human carriers of the inactivating E40K variant in the ANGPTL4 
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gene present with increased rates of ascites, peritonitis or abdominal discomfort com-
pared to the general population, but more in-depth investigations of these subjects are 
required (53). Further studies on the physiological role of ANGPTL4 in humans will 
need to indicate whether ANGPTL4 might indeed be a safe therapeutic target to low-
er plasma triglycerides and the risk for cardiovascular disease. If so, ANGPTL4 may 
be the second member of the ANGPTL family that is targeted to lower cardiovascular 
disease risk, with an anti-sense oligonucleotide and a monoclonal antibody against 
ANGPTL3 currently being in Phase 2 clinical trials (130, 131). 
Gastro-intestinal lipolysis and the function of intestinal ANGPTL4 
The expression of ANGPTL4 in the human intestine is relatively high (55). However, 
despite the observation that enterocytes take up circulating lipids at their basolateral 
membrane, there are currently no indications that LPL is involved in intravascular 
lipolysis in the intestine, suggesting that the primary function of intestinal ANGPTL4 
is likely not the local inhibition of LPL (132). It has been hypothesized that intestinal 
ANGPTL4 serves an endocrine function by inhibiting LPL in distal tissues, but so far 
a direct link remains to be established (133, 134). A clue about the function of intesti-
nal ANGPTL4 came from a recent paper that identif ied ANGPTL4 as a potent inhib-
itor of pancreatic lipase and, thus, implicated ANGPTL4 in gastro-intestinal lipolysis 
(135). In Chapter 7, we extend these observations and demonstrate that ANGPTL4 
impacts intestinal bile acid uptake and gut microbial composition. More specif ically, 
deletion of Angptl4 in mice signif icantly attentuated the increase in plasma bile acid 
levels induced by dietary taurocholic acid supplementation, as compared to wild-type 
mice, via a reduction in bile acid uptake in the ileum (Chapter 7). At the same time, 
gut microbial composition was signif icantly different between wild-type and Angptl4 -/- 
mice (Chapter 7). 
 An intricate crosstalk exists between bile acids and the gut microbial compo-
sition. Bile acids impact the composition of the gut microbiota, while the gut micro-
biota deconjugate bile acids and convert primary bile acids to secondary bile acids by 
7α-dehydroxylation (136–139). As a result, it is challenging to identify the origin of the 
differences in gut microbial composition and bile acid uptake between the wild-type 
and the Angptl4-/- mice. Given the established impact of ANGPTL4 on gastro-intesti-
nal lipolysis, it may be hypothesized that the impact of Angptl4 genotype on bile acid 
uptake and gut microbial composition originates from an altered intestinal dietary 
fat metabolism. Indeed, multiple studies indicate that elevated levels of lipids in the 
ileum and colon signif icantly impact the gut microbial composition (140, 141). Fur-
thermore, the treatment of human subjects with the lipase inhibitor orlistat altered 
gut microbial composition and signif icantly reduced the secretion of  bile acids in the 
faeces (142, 143). One may speculate that the origin of differences in gut microbial 
composition between wild-type and Angptl4-/- mice may commence during the suck-
ling period when pups receive a high amount of lipid-containing milk. Future studies 
should further establish the inf luence of intestinal ANGPTL4 on the bile acids – gut 
microbes – dietary fat crosstalk by, for example, modulating the gut microbiota of 
wild-type and Angptl4-/- mice with antibiotics.   
 An intriguing question relates to the origin of intestinal ANGPTL4. Recent-
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ly, we demonstrated that carboxyl-terminal ANGPTL4 is specif ically present in the 
entero-endocrine cells of the human intestinal tract, suggesting secretion of carbox-
yl-terminal ANGPTL4 into the bloodstream (144). In analogy with LPL, however, it 
is most reasonable to expect that the amino-terminal portion of ANGPTL4 inhibits 
pancreatic lipase activity (87). However, what cells in the intestinal tract produce and 
secrete amino-terminal ANGPTL4 into the intestinal lumen remains unclear and 
should be studied once an antibody that detects amino-terminal ANGPTL4 becomes 
available. Most likely, amino-terminal ANGPTL4 is secreted by the enterocytes to 
function as a negative feedback signal to regulate the uptake of dietary fat into entero-
cytes. Indeed, ANGPTL4 is potently regulated by the fatty acid-sensing PPARα and 
PPARγ in the small intestine and colon, respectively (145, 146). Furthermore, both the 
localization and regulation of intestinal ANGPTL4 following a meal should be ad-
dressed in future studies, possibly by employing enterocyte-specif ic Angptl4 knockout 
mice.
INTRACELLULAR LIPOLYSIS  
Recently, HILPDA was identif ied as a novel PPAR-regulated gene that promotes he-
patic lipid accumulation by lowering triglyceride hydrolysis and triglyceride turnover 
in hepatocytes (6, 147). In Chapter 8, we show that HILPDA is abundantly ex-
pressed in the adipose tissue and is associated with lipid droplets. However, in contrast 
to the reported inhibitory effect of HILPDA on triglyceride hydrolysis in the liver, we 
did not f ind a major impact of adipocyte-specif ic deletion of Hilpda on adipose tissue 
lipolysis following fasting, cold exposure or pharmacological β-adrenergic activation 
in mice (Chapter 8). Nonetheless, we did observe potent regulation of HILPDA by 
β-adrenergic signaling and PPARγ in adipocytes, hinting at an important yet not fully 
understood role of HILPDA in adipocyte biology. 
 Given HILPDA’s small size (~8 kDa) and expression in both liver and adipose 
tissue, it may be hypothesized that HILPDA collaborates with or regulates a protein 
common to hepatocyte and adipocyte lipid droplet metabolism (148, 149). PLIN2 is 
a PPAR-regulated lipid droplet-associated protein that has a similar tissue expres-
sion prof ile as HILPDA (147, 150, 151). Important work by Gimm et al. suggests that 
HILPDA colocalizes with PLIN2 at the surface of some, but not all lipid droplets 
(152). Similar to HILPDA, liver-specif ic knockdown of PLIN2 signif icantly reduced 
hepatic lipid accumulation, whereas PLIN2 overexpression resulted in the develop-
ment of a fatty liver (6, 150, 153, 154). Furthermore, again similar to HILPDA, knock-
out of PLIN2 did not alter adipose tissue lipolysis or adipocyte differentiation, an 
observation that may be linked to the observation that PLIN2 primarily localizes to 
the surface of smaller, possibly less mature lipid droplets (155, 156). Indeed, replace-
ment of PLIN1 by PLIN2 on the lipid droplets of Plin1-null adipocytes signif icantly 
reduced adipocyte lipolysis via the exclusion of adipose triglyceride lipase (ATGL/
PNPLA2) from the lipid droplet (153, 157–159). 
 Another protein that HILPDA might collaborate with or regulate is CIDEC, 
also an established PPAR target gene (148, 149). Adenoviral-mediated silencing of 
CIDEC prevented the development of fasting-induced steatosis in liver, while silenc-
ing in human adipocytes signif icantly increased both basal and stimulated lipolysis 
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(148, 160). CIDEC thus promotes lipid accumulation in the adipose tissue and liver, 
conceivably by facilitating lipid transfer and the formation of unilocular lipid droplets 
and/or by acting as a barrier for ATGL (160–163). In support of a possible connection 
between HILPDA and CIDEC, loss of either HILPDA or CIDEC in hepatocytes 
resulted in more, yet smaller lipid droplets (6, 161). Hypothetically, HILPDA may 
participate in or regulate the lipid droplet fusion complex that comprises Rab8A – 
AS160 – CIDEC (164). 
 A common denominator between the PPAR-targets PLIN2 and CIDEC is 
that they promote lipid accumulation by preventing access of ATGL (PNPLA2) to the 
lipid droplets. Although HILPDA does not directly impact ATGL activity, it may be 
hypothesized that HILPDA prevents access of ATGL to the lipid droplet, resulting 
in the mild reduction in adipocyte lipolysis that we observed upon HILPDA overex-
pression (147) (Chapter 8). Alternatively, HILPDA might regulate or prevent access 
of the ATGL-related lipase patatin-like phospholipase domain-containing protein 3 
(PNPLA3) to the lipid droplet, a protein that is upregulated following intracellular 
lipid accumulation and that affects lipid droplet morphology (165). Indeed, HILP-
DA’s protein structure is remarkably similar to G0S2, a small ~11 kDa protein that 
is known to inhibit ATGL activity and to inf luence ATGL localization (6, 166, 167) 
(unpublished observations). Whether HILPDA cooperates with and/or physically inter-
acts with PLIN2, CIDEC, ATGL or PNPLA3 requires further investigation, possibly 
by employing state-of-the-art techniques such as FRET-FLIM. Alternatively, it may 
be that HILPDA simply competes for lipid droplet access with other lipid droplet pro-
teins, such as ATGL, via protein crowding (168). Protein crowding is a major determi-
nant of lipid droplet protein composition and describes the phenomenon that proteins 
are gradually expelled from the shrinking surfaces of lipid droplets during lipolysis 
dependent on their binding strength to the lipid droplet surface (168). 
 An important step to further elucidate the functional signif icance of HILP-
DA is to clarify HILPDA’s intracellular localization and mobility. HILPDA has been 
shown to localize to the lipid droplet surface numerous times (6, 152) (Chapter 8). 
However, as opposed to other lipid droplet-associated proteins, HILPDA is not solely 
localized to the lipid droplet surface and has so far not been detected in proteomic 
screens of lipid droplet-associated proteins (169–171) (unpublished observations). At this 
moment, no information is available about the mobility of HILPDA upon, for exam-
ple, β-adrenergic stimulation and the localization of HILPDA to other organelles. In 
our microscopy studies, we frequently observe intense staining of HILPDA in what 
we believe to be the ER, an observation that is perhaps not surprising given that lipid 
droplets originate from and interact with the ER (172, 173). In fact, several lipid drop-
let proteins accumulate in the ER upon the induction of lipid droplet formation before 
migrating onto lipid droplets (173). Alternatively, ER-localized HILPDA might regu-
late ER proteins involved in either the formation of triglycerides (e.g. glycerol-3-phos-
phate acyltransferases (GPATs), Lipin, or acyl-coA:diacylglycerol acyltransferases 
(DGAT)) or the formation of lipid droplets (e.g. Seipin, fat storage–inducing trans-
membrane protein (FITM/FIT) or members of the PLIN family) (174–177). Future 
microscopy and cellular fractionation studies should conf irm whether (endogenous) 
HILPDA indeed localizes to the ER and whether HILPDA is involved in the ER-lipid 
droplet interface. 
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 Despite the minor phenotype observed in mice with an adipocyte-specif ic 
deletion of Hilpda, we cannot exclude a functionally signif icant role for HILPDA in 
adipocytes. Possibly, we did not employ the appropriate stimulus or perhaps over-
expression may more effectively reveal HILPDA’s function in adipocytes (Chapter 
8). Alternatively, it may be that HILPDA’s function is more important in other lipid 
droplet-containing cells such as hepatocytes, myocytes, adrenocortical cells, entero-
cytes and macrophages (178). Indeed, although the underlying mechanisms in lipid 
droplet formation and triglyceride mobilization are similar, the levels of regulatory 
proteins that cover the surface of lipid droplets vary between cell types (159, 179, 180). 
It would thus be of great interest to assess the function of HILPDA and HILPDA’s 
impact on intracellular lipid accumulation in these different cell types. For example, 
we initially identif ied HILPDA as a gene that is highly induced upon lipid loading of 
macrophages, which is observed in obese adipose tissue and in atherosclerotic plagues 
in vivo (unpublished observations) (181, 182). To investigate the role of HILPDA in mac-
rophages, mice with a macrophage-specif ic deletion of Hilpda might be fed a high-fat 
diet to assess adipose tissue inf lammation or crossed with APOE3-Leiden mice to 
assess atherosclerotic plaque development. Another area of exploration is the function 
of HILPDA in humans. We know that the HILPDA gene is highly conserved and that 
human HILPDA is potently regulated by PPARs (147) (Chapter 8). Besides that, 
HILPDA expression has been associated with the activation of hypoxia-inducible fac-
tor 1-α and the progression of different types of cancers in humans (152, 183–185). To 
examine a potential function for HILPDA in human lipid metabolism, it would be of 
interest to assess the assocation of HILPDA expression in adipose tissue with plasma 
free fatty acid and glycerol levels, as well as other relevant metabolic parameters such 
as insulin resistance and plasma cholesterol and triglyceride levels. 
PPAR-MEDIATED REGULATION OF LIPOLYSIS 
A common denominator in the regulation of ANGPTL4 and HILPDA is their potent 
regulation by the PPAR transcription factors (46, 147, 186) (Chapter 4, Chapter 
8). Indeed, the expression of ANGPTL4 in WAT, BAT, heart, liver, intestine, muscle 
and macrophages is potently regulated by different isoforms of the PPAR family (see 
Chapter 3 for an overview). Similarly, HILPDA is strongly regulated by PPARα in 
the liver and PPARγ in the adipose tissue (147) (Chapter 8). PPARα, PPARδ and 
PPARγ are key regulators of lipid partitioning and lipid utilization and their activa-
tion by fatty acids and fatty acid derivatives directly links changes in lipid metabolism 
to changes in gene expression (187, 188). Although their differential tissue distribu-
tions and ligand specif icities make that PPARα, PPARδ and PPARγ have distinct 
physiological roles, the three transcription factors all regulate genes that participate 
in metabolic processes that involve the handling of fatty acids (189). For example, 
PPARs control the effective storage of incoming fatty acids by regulating the expres-
sion of genes involved in triglyceride synthesis and lipid droplet formation, but also 
promote the expression of genes involved in fatty acid oxidation and fatty acid uptake 
(148, 190–192) (Chapter 8). Perhaps not suprising given their pivotal role in fatty 
acid metabolism (and as highlighted by this thesis), PPARs also tightly control the 
rates of intracellular and extracellular lipolysis, via both positive and negative feed-
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back loops. Indeed, PPARs potently regulate the transcription of genes that promote 
lipolysis, such as LPL and ATGL, of which the resultant fatty acids positively feed 
back to activate PPARs (193–195). At the same time, PPAR activation also promotes 
the expression of genes that inhibit lipolysis and that promote lipid storage, such as 
ANGPTL4, G0S2 and possibly HILPDA (46, 147, 186) (Chapter 4, Chapter 8). 
Also, treatment of mice and humans with the PPARα agonist fenof ibrate potently low-
ers plasma triglyceride levels by promoting the clearance of TRLs by LPL, but at the 
same time paradoxically increases levels of ANGPTL4 (55, 196–198). Currently, the 
rationale for the simultaneous, opposite regulation of lipolysis by PPARs is unclear, 
but one may speculate that this type of regulation attenuates or tempers the effective 
uptake and/or the release of fatty acids following PPAR activation to prevent cellular 
lipotoxicity and/or lipid depletion. An intriguing question is how PPARs balance the 
expression levels of genes that positively and negatively regulate lipolysis. Unfortu-
nately, the complexity of PPAR-mediated gene regulation renders it diff icult, if not 
impossible to provide a unif ied answer, with gene regulation being context depend-
ent and determined by factors such as ligand availability, the abundance of specif ic 
isoforms, the sensitivity of target genes to specif ic PPAR isoforms and the degree of 
PPAR activation (199). In fact, even the source of the fatty acid ligands might play 
part, as it has been proposed that, during fasting, liver PPARα is mainly activated by 
lipoprotein-derived fatty acids, whereas circulating free fatty acids primarily activate 
liver PPARδ (200). Another layer of complexity is added by the co-activators and 
co-repressors of PPARs, such as CBP/P300 and proteins of the p160 family, that may 
f inetune the expression of genes involved in the positive and negative feedback loops 
during specif ic physiological conditions (201). Indeed, we show in Chapter 4 that 
the inactivation of P300 upon sustained cold exposure is involved in the reduction in 
ANGPTL4 expression in BAT. Similarly, the PPARγ co-activators SRC-1 and TIF2 
have been reported to impact intracellular lipolysis (202). Overall, it is evident that 
many details of the PPAR-mediated regulation of lipolysis require further investiga-
tion. Especially, studies into the activity of co-regulators might provide better insight 
into how PPARs delicately balance the different fatty acid-driven processes, including 
intracellular and intravascular lipolysis, within a cell. Alternatively, the identif ication 
of novel PPAR-target genes may uncover regulators of extracellular or intracellular 
lipolysis.
CONCLUSION 
In this thesis, we investigated the molecular mechanisms that underlie extracellular 
and intracellular lipolysis. In Figure 3, an overview of our f indings related to intra-
vascular and intracellular lipolysis in adipocytes is provided. We demonstrate that 
the regulation of ANGPTL4 expression is an integral component of the shuttling of 
lipid fuel towards BAT during sustained cold exposure (Figure 1). Furthermore, our 
studies show that ANGPTL4 regulates intravascular lipolysis in the adipose tissue via 
a mechanism that comprises the intracellular degradation of LPL (Figure 3). We also 
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Figure 3: The roles of HILPDA and ANGPTL4 in intracellular and extracellular lipolysis in the adipose tissue. 
On the left side, the potential roles of  HILPDA in adipocytes are highlighted. HILPDA is potently regulated by PPARγ and 
β-adrenergic signaling in adipose tissue. Following translation, HILPDA is found in the ER and on lipid droplets. Overex-
pression of  HILPDA lowers the release of  fatty acids from adipocytes. upon induction of  intracellular lipolysis. However, 
adipocyte-specific deletion of  Hilpda did not reveal a major impact of  plasma non-esterified fatty acid levels, which questions 
whether HILPDA is a physiological regulator of  intracellular lipolysis in the adipose tissue. A possible interacting partner of  
HILPDA is PLIN2, but also a role for HILPDA in lipid droplet formation or morphology cannot be excluded. On the right 
side, the role of  ANGPTL4 in extracellular lipolysis is depicted. Similar to HILPDA, ANGPTL4 is regulated by PPARs. 
Upon translation, ANGPTL4 inhibits LPL at multiple levels: in the trans-Golgi, on the cell surface, and at the endothelium. 
Although the exact mechanism by which ANGPTL4 inhibits LPL remains to be clarified, the inhibition may include the 
de-dimerization of  LPL and subsequent cleavage by PCSKs. By acting upon LPL, ANGPTL4 limits the amount of  fatty 
acids that enter adipocytes.
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extend our knowledge on the function of ANGPTL4 in the intestine by showing that 
intestinal ANGPTL4 impacts bile acid metabolism and gut microbial composition. 
Lastly, we identify the lipid droplet-associated protein HILPDA as a novel target of 
PPARγ and β-adrenergic signalling in the adipose tissue, although we did not f ind a 
major role for HILPDA in the regulation of intracellular lipolysis in adipocytes (Fig-
ure 3). Taken together, our studies clarif ied several of the regulatory pathways un-
derlying lipolysis, but also highlight that knowledge gaps remain to be f illed. Further 
insights into the physiological regulation of extracellular and intracellular lipolysis 
may improve our understanding of metabolic disorders such as cardiovascular disease 
and may uncover possible treatment strategies. Hopefully, future mechanistic studies 
and translational studies will side-by-side clarify the function of HILPDA in the adi-
pose tissue, as well as the physiological role of ANGPTL4. 
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ABSTRACT 
The body eff iciently stores energy in the form of triglyceride (fat) molecules. However, 
triglycerides cannot directly enter or exit our cells, but f irst need to be degraded to so-
called fatty acids before moving in or out. This degradation process, called lipolysis, 
is crucial for human physiology and is tightly regulated to prevent the accumulation 
of fats either within organs or within the bloodstream - hallmarks of diseases such as 
obesity and cardiovascular disease.
 
To allow for uptake by underlying organs, triglycerides in the circulation are eff i-
ciently broken down to fatty acids by an enzyme called lipoprotein lipase that sits 
in the bloodstream of multiple organs (also called extracellular lipolysis). In this thesis, 
we characterized a protein named angiopoietin-like 4 (ANGPTL4) that potently in-
hibits lipoprotein lipase (LPL) and, thereby, inhibits the breakdown of triglycerides 
in the bloodstream. Our data show that by adjusting the tissue expression levels of 
ANGPTL4, different organs collaborate to ensure that triglycerides are distributed to 
organs in need of energy. Moreover, we uncovered that, in the fat tissue, ANGPTL4 
starts to inhibit LPL before LPL arrives in the bloodstream. By preventing the ar-
rival of LPL in the bloodstream, ANGPTL4 is capable of rapidly adjusting the rates 
of triglyceride degradation and the concomitant uptake of fatty acids to the energy 
requirements of the underlying organ.
 
To exit our cells, stored triglycerides that are for example present in our fat tissue need 
to be broken down (also called intracellular lipolysis). Subsequently, the released fatty 
acids can fuel other organs in need of energy. To further clarify the mechanisms un-
derlying this process of intracellular lipolysis, we investigated the role of a promising 
new protein called HILPDA. Our data show, however, that a loss of HILPDA did not 
impact the release of fatty acids from the fat tissue, while a high abundance of HILP-
DA only had a mild attenuating effect on the release of fatty acids. This suggests that 
HILPDA is not a major physiological regulator of intracellular lipolysis in fat cells.
 
In conclusion, in this thesis, we have clarif ied the regulation of intracellular and ex-
tracellular lipolysis by studying the respective roles of the proteins ANGPTL4 and 
HILPDA. Such efforts are clinically relevant, as regulators of lipolysis are potential 
therapeutic targets to lower cardiovascular disease risk.
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SUMMARY
Fatty acids are highly eff icient energy substrates that are mostly found incorporated 
into triglycerides to facilitate their transport and storage. The inability of triglycerides 
to move across cellular membranes necessitates that they are hydrolysed to fatty acids 
before moving in or out a cell. This degradation process, called lipolysis, is crucial for 
human physiology: lipolysis in the intestine (gastro-intestinal lipolysis) makes that die-
tary triglycerides can be taken up by our body, lipolysis in the bloodstream (intravas-
cular lipolysis) assures that circulating triglycerides can move into tissues that require 
energy, and lipolysis within cells (intracellular lipolysis) mobilizes stored triglycerides 
that are used for energy or distributed to provide fuel to other organs. Perhaps not 
surprisingly, dysregulation of gastro-intestinal, intravascular or intracellular lipolysis 
may have severe consequences for health, including ectopic fat storage and dyslipi-
demia  ̶ hallmarks of metabolic disorders such as obesity and cardiovascular disease. 
Despite the importance of a tight regulation of lipolysis for metabolic health, however, 
the underlying molecular mechanisms are far from being completely understood.
In the f irst part of this thesis, we focused on the regulation of lipoprotein lipase (LPL), 
the enzyme responsible for intravascular lipolysis. LPL sits on the endothelium of 
many metabolically active tissues, such as the heart and the adipose tissue. At the 
endothelium, LPL releases fatty acids from circulating triglycerides to assure that 
these tissues obtain adequate amounts of lipid fuel. Since the fuel demands of tissues 
continuously change, the activity of endothelial LPL needs to be dynamically regu-
lated in a tissue-specif ic manner. For example, following a prolonged fast, the heart 
and not our adipose tissue should preferentially take up fatty acids derived from cir-
culating triglycerides. Accordingly, the activity of LPL in the heart increases upon 
fasting, while the activity of LPL in the adipose tissue decreases. This fasting-induced 
reduction in LPL activity in the adipose tissue is mediated by the protein angiopoi-
etin-like 4 (ANGPTL4), a protein that potently inhibits LPL (Chapter 2, Chapter 
3). Another physiological situation that signif icantly impacts the metabolic demand 
of tissues is cold exposure. During cold exposure, the activity of the brown adipose 
tissue increases dramatically, as the brown adipose tissue combusts large amounts 
of fatty acids to generate heat for the maintenance of core body temperature. To re-
plenish intracellular lipid stores and to supply fatty acids for combustion, the activity 
of LPL in the brown adipose tissue increases signif icantly upon cold exposure. How-
ever, the underlying regulatory mechanisms had remained unclear. In Chapter 4, 
we hypothesized that the changes in LPL activity in the brown adipose tissue upon 
cold exposure might be controlled by changes in the abundance of the LPL inhibitor 
ANGPTL4. To test this hypothesis, we exposed mice without ANGPTL4 (so-called 
Angptl4 knockout mice), control mice (so-called wild-type mice), and mice with more 
ANGPTL4 (so-called Angptl4-transgenic mice) to a cold environmental temperature 
(4 ˚C) or a thermoneutral temperature (28 ˚C) for 10 days. We found that the amount 
of ANGPTL4 was signif icantly decreased in the brown adipose tissue of wild-type 
mice upon cold exposure, concurrent with the increase in LPL activity. In contrast, 
the abundance of ANGPTL4 in the brown adipose tissue of Angptl4-transgenic mice 
did not change following cold exposure and, conf irming our initial hypothesis, the in-
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crease in LPL activity in Angptl4-transgenic mice was signif icantly blunted compared 
to the wild-type mice. Surprisingly, upon examination of the white adipose tissue 
of these mice, we found that the amount of ANGPTL4 in the white adipose tissue 
was increased rather than decreased, resulting in the repression of LPL activity in 
the white adipose tissue. Together, these data suggest that ANGPTL4 promotes the 
shuttling of lipid fuel towards the brown adipose tissue upon sustained cold exposure 
by enhancing the uptake of triglyceride-derived fatty acids into the brown adipose 
tissue and by inhibiting their uptake into the white adipose tissue. To conf irm the 
role of ANGPTL4 in regulating LPL activity and concomitant fatty acid uptake in 
the brown and white adipose tissue upon cold exposure, we intravenously injected 
radiolabeled and f luorescently labeled triglycerides into cold-exposed Angptl4 knock-
out mice, wild-type mice, and Angptl4-transgenic mice and tracked the fate of the in-
jected triglycerides. Consistent with our initial experiments, the uptake of fatty acids 
released by LPL from the radiolabeled and f luorescently labeled triglycerides was 
inversely associated with the amount of ANGPTL4 in the brown and white adipose 
tissue. Taken together, our data show that the opposite regulation of ANGPTL4 in the 
brown and white adipose tissue assures an adequate provision of fatty acids derived 
from circulating triglycerides to the brown fat during cold exposure. 
Although we convincingly showed that ANGPTL4 potently regulates the activity of 
LPL in the brown adipose tissue, our data did not shed light on the mechanism by 
which ANGPTL4 inhibits LPL activity in the adipose tissue. Accordingly, our objec-
tive in Chapter 5 was to investigate the cellular location and mechanism by which 
ANGPTL4 inhibits LPL in the adipose tissue by employing a combination of cell 
culture studies and studies with adipocytes and adipose tissue from wild-type and 
Angptl4 knockout mice. We found that co-transfection of ANGPTL4 and LPL mark-
edly reduced the amount of LPL within cells, whereas co-plating of independently 
transfected cells did not. These observations suggested that ANGPTL4 lowers the 
amount of LPL protein within cells, but only when expressed in the same cell as LPL. 
Conversely, in adipocytes, the absence of ANGPTL4 resulted in a pronounced accu-
mulation of LPL on the adipocyte cell surface. Together, our data show, for the f irst 
time, that ANGPTL4 has the capacity to inhibit LPL intracellularly in adipocytes, 
possibly by promoting the intracellular degradation of LPL. Our identif ication of the 
intracellular regulation of LPL by ANGPTL4 complements the established regula-
tion of LPL by ANGPTL4 in the subendothelial spaces and at the endothelium. In 
Chapter 6, our objective was to further clarify the mechanism by which ANGPTL4 
promotes the intracellular degradation of LPL. Here, we showed that adipose tissue 
LPL is potently cleaved intracellularly and extracellularly by proteins of the so-called 
proprotein convertase subtilisin/kexin (PCSK) family, resulting in the inactivation 
of LPL. Furthermore, we provide evidence that the cleavage of LPL by PCSKs in 
adipocytes can be promoted by ANGPTL4, suggesting that PCSK-mediated cleavage 
may at least partially explain how ANGPTL4 promotes the intracellular degradation 
of LPL in the adipose tissue. 
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Besides LPL, ANGPTL4 is also known to inhibit the activity of pancreatic lipase, 
the enzyme responsible for the gastro-intestinal lipolysis of dietary triglycerides. In 
the intestine, the abundance of ANGPTL4 is modulated by the gut microbiota and 
by bile acids. Bile acids emulsify dietary triglycerides in the intestinal tract and fa-
cilitate triglyceride digestion. In Chapter 7, we examined the impact of intestinal 
ANGPTL4 on gut microbial composition and host bile acid metabolism. To that end, 
we challenged Angptl4 knockout mice and wild-type mice with a diet enriched in tau-
rocholic acid, a conjugated bile acid, and assessed the differences in gut microbial 
composition and bile acid metabolism between Angptl4 knockout and wild-type mice. 
We found that taurocholic acid feeding dramatically increased the levels of bile acids 
in the blood of wild-type mice but not of Angptl4 knockout mice, which could be attrib-
uted to a lower re-absorption of bile acids in the intestine of Angptl4 knockout mice. 
Furthermore, we found signif icant differences in gut microbial composition between 
the wild-type and the Angptl4 knockout mice, which we believe may provide a reason-
able explanation for the observed differences in bile acid metabolism between Angptl4 
knockout and wild-type mice. Conceivably, the differences in bile acid uptake and gut 
microbial composition between Angptl4 knockout and wild-type mice might originate 
from differences in gastro-intestinal lipolysis, as elevated levels of fat in the intestine 
signif icantly impact the gut microbial composition. This hypothesis remains, howev-
er, to be tested. 
Next, we investigated the function of a newly-identif ied protein called HILPDA in 
the regulation of intracellular lipolysis in adipocytes. HILPDA is abundantly present 
in the adipose tissue where it localizes to the lipid droplets. Given that HILPDA was 
previously shown to prevent intracellular lipolysis in hepatocytes, we hypothesized in 
Chapter 8 that HILPDA might regulate intracellular lipolysis in the adipose tissue. 
Our initial experiments indicated that the abundance of HILPDA in adipocytes is 
regulated by the fatty acid-inducible transcription factor peroxisome proliferator-ac-
tivated receptor γ (PPARγ) and by β-adrenergic signaling, the key signaling pathway 
initiating intracellular lipolysis. However, loss of HILPDA did not signif icantly im-
pact intracellular lipolysis and the concomitant release of fatty acids from adipocytes, 
whereas overexpression of HILPDA modestly attenuated the release of fatty acids 
from adipocytes. To examine a potential role for HILPDA in adipocyte lipolysis in 
vivo, we subsequently generated mice that are def icient for Hilpda specif ically in the 
adipocytes. We challenged these mice either by the injection of a β-adrenergic ago-
nist, by cold exposure or by prolonged fasting, in order to promote adipocyte lipolysis 
and the concomitant release of fatty acids from the adipose tissue. In contrast to our 
expectations, however, we did not observe an effect of Hilpda deletion on the amount 
of fatty acids in the plasma nor on any other relevant metabolic parameters. Taken 
together, our data suggest that HILPDA is not a major physiological regulator of in-
tracellular lipolysis in adipocytes. 
In conclusion, the studies presented in this thesis clarify several of the regulatory 
pathways underlying lipolysis. We demonstrate that the regulation of ANGPTL4 ex-
pression in brown and white adipose tissue is an integral component of the shuttling 
of lipid fuel towards BAT during cold exposure via a mechanism that comprises the 
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intracellular degradation of LPL, the key enzyme for intravascular lipolysis. We also 
extend our knowledge on the function of ANGPTL4 in the intestine by showing that 
intestinal ANGPTL4, possibly via its impact on gastro-intestinal lipolysis, impacts 
bile acid metabolism and gut microbial composition. Lastly, we identify the lipid 
droplet-associated protein HILPDA as a novel target of PPARγ and of β-adrenergic 
signalling in the adipose tissue. However, in contrast to the proposed inhibition of 
lipolysis by HILPDA in the liver, our data did not reveal a major role of HILPDA in 
the regulation of intracellular lipolysis in the adipose tissue. A better understanding 
of the molecular mechanisms underlying lipolysis is clinically relevant. For example, 
physiological regulators of LPL activity, such as ANGPTL4, have recently regained 
interest from pharmaceutical companies as potential therapeutic targets to lower 
cardiovascular disease risk. Hopefully, future mechanistic studies and translational 
studies will side-by-side clarify the underlying regulatory processes, as well as their 
relevance for human physiology. 
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and the inspiring meetings the past years. It was a real privilege to be part of the net-
work and highly stimulating to see what paths are taken to conduct high-quality and 
innovative science. Special thanks go to Joerg, Ludger and Markus for accommo-
dating me in the Hamburg lab, making me feel at home in Hamburg, and helping me 
with the experiments on the Angptl4 -/- mice. 
Ook buiten het lab hebben veel mensen me gestimuleerd bij het volbrengen van mijn 
PhD. Joeri, Haimil, and Christa, my “sport buddies”. It started with just sports, 
but became so much more! I’m extremely grateful for all the interesting discussions, 
the lovely dinners and the fun parties. Ana, I’m glad you decided to come back to 
Wageningen to do your Master. You’re such a positive and fun person to be around! 
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Lieve meiden van ‘Vocus, Thes, Dolf, Suus, Nic, Han, Piek, El, Mir, en Val, 
samen sporten schept een stevige band; bijna tien jaar na oprichting van ons roeiclub-
je zien we elkaar nog steeds! Zonder alle feestjes, etentjes, housewarmings, ploegweek-
enden en eindeloze potten thee, waren de afgelopen jaren een stuk minder gezellig 
geweest. Dolf en Piek, gaaf dat jullie nu ook aan het promoveren zijn! El, dankzij 
jouw aansporingen en sportiviteit begon ik een beetje vertwijfeld aan een triathlon. 
Nooit gedacht dat ik dat zo leuk zou vinden! 
Lieve San, grappig om te zien hoe we al een jaar of 10 een heel vergelijkbaar parcours 
volgen! Ik heb altijd veel bewondering voor je positieve kijk en de bijzondere manier 
waarop je over dingen nadenkt. Ik denk dat het interdisciplinaire onderzoek wat je nu 
doet heel erg goed bij je past en ik hoop dat onze wegen zich de komende jaren nog 
vaak zullen kruisen. 
Lieve Berrie en Nicolette, a.k.a. Chris & Connie, waar zou ik zonder jullie zijn gewe-
est? Als partners in crime vanaf het eerste uur, zou ik in ieder geval nooit in Canada 
zijn geweest om feest te vieren op het stand van Llorett of in Spanje zijn geweest om 
het Collosseum te bekijken. Ik bewonder jullie positiviteit en humor en lach me altijd 
krom bij jullie. Wie had gedacht dat we allemaal zouden gaan promoveren (behalve 
Klaas dan misschien)? Ber, als nummer 3; ik zet 23 december 2018 alvast in de agen-
da, je begrijpt dat je daar nu niet meer onderuit kan! 
Lieve Lianne, ik ben heel erg trots op onze bijzondere band. Ondanks de afstand 
hebben we elkaar altijd opgezocht en ik weet 100% zeker dat jij de eerste bent die op 
de stoep staat in Nantes. Ik ben zo blij dat je je geluk bij Jan-Erik hebt gevonden en ik 
wens jullie heel veel geluk toe in jullie nieuwe huisje. 
Je suis très heureuse de savoir qu’en France il y aura aussi les gens qui seront toujours 
là pour moi. Jean-Marie, Marie, Fanny et le Titi, vous êtes vraiment une deux-
ième famille pour moi. Fanny, je trouve très cool que tu as choisi de faire un doctorat 
aussi, bon courage! Céline, Philippe et Kévin, revenir au camping a toujours été 
comme rentrer dans un bain chaud. Patrice et Mimère, merci d’avoir “pris soin” 
de Thomas au cours des dernières années, il est maintenant temps que nous vous re-
tournons les nombreux dîners!
Ik denk dat veel mensen weten dat ik enorm gek op mijn familie ben. Het weggaan 
bij de familie vind ik dan ook het lastigste van mijn verhuizing naar Frankrijk. Lieve 
Hannie, Fred, Geke, Tycho, Elise, Jacob, Aline, Niels, Jesse, Mirthe, Wil-
lem, Anita, Jantina, Johannes, de meisjes, Winanda en Thomas(2), jullie be-
langstelling voor mij, maar ook mijn promotie heeft me altijd getroffen. Hoewel de 
afstand ietsje groter wordt, weet ik zeker dat de band blijft en ik verwacht dat iedereen 
regelmatig op de stoep staat! 
Lieve Opa en Oma, Pake en Beppe, wie heeft er nu vier grootouders die allemaal 
op mijn promotie aanwezig kunnen zijn! Ik vind het bijzonder te zien hoe f it, sportief 
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en ondernemend jullie zijn. Blijven f ietsen, zingen, volleyballen, zwemmen, gymmen, 
vrijwilligerswerk doen, tuinieren, wandelen en kamperen is blijkbaar dé manier om f it 
oud te worden! Ik vind het ook fantastisch dat jullie altijd zo geïnteresseerd waren en 
zo goed mogelijk wilden begrijpen wat ik nou precies met de muisjes aan het onder-
zoeken was. 
Lieve Bert, mijn niet-zo-kleine broertje of mon petit frère cheri, zoals Thomas altijd 
zegt. Ik denk dat wij uit hetzelfde spreekwoordelijke hout gesneden zijn; we werken 
hard, gaan geen (buitenlandse) uitdaging uit de weg en hebben, tot verbazing van veel 
mensen, een gezamenlijke voorkeur voor buitenlandse liefdes. Ik wil je bedanken voor 
je liefde en steun de afgelopen jaren en ik hoop dat je samen met Paula, in Duitsland 
of ergens anders, een mooie toekomst tegemoet gaat. 
Lieve pap en mam, dit proefschrift is voor jullie. Ik heb me altijd onvoorwaardelijk 
gesteund gevoeld in mijn keuzes en in het volgen van mijn hart, ook al stuurt dat hart 
me nu richting Frankrijk. Niks was en is te gek en jullie hebben me altijd gestimuleerd 
om het beste uit mezelf te halen, met dit als resultaat. Ik kom altijd erg graag thuis en 
geniet van de rustig weekendjes bij jullie en Bas in het prachtige Oranjewoud. Daar 
gaat ook nooit verandering in komen, ook al zit ik misschien een paar honderd kilo-
meter verderop. 
Cher Thomas, je trouve si spécial que t’as dit il y a quatre ans: retourne aux Pays-
Bas, va faire ce que tu aimes. Je pense que nous avons brisé les attentes de presque tout 
le monde en restant ensemble à longue distance pendant ces années. Le fait que nous 
avons surmonté cela ensemble, m’assure que nous aurons un très bel avenir à Nantes, 
enf in tous les deux.
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